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Chapter 1 
 
 
 
 
Introduction  
 
 
 
 
 
 
 
 
Health technology assessment (HTA) originated from the spread of costly medical 
equipment and growing concerns over the ability and willingness of taxpayers and 
health insurers to pay for them (Banta 2003). There was greater public scrutiny of 
health care rationing decisions and a growing consumerist approach, both of 
which called for decision-making processes that were more accountable, 
transparent, and legitimate. A more comprehensive approach was needed to help 
decision-makers set priorities and obtain maximum benefit from limited resources, 
without compromising the ethical and social values underpinning health systems 
(Hutton 2006). The growth and development of HTA reflected this demand for 
well-founded information to support decisions regarding the development, uptake, 
and spread of medical technologies. 
After the 1970s, HTA broadened to include a range of medical 
interventions, including drugs, medical devices, medical and surgical procedures, 
and the organizational and support systems used in care provision (Jonsson 
2002). However, most HTAs so far have been directed at pharmaceuticals, rather 
than at other technologies such as medical devices and surgical procedures 
(Hutton 2006). 
HTA can be defined as ‘the systematic evaluation of the properties, 
effects, and/or other impacts of health care technology’ (Jonsson 2002). It 
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involves evaluating an intervention through the production, synthesis, and/or 
systematic review of a range of scientific and non-scientific evidence. The 
evidence typically considered includes safety, efficacy, cost, and cost-
effectiveness, as well as the social, organizational, legal, and ethical implications 
(Jonsson 2002). For example, HTA often considers the macro-economic impacts 
of health technologies on national healthcare budgets, resource allocation among 
different health programs, regulation, and other policy changes on technological 
innovation, investment, technology transfer, and employment (Goodman 1998). 
As well as identifying valuable technologies, HTA can reduce or eliminate 
interventions that are unsafe and ineffective, or whose cost is too high compared 
to the benefits. HTA can also help to identify technologies that are underused 
(e.g. preventive screening or smoking cessation interventions) and identifying the 
reasons for lack of use. 
The main aim of HTA is to provide a range of stakeholders, typically those 
involved in funding, planning, purchasing, and investing in healthcare, with 
accessible, useable, and evidence-based information that will guide decisions 
about technology and the efficient allocation of resources. It has been called ‘the 
bridge between evidence and policy making’, because it provides information for 
healthcare decision-makers at macro-, meso-, and micro-levels (Battista 1999). In 
particular, the increased use of medical technologies has encouraged decision-
makers to rely on HTA to help determine the reimbursement status and pricing of 
interventions. HTA also contributes in many ways to the knowledge base for 
improving the quality of care, especially in supporting the development of clinical 
practice guidelines and health service standards. 
In Europe, the first organizations dedicated to evaluating healthcare 
technologies were set up in the 1980s.  Over the following 25 years most 
countries set up HTA programs, either by providing new agencies or institutes, or 
by setting up academic units or governmental and non-governmental entities. The 
diversity of HTA activities in the EU reflects the different healthcare and political 
systems, with different mandates, funding mechanisms, and roles in policy 
formulation (Banta 2003). The use of HTA in decisions that influence the spread 
and uptake of technologies can be influenced by several factors, such as income 
levels, reimbursement mechanisms, regulatory environments and behavioral 
determinants i.e. demand for new technologies. As HTA strives to bring together 
policy and evidence, it reflects the specific needs of decision-makers within a 
specific system, which explains the variation between countries. 
Economic evidence is needed to restrict the use of products, especially 
innovative and expensive technologies where there may be uncertainty. 
Reimbursing such technologies can be confined to certain indications, patient 
populations, treatment settings, and therapeutic positioning i.e. first- or second-
line therapy (Zentner 2005). In the Netherlands, for example, if expensive 
inpatient drugs meet certain criteria after an initial assessment (e.g. projected 
sales higher than 0.5% of total drug sales in the hospital) then they will be given 
conditional reimbursement for three years. In this time additional information on 
the drug’s ‘real world’ cost-effectiveness is collected. If the evidence does not 
show value for money then reimbursement will be withdrawn. Conditional 
approvals have an important role because they allow use of the technology under 
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limited conditions in an attempt to minimize uncertainty. However, the usefulness 
of conditional approvals depends on further data collection and the subsequent 
re-evaluation of the product. These arrangements are known as a “risk-sharing 
agreements” (Drummond 2007). Technologies are generally reimbursed without 
conditions when cost-effectiveness and marginal therapeutic and patient benefits 
have been established (Anell 2005). But some drugs with poor cost-effectiveness 
are covered if the disease is severe (with a small patient population) or there is a 
lack of treatment alternatives such as in the case of orphan drugs. Payers favor 
such an approach because it reduces the risk that they will pay too much for a 
drug, at least in the long term. Manufacturers welcome the prospect of faster 
market access for their products as a result of accelerated pricing and 
reimbursement negotiation prior to launch. However, these deals can present 
certain practical difficulties. For example, who will decide on the additional data 
requirements? Who will pay for the studies? How will any “performance criteria” 
be determined? (Drummond 2007). 
The results of health technology assessments are also used to develop 
clinical or practice guidelines. Guidelines typically include recommendations on 
priority-setting, and provide national support to help decision-makers. However, 
health economic evidence is not used as well as it could be when developing 
guidelines, with only a few recommendations grounded in HTA. Berg et al. (2004) 
suggest that this could be caused by a gap between the data generated and the 
requirements of clinical practice; aversion among the doctors to combine 
economics and health; and the fact that guidelines rely more on data on 
effectiveness, rather than on cost-effectiveness. Therefore guidelines are of 
limited value for influencing the use or uptake of new health technology (Berg 
2004). This situation is probably made worse by the lack of coordination between 
the bodies that produce guidelines and those that set priorities and fund HTA 
studies. However, guideline development and HTA are beginning to come 
together. 
There remains a lack of evidence on the ’real world‘ effectiveness of 
economic evaluation in terms of healthcare planning, clinical practice, spread of 
technologies, or overall healthcare costs. Decision-makers continue to ignore the 
principles of economic evaluation, despite the advances in techniques and 
methodology (Goddard 2006). In addition, the available evidence on the impact of 
HTA and research development is relatively weak, with an explicit link only in the 
Netherlands and the UK (Jonsson 2002). Many factors may prevent decision-
makers from using strict cost-effectiveness criteria when setting priorities and 
other stakeholders from using HTA products (e.g. reports, practice guidelines) in 
healthcare decisions. Goddard et al. (2006) argue that the lack of impact is not so 
much caused by methodological shortcomings than by the wider context of public-
sector decision-making. While decision-makers may value health economics 
information, other aspects of the public policy process result in sporadic and 
unsystematic application of HTA. 
The place of HTA in the decision-making process can affect the extent to 
which evidence is used to inform policy and priority-setting. Countries often 
disagree on the use of HTA recommendations (Draborg 2005). Some support 
recommendations on the grounds that experts are the best people to provide 
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them, while others prefer decision-makers to make recommendations in the light 
of political context and other country-specific circumstances. However, decision-
makers may not have the technical expertise to understand the methodological 
strengths and weaknesses of an assessment. Improvements are still needed, but 
much has been done by assessment bodies to enhance the accessibility and 
usability of HTA among different audiences such as policy-makers, health 
professionals, and general public. Although different decision structures provide 
policy-makers with a wide range of discretion, not employing HTA evidence may 
lead to inefficient, ineffective, and inequitable healthcare. 
The present thesis will address some of the methodological challenges of 
the health technology assessment and will assess the impact of economic 
evaluations in healthcare decision-making process. 
 
Methodological and practical challenges of health 
technology assessments 
 
The use of meta-analysis in systematic literature review 
Systematic reviews have a central role in evidence based-medicine. The 
quantitative systematic review, also known as meta-analysis provides a logical 
structure for quantifying the existing evidence (Berman 2002). Meta-analysis now 
offers the opportunity to critically evaluate and statistically combine results of 
comparable studies or trials. The aim is to get a consistent estimation of the 
global effect of a procedure on a specified outcome by increasing the number of 
observations and statistical power. There are several reasons to perform a meta-
analysis in a systematic literature review (Cochrane Manual 2008): 
a) To increase power. Power is the chance of detecting a real effect as 
statistically significant if it exists. Many individual studies are too small to 
detect small effects, but when several are combined there is a higher chance 
of detecting an effect. 
b) To improve precision. The estimation of a treatment effect can be improved 
when it is based on more information. 
c) To answer questions not posed by the individual studies. Primary studies 
often involve a specific type of patient and explicitly defined interventions. A 
selection of studies in which these characteristics differ can allow 
investigation of the consistency of effect and, if relevant, allow a reason for 
differences in effect estimates to be investigated. 
d) To settle controversies arising from apparently conflicting studies or to 
generate new hypotheses. Statistical analysis of findings allows a degree of 
conflict to be formally assessed, and reasons for different results to be 
explored and quantified 
There are some methodological issues that need to be addressed before 
performing a meta-analysis such as quality of original studies, combinability of the 
selected studies, publication bias and bias in the abstraction of data. However, if 
used appropriately, meta-analysis is a powerful tool for deriving meaningful 
conclusions from data and can help physicians and health policy makers to 
answer specific questions. Although there has been some controversy about its 
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validity (Bailar 1997), meta-analysis has become increasingly popular, as the 
number of studies with similar protocols has grown. 
 
Measurement of patient reported outcomes 
Patient reported outcomes (PRO) provide the patient perspective on the 
effectiveness of treatment, and for many diseases the patient is the only source of 
health outcome data (Revicki 2000). Patients, clinicians, pharmaceutical industry, 
decision-makers, payers and regulatory authorities acknowledge the need to 
understand the impact of symptoms and diseases on patients’ lives and to 
evaluate how treatment affects patient functioning and well-being as a criterion for 
licensing new medications and for policy decisions. During the past decade a 
number of products have been submitted to regulatory bodies, such as the Food 
and Drug Administration (FDA) in the United States and the European Agency for 
the Evaluation of Medicinal Products (EMEA) for approval to communicate patient 
benefits. Along with these submissions have come questions about the underlying 
methodology of patient based data and health-related quality of life research and 
its application to the drug approval process. For PRO endpoint data to be 
accepted as evidence of treatment effectiveness there must be evidence 
documenting the instrument’s conceptual framework, content validity, and 
psychometric qualities, including reliability, validity and responsiveness. Health 
outcomes researchers throughout the world have actively debated diverse 
conceptual and methodological issues related to all types of PROs, resulting in 
the publication of various “best practices” documents (Wildd 2005, Aquadro 
2003). Regulatory agencies have recently developed statements to guide the 
development and use of these measures, especially by the pharmaceutical 
industry in the drug approval process (FDA 2006, EMEA 2005).  
Traditionally, health-related quality of life research has predominately 
been conducted with the use of paper-and-pencil questionnaires.  However, as 
computers become smaller and hand-held units more prevalent, a greater number 
of studies are utilizing/developing technology in what is termed as electronic data 
capture to eliminate the need for lengthy or cumbersome paper surveys. 
Electronic data capture offers many benefits, including personalization of 
questionnaires both to study protocols and specific populations, automatic data 
stamping, programmable skip patterns, and immediate data entry which 
eliminates the possibility of entry errors that may be made manually.  Several 
studies have been conducted to test for differences between the traditional paper-
and-pencil and electronic data capture, all concluding that data collected 
electronically is more complete (Bushnell 2003, Drummond 1995), equivalent 
(Pouwer 1998), reliable (Velikova 1999), and cost-effective (Johannes 2000).  For 
health technology manufacturers it is important to provide evidence of the validity 
of the quality of life instruments in the electronic format as compared to paper 
version.   
 
The use of decision analytic models 
Mathematical modeling is used widely in economic evaluations of medical 
interventions. Health economic models represent an important analytic framework 
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to generate estimates of cost-effectiveness based on a synthesis of available data 
and explicit representation of uncertainty (Claxton 2002). The purpose of 
modeling is to structure evidence on clinical and economic outcomes in a form 
that can help to inform decisions about clinical practices and healthcare resource 
allocations. Models synthesize evidence on health consequences and costs from 
many different sources, including data from clinical trials, observational studies, 
insurance claim databases, case registries, public health statistics, and 
preference surveys. The use of decision-analytic modeling for health technology 
assessment has increased exponentially in recent years, and therefore practice 
guidelines have been defined (Philips 2006). 
The use of models in the economic evaluation is also controversial. One 
aspect is related to the use of models to synthesize comparisons of two 
treatments in the absence of head-to-head trials. Because of the difficulties in 
conducting comparative trials for all available treatment options, models are often 
used as a proxy for head-to-head comparisons in economic evaluations of health 
technologies. However, indirect comparisons are potentially subject to bias. It can 
be very difficult to ensure that all the studies used in the model were equivalent in 
terms of variables such as patients’ baseline risk, treatment settings, and the 
measurement of clinical outcomes. The apparent superiority of one therapy over 
another may be attributable to differences in trial design rather than inherent 
differences between therapies. Nevertheless, indirect comparisons are 
sometimes necessary. The standard approach is to find trials of the therapies of 
interest again a common comparator. 
Another controversial aspect in decision-analytic models is related to the 
extrapolation of treatment beyond the duration observed in clinical studies. 
Extrapolation is usually required in reimbursement applications because clinical 
trials generally do not last long enough to demonstrate the full benefits and 
disadvantages of a therapy. Nevertheless, cost-effectiveness models offer a 
structured, rational, quantitative approach to help decision-makers to achieve 
better value for health resources expended. Consensus groups and experts have 
recommended the technique as an aid to guide resource allocation decisions in 
healthcare (Drummond 2008, Neumann 2008). As a consequence, many 
countries have incorporated decision analytic models into their health technology 
assessment and reimbursement procedures. 
 
Characterizing uncertainty in decision analytic models 
Most review bodies conduct or require sensitivity analyses on all variables that 
could potentially influence the overall results, or on a subset of inputs. This is 
because of the uncertainty inherent in conducting economic evaluations, 
specifically over the value of particular estimates and their relative effect on costs 
and benefits. The stipulation for sensitivity analyses comes from the need to test 
or verify the robustness of the findings. Different countries have different 
requirements for sensitivity analysis (e.g. univariate or multivariate) so the choice 
of parameters and methods must be substantiated and well documented. Most 
countries recommend or require this, and it is particularly important in the case of 
assessments for new technologies, where the necessary data for evaluations is 
seldom clear. 
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 The use of sensitivity analysis and modeling as well as subgroup analysis 
may also be used to predict the effect of certain patient characteristics (e.g. age, 
sex, and ethnicity) on cost-effectiveness and equity (Michaels 2006). Some 
review bodies (e.g. National Institute for Health and Clinical Excellence, NICE) 
suggest that modeling for subgroups of patients might be appropriate, but there 
are no recommendations as to which variables would be considered ethical. 
Outlining clear criteria for subgroup analysis, based on specific variables, could 
help to incorporate social values into decision-making in an explicit, transparent, 
and consistent way. 
Traditionally, the uncertainty has been examined using sensitivity 
analysis. In the recent years there has been considerable emphasis on the 
development of appropriate statistical methods for handling uncertainty in 
economic evaluations of medical interventions, with a tendency to move from 
univariate sensitivity analysis towards probabilistic descriptions of uncertainty e.g. 
cost-effectiveness planes, cost-effectiveness acceptability curves and 
distributions of incremental net benefit (Briggs 1999). 
Value of information analysis is a natural methodological extension of 
Bayesian decision theory that quantifies the existing level of uncertainty and 
estimates the impact on the expected net benefit of alternative decision options 
through obtaining perfect information on model parameters. Information is 
valuable because it reduces the expected costs of uncertainty surrounding a 
clinical decision. The expected costs of uncertainty are determined by the 
probability that a treatment decision based on existing (prior) information will be 
wrong and by the consequences if the wrong decision is made (loss function). 
The expected costs of uncertainty can also be interpreted as the expected value 
of perfect information, since perfect information (as an infinite sample) can 
eliminate the possibility of making the wrong decision (Claxton 2001). It is also the 
maximum a decision maker should be willing to pay for additional evidence to 
inform this decision in the future. In the last decade, there has been a huge 
interest in developing and applying value of information methods within health 
economic decision analysis and clinical trial design (Felli 1999, Claxton 2004, 
Schulpher 2005). 
The approaches to quantify the uncertainty are useful for several reasons. 
First, the uncertainty analysis helps to test the hypotheses about the sign and 
magnitude of costs, effectiveness and cost-effectiveness ratio. Second, decision-
makers are informed about the confidence they should place on the result of the 
economic evaluation of medical interventions. Third, uncertainty enables 
continuous update of the model by identifying the sensitive parameters that 
require more information. In addition, analysis of uncertainty can assess the 
benefits and costs of obtaining or requiring more information and, therefore, help 
guide decision about future research. 
 
The use of economic evaluations in decision-making  
The importance of health economics research utilization in policy-making and of 
understanding the mechanisms involved is increasingly recognized. The 
existence of relevant research, though necessary, is not sufficient. Evidence-
based policy is difficult to achieve and it is widely agreed that health policies do 
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not reflect research evidence to the extent that in theory they could (Davis 1996, 
van Velden 2005). Understanding the reasons behind the resistance of policy-
makers to use health economics research has been the source of numerous 
scholarly papers, books and conferences (Nuemann 2004, Tunis 2004). 
Examination of the policy-making process confirms be complex, with many 
genuine obstacles to evidence-based policy-making at the same time as there are 
factors that could increase research utilization. Examinations of the use of 
economic evaluations and HTA in policy-making have considered the importance 
of the quality, reliability, timeliness and comprehensiveness of research in 
influencing the level of utilization (Drummond 2000, Jonsson 2002) 
The purpose of this thesis is to address some of the challenges discussed 
above by giving practical examples of how these methodological and practical 
challenges can be addressed in the economic evaluations of medical 
interventions.  
 
Outline of this thesis 
Chapter 2 presents the results of a systematic literature review with meta-analysis 
on the effectiveness of lifestyle intervention in the prevention and treatment of 
obesity. The global rise in obesity prevalence continues to be a threat to people’s 
health. This review is part of a HTA in the prevention and treatment of obesity 
performed for Swiss Ministry of Health to support the decision to allocate funds in 
the prevention of obesity programs in Switzerland in 2007. The systematic review 
provides new information on the effectiveness of lifestyle interventions by 
assessing the mid- to long-term effects on weight and cardiovascular risk profile 
in overweight and obese people. 
Chapter 3, using data collected from a stand-alone study, establishes the 
validity of the electronic versions of three quality of life measures in comparison to 
the existing paper versions.  As a part of Novartis Pharma development program, 
a selective 5-HT4 receptor partial agonist was developed for the treatment of 
functional gastrointestinal dysmotility disorders. A multinational clinical trial has 
been completed using electronic data collection. In order to evaluate changes in 
patient reported outcomes, standard instruments were included to assess change 
in patients’ quality of life (IBS-QOL), productivity (WPAI:IBS-C), and utility (EQ-
5D).  For the manufacturer, it is important to assess these measures to provide 
evidence of validity in the electronic format that would meet satisfactory claims of 
equal performance in an electronic mode compared with paper version. 
Chapter 4 presents the development and results of a cost-effectiveness 
model of zoledronic acid versus risedronate in Paget’s disease of bone. 
Zoledronic acid is a third generation of nitrogen containing bisphosphonate 
seeking approval for Paget’s disease of bone indication. For registration purposes 
two six-month randomized clinical trials were performed in order to evaluate the 
safety and efficacy of intravenous zoledronic acid for the treatment of Paget’s 
disease of bone using oral risedronate as a comparator. Our economic model, 
based on the two clinical trials, goes beyond six-month and evaluates the cost-
effectiveness of zoledronic acid versus standard therapy, risedronate, for the first 
two years of market access of zoledronic acid in the United Kingdom. 
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Chapter 5 presents the development and results of an economic model 
that evaluates the lifetime effects of three-year lifestyle intervention in the 
prevention and treatment of obesity. The model estimates the cost-effectiveness 
of lifestyle intervention versus standard treatment in overweight and obese people 
in Switzerland. The model is a key component of the HTA that was carried out for 
lifestyle intervention in the obesity area. Probabilistic sensitivity analysis was 
undertaken to establish the uncertainty associated with the decision to adopt the 
lifestyle intervention program in the prevention and treatment of obesity. 
Chapter 6 addresses the uncertainty in decision-making by evaluating the 
value of additional information. We used the value of information analysis on a 
probabilistic cost-effectiveness model of lifestyle intervention in overweight and 
obese people to evaluate the uncertainty. Our analysis quantified the uncertainty 
surrounding the decision to adopt lifestyle intervention. 
Chapter 7 assesses the use of research evidence relating to economic 
analyses in healthcare decision-making. We conducted a literature review to 
summarize and synthesize published literature on self-reported attitudes of 
healthcare decision-makers towards economic evaluations of medical 
technologies. The aims of this literature review was to determine the extent to 
which economic evaluations are used in health policy decision-making, and to 
consider factors associated with the utilization of such research findings.  
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Chapter 2 
 
 
 
Systematic Review and  
Meta-Analysis in  
Health Technology Assessment 
 
 
 
 
Summary 
Systematic review has a central role in health technology assessment. The aim of 
the present chapter is to assess the mid- to long-term effectiveness of lifestyle 
interventions in the prevention and treatment of obesity.  A systematic literature 
review with meta-analysis was performed. Electronic databases, reference lists, 
books and reports covering topic of obesity were searched. The included studies 
were randomized clinical trials of lifestyle interventions in overweight and obese 
subjects that had a minimum observation period of one year. Outcomes evaluated 
were measurements of body weight, body mass index, waist circumference, 
systolic and diastolic blood pressure, blood lipids: total cholesterol, low density 
lipoprotein, high density lipoprotein, triglyceride, blood glucose control: two-hour 
plasma glucose, fasting plasma glucose, and glycosylated haemoglobin. Thirteen 
studies have been selected in the prevention and seventeen in the treatment of 
obesity. Compared with standard care, lifestyle intervention reduced significantly 
body weight, body mass index, waist circumference, blood pressure, blood lipids 
and blood glucose in overweight and obese people. The favorable effects were 
maintained up to three years. Lifestyle interventions were efficacious in the mid- 
to long-term prevention and treatment of obesity leading to a significant reduction 
in body weight and cardiovascular risk factors. 
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Introduction 
Obesity is a chronic disease whose prevalence is reaching epidemic proportions 
around the world (World Health Organization 2000). Obesity is associated with a 
high risk of morbidity, mortality as well as reduced life expectancy. The major 
health consequences of overweight and obesity are type 2 diabetes mellitus, 
hypertension, coronary heart disease, gallbladder disease, psychosocial 
problems and certain types of cancers (Fontaine 2003). 
The increasing prevalence of overweight and obesity highlight the need 
for improved prevention strategies to overcome this significant public health 
problem. Many government initiatives and awareness campaigns have been 
initiated worldwide to combat obesity i.e. International Obesity Task Force (IOTF). 
The best strategies to prevent and treat obesity have not been settled yet. A wide 
variety of obesity treatments are available, including diet, exercise, behavioral 
modification, pharmacological treatment and surgery. Among several strategies, 
lifestyle intervention has been documented to lead safely to improvements in 
metabolic abnormalities such as increased body weight, dyslipidemia, elevated 
blood pressure, glucose control, pro-coagulant and pro-inflammatory activity that 
are linked to the development of obesity, diabetes, metabolic syndrome and 
cardiovascular disease (Pritchett 2005). Lifestyle programs are multi-factorial 
interventions that are designed for each patient or group of patients according to 
their risk factor status and the needs of the subjects. These include promoting 
healthy lifestyle habits, dietary counseling, physical exercise training, and 
behavioral change targets. Individuals at risk for obesity, diabetes and 
cardiovascular disease may be influenced trough learning process to allow the 
lifestyle changes to control risk factors such as body weight, blood pressure, 
blood cholesterol and blood glucose levels. Several individual lifestyle 
interventions proved to be efficacious in the prevention of diabetes (Pan 1997, 
Lindström 2003). The aim of the present study was to systematically assess the 
mid- to long-term effectiveness (1 – 6 years) of lifestyle interventions in the 
prevention and treatment of obesity.  
 
Methods 
Titles and abstracts were obtained from systematic searches of electronic 
databases: Medline, CINHAL, MBASE, and PubMed. The searches were carried 
out using search terms ‘obesity prevention’, ‘overweight treatment’, ‘obesity 
treatment’, ‘lifestyle intervention’, ‘weight change’, ‘weight control’, ‘body mass 
index’, ‘cardiovascular disease’, and ‘diabetes mellitus’. The search was restricted 
to the period from 1995 to 2005 due to advancements in research towards 
conducting high quality studies and/or better reporting. The rapid changes in the 
obesity environment made the last ten years more suitable for study selection. 
Books and reports covering the topic of obesity were searched. The reference 
lists of all included studies were checked and all potentially appropriate studies 
were obtained and assessed for additional evidence to be used in this study. In 
addition, several individual-based studies that focused on prevention of type 2 
diabetes and cardiovascular disease were reviewed. 
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For the purpose of this study, we defined ‘prevention of obesity’ as 
interventions that target overweight individuals with body mass index (BMI) 
between 25 and 29.9 kg/m2 aiming to prevent the transition from overweight to 
obesity and ‘treatment of obesity’ as interventions that target obese individuals 
with a BMI ≥ 30 kg/m2 aiming to reduce the progression of obesity and associated 
co-morbidities.  
The inclusion criteria consisted of randomized controlled trials of lifestyle 
interventions performed in overweight or obese subjects over 18 years of age that 
had a minimum observation period, including treatment and follow-up, of at least 
one year. Lifestyle interventions had to include dietary counseling and physical 
exercise associated or not with behavioral modification techniques. The goals of 
lifestyle interventions were to achieve and maintain a weight reduction through 
consumption of a healthy low-calorie, low-fat diet and to engage in regular 
physical activities.  
The study population was classified according to the type of intervention: 
lifestyle intervention and control group regarded as standard care. The common 
characteristic of all selected studies is that interventions were carried out in 
overweight or obese people with or without associated co-morbidities. Additional 
subgroup analyses were performed in overweight subjects with cardiovascular 
risk factors and overweight or obese subjects with impaired glucose tolerance at 
risk of developing type 2 diabetes. 
For studies that fulfilled the inclusion criteria, the following outcomes were 
evaluated: body weight, BMI, waist circumference, systolic blood pressure (SBP) 
and diastolic blood pressure (DBP), blood lipids: total cholesterol (TC), low 
density lipoprotein cholesterol (LDL), and high density lipoprotein cholesterol 
(HDL), triglyceride (TG), and blood glucose control: two-hour plasma glucose (2h-
PG), fasting plasma glucose (FPG), and glycosylated haemoglobin (HbA1c). 
Meta-analysis technique was used to combine the results from distal follow-up 
(the last follow-up reported) from independent studies. The summary outcome 
measure calculated was the difference in means between lifestyle intervention 
and standard care. Effects were combined using a random effects model. The 
pooled estimates of the effect were obtained using Comprehensive Meta-Analysis 
software (CMA 2005).  
Methodological quality of the selected studies was assessed by an 
adjusted Jadad scale (Jadad 1996). Since lifestyle interventions are usually not 
blinded, an adjustment in the five point Jadad scale was made excluding the 
double blinding score. A quality checklist assessed the overall quality of the study 
including the sample size, conduct of the study, follow-up, analysis and the 
interpretation of the results (Avenell 2004). Sensitivity analysis was performed in 
high quality studies i.e Jadad score ≥ 2 points and quality score > 80 points, to 
test the robustness of the study results. One reviewer abstracted the relevant 
study population and intervention characteristics using a standardized template. 
Two reviewers assessed the methodological quality of evaluated studies 
independently.  Discrepancies were resolved by consensus discussion. 
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Results 
Thirteen studies were selected for evaluation of the prevention of obesity 
approach and 17 studies investigated the treatment of obesity approach. The 
flowchart provides an overview of all included and excluded studies (Figure. 1).  
 
Figure 1. Flowchart 
 
 
Prevention of obesity  
Table 1 presents the descriptive data of the 13 studies selected investigating the 
prevention of obesity. Lifestyle intervention components of each study are 
presented in Appendix 1. The studies included a total of 3566 participants with an 
average BMI of 28 kg/m2 and an average body weight of 81 kg. The study 
participants had a mean age of 49 years and were predominantly of female 
gender.  
Potentially relevant 
publications:  
 Prevention 273 
 Treatment 315 Excluded on the basis of titles and 
abstract due to study design, type of 
intervention and/or study population:  
 Prevention 175 
 Treatment 145 
RCTs selected:  
 Prevention 98 
 Treatment 170 RCT excluded due to double 
reporting, follow-up time less than 
one year, and incomplete data 
reported: 
 Prevention 85 
 Treatment 153
Selected studies:  
 Prevention 13 
 Treatment 17 
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Table 1. Characteristics of included studies in overweight people 
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Anderssen 
1996 NOR Ov CV risk 1 219 95% 45 28.8 1 68 
Burke  
2005 
AU Ov HT 1 241 85% 56 29.9 2 73 
Carr 
2005 
USA Ov  IGT 2 64 97% 56 26.2 1 73 
Dyson  
1997 
UK, 
FRA Ov D risk 1 227 50% 50 28.5 2 70 
He 
2000 
USA Ov HT risk 7 208 87% 43 28.9 2 75 
Kastarinen 
2002 FIN Ov HT risk 2 715 82% 43 28.7 1 78 
Ketola  
2001 
FIN Ov CV risk 2 150 95% - 27.8 3 65 
Liao 
2002 
USA Ov IGT 2 74 72% 54 26.1 3 70 
Mensink 
2003ab NL Ov IGT
 2 114 77% 57 29.7 3 85 
Pan 1997 CHI Ov  IGT , D 6 530 92% 45 25.8 2 60 
Simkin-
Silverman 
2003 
USA Ov 4.5 535 95% 47 25 2 83 
Stefanick 
1998 USA Ov CHD
 1 377 97% 52 28 2 83 
Trento  
2001 
ITA Ov D 4 112 71% 62 28.9 3 88 
a N, percentage of subjects finishing the study; b Adjusted Jadad score: 1 Low, 2 Moderate, 
3 High, c Quality score: 1-50 Low, 51-80 Moderate, 81-100 High;  Ov, overweight; CV, 
cardiovascular; D, diabetes; HT, hypertension; IGT, impaired glucose tolerance; CHD, 
coronary heart disease; N, number 
 
The results of the meta-analysis are summarized in Table 2. At an average follow-
up of three years, the pooled effect size showed significance in favor of the 
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lifestyle intervention compared with standard care in reducing body weight (-2.2 
kg, Figure 2) and cardiovascular risk factors with the exception of HDL and 
HbA1c. 
 
Table 2. Meta-analysis results in overweight people 
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Weight (kg) 11 2373 -2.19 0.32 -2.81 -1.57 <0.0001 
BMI (kg/m2) 5 926 -1.11 0.23 -1.56 -0.66 <0.0001 
Waist (cm) 3 208 -2.12 0.23 -2.56 -1.68 <0.0001 
SBP (mmHg) 9 2239 -2.08 0.61 -3.28 -0.89 0.001 
DBP (mmHg) 9 2239 -1.59 0.55 -2.67 -0.51 0.004 
TC (mmol/l) 7 1516 -0.26 0.07 -0.41 -0.12 <0.0001 
HDL (mmol/l) 7 1875 0.01 0.01 -0.22 0.04 0.640 
LDL (mmol/l) 5 1690 -0.16 0.06 -0.28 -0.03 0.013 
TG (mmol/l) 7 1875 -0.23 0.08 -0.38 -0.08 0.003 
HbA1c (%) 3 397 -0.50 0.52 -1.52 0.52 0.339 
FPG (mmol/l) 6 804 -0.28 0.09 -0.45 -0.11 0.001 
2h-PG (mmol/l) 2 284 -0.63 0.24 -1.10 -0.16 0.009 
 
Figure 2. Meta-analysis weight change (kg) in overweight people 
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A funnel plot of the mean difference in body weight reduction plotted against the 
study size, represented by standard error, is shown in Figure 3. The vertical line 
indicates the pooled mean difference of all trials (-2.2 kg). Usually, studies with 
larger sample size appear toward the top of the graph and a distributed 
symmetrically around the combined effect size. Smaller studies usually appear 
toward the bottom of the graph, and since there could be more sampling variation 
in the effect size estimates in the smaller studies, they are dispersed across a 
range of values. Visual inspection implies that the evaluated lifestyle intervention 
studies participated equally to the pooled mean difference i.e. the studies are 
dispersed symmetrically around the combined effect size.    
 
Figure 3. Funnel plot of the mean difference in body weight in overweight people 
plotted against standard error 
 
A sensitivity analysis was performed on high quality studies (Mensink 2003ab, 
Simkin-Silverman 2003, Stefanick 1998, Trento 2001). The studies included a 
total of 1168 participants with an average age of 51 years and an average BMI of 
27 kg/m2. The results of the sensitivity analysis confirmed the results of the main 
analysis: compared with standard care, lifestyle intervention reduced significantly 
body weight and cardiovascular risk factors in overweight people with the 
exception of SBP, HDL and HbA1c. The difference in means was -3.1 kg in body 
weight (p=0.0001), -1.6 mmHg in SBP (p=0.068), -2 mmHg in DBP (p=0.03),         
-0.32 mmol/l in TC (p=0.0001), 0.001 mmol/l in HDL (p=0.96), -0.22 mmol/l in LDL 
(p=0.006), -0.21 mmol/l in TG (p=0.002), -0.75 % in HbA1c (p=0.37), and -0.35 
mmol/l in FPG (p=0.002). 
A subgroup analysis was performed in overweight people with 
cardiovascular risk factors (Anderssen 1996, Burke 2005, He 2000, Kastarinen 
2002, Ketola 2001, Stefanick 1998). The studies included a total of 1910 
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participants with an average BMI of 27 kg/m2. The results of the meta-analysis are 
presented in Table 3. At an average follow-up of three years, compared with 
standard care, lifestyle intervention reduced significantly body weight and 
cardiovascular risk factors in overweight people with identified cardiovascular risk 
with the exception of TG and HDL. 
 
Table 3. Subgroup analysis in overweight people with cardiovascular risk factors 
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Weight (kg) 5 1343 -2.30 0.70 -3.67 -0.92 0.001 
SBP (mmHg) 6 1419 -2.43 0.78 -3.96 -0.91 0.002 
DBP (mmHg) 6 1419 -2.16 0.77 -3.67 -0.67 0.005 
TC (mmol/l) 4 1120 -0.35 0.09 -0.53 -0.16 <0.0001 
TG (mmol/l) 3 970 -0.24 0.14 -0.52 0.04 0.087 
HDL (mmol/l) 3 970 0.01 0.02 -0.04 0.05 0.798 
LDL (mmol/l) 2 897 -0.27 0.08 -0.43 -0.43 0.001 
 
 
Treatment of obesity 
Table 4 presents the descriptive data of the 17 studies selected in the treatment 
of obesity. The lifestyle intervention components of each study are presented in 
Appendix 1.  
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Table 4. Characteristics of included studies in obese people 
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DPP 
2005ab USA Ob D risk 2.8 2161 93% 51 34 2 93 
Esposito 
2003 ITA Ob 3 120 93% 35 35 2 85 
Harvey-
Berino 2004 USA Ob 1 255 76% 46 32 2 58 
Jeffery 
1995 USA Ob 2.5 202 88% 37 31 1 53 
Lindhal 
1999 SWE Ob D risk 1 186 96% 56 30 2 78 
Lindstrom 
2003 FIN Ob D risk 3 522 83% 55 31 2 95 
Messier 
2004 USA Ob OA 1.5 316 80% 69 34 2 73 
Moore 2003 UK Ob 1.5 991 62% 48 37 2 65 
Narayan 
1998 USA Ob 1 98 95% 34 35 1 55 
Sbrocco 
1999 USA Ob 1 24 88% 42 33 2 60 
Stevens 
2001 USA Ob D risk 3 1191 92% 43 31 1 68 
Tate 2003 USA Ob D risk 1 92 84% 49 33 3 63 
Wylie-
Rosset 
2001 
USA Ob CV risk 1 588 81% 52 36 1 75 
Whelton 
1998 USA Ob HT 2.5 886 86% 46 36 2 85 
Wing 1998 USA Ob D risk 2 154 84% 46 36 1 83 
Wolf 2004 USA Ob D 1 147 80% 53 37 3 58 
Yeh 2003 USA Ob 2 80 66% 50 37 2 75% 
aN, percentage of subjects finishing the study;  bAdjusted Jadad score: 1 Low, 2 Moderate, 
3 High;c Quality score: 1-50 Low, 51-80 Moderate, 81-100 High, Ob, obese; D, diabetes; 
HT, hypertension; OA, osteoarthritis; CV, cardiovascular 
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The studies included 8013 participants, predominantly females, with an average 
age of 49 years and an average BMI of 34 kg/m2. The meta-analysis results are 
presented in Table 5. Compared with standard care, lifestyle intervention reduces 
significantly body weight (-3.49 kg, see Figure 4) and cardiovascular risk factors 
in obese people with the exception of FPG and HbA1c. The average follow-up 
time of interventions was three years. 
 
Table 5. Meta-analysis results in obese people 
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Weight (kg) 12 5124 -3.49 0.62 -4.70 -2.27 <0.0001 
BMI (kg/m2) 7 3522 -1.33 0.31 -1.93 -0.72 <0.0001 
SBP (mmHg) 6 4182 -2.78 0.82 -4.38 -1.18 0.001 
DBP (mmHg) 6 4063 -1.42 0.43 -2.23 -0.57 0.001 
TC    (mmol/l) 5 893 -0.14 0.05 -0.24 -0.03 0.011 
HDL (mmol/l) 4 2778 0.04 0.02 0.004 0.08 0.028 
TG   (mmol/l) 4 2964 -0.15 0.06 -0.27 -0.04 0.011 
FPG (mmol/l) 5 2934 -0.15 0.08 -0.31 0.02 0.079 
2h-PG (mmol/l) 2 692 -0.54 0.16 -0.84 -0.24 0.001 
HbA1c (%) 2 497 -0.09 0.03 -0.40 0.23 0.599 
 
Figure 4. Meta-analysis weight change (kg) in obese people 
 
A sensitivity analysis was performed on high quality studies (DPP 2005ab, 
Esposito 2003, Lindstrom 2003, Whelton 1998, Wing 1998). The studies included 
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a total of 3023 participants with an average BMI of 33 kg/m2 and a mean age of 
52 years. The results of the sensitivity analysis confirmed the results of the main 
analysis: compared with standard care, lifestyle intervention reduced significantly 
body weight and cardiovascular risk factors in obese people with the exception of 
FPG. The difference in means was -5.1 kg in body weight (p<0.0001), -1.8 kg/m2 
in BMI (p=0.001), -3 mmHg in SBP (p=0.0001), -2 mmHg in DBP (p=0.0001),       
-1.15 mmol/l in TC (p=0.01), 0.04 mmol/l in HDL (p=0.02), -0.17 in TG (p=0.02), 
and -0.13 in FPG (p=0.24). 
A subgroup analysis was performed in overweight and obese people 
subjects with impaired glucose tolerance in the prevention of diabetes studies. 
Nine such studies were identified, in four studies participants had a BMI of < 30 
kg/m2 (Carr 2005, Dyson 1997, Liao 2002, Mensink 2003ab) and in the other five 
studies participants had a BMI of > 30 kg/m2 (DPP 2005ab, Lindahl 1999, 
Lindstrom 2003, Tate 2003, Wing 1998). The studies included a total of 3502 
participants, predominantly females, with an average BMI of 33 kg/m2. Meta-
analysis results are presented in Table 6. Compared with standard care, lifestyle 
intervention reduced significantly body weight and cardiovascular risk factors (see 
Figure 5) with the exception of LDL and HbA1c. 
 
Table 6. Subgroup analysis in overweight and obese people at risk of diabetes 
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Weight (kg) 8 3150 -2.93 0.72 -4.35 -1.52 <0.0001 
BMI (kg/m2) 6 2890 -1.29 0.33 -1.94 -0.64 <0.0001 
SBP (mmHg) 5 3115 -3.45 0.68 -4.78 -2.13 <0.0001 
DBP (mmHg) 5 3115 -1.83 0.34 -2.50 -1.17 <0.0001 
TC (mmol/l) 5 867 -0.13 0.06 -0.25 -0.02 0.027 
HDL (mmol/l) 5 2842 0.02 0.01 0.00 0.04 0.030 
LDL (mmol/l) 3 357 -0.05 0.08 -0.22 0.12 0.555 
TG (mmol/l) 6 3028 -0.20 0.07 -0.33 -0.07 0.002 
HbA1c (%) 4 682 -0.04 0.09 -0.21 0.14 0.686 
FPG (mmol/l) 6 3029 -0.23 0.05 -0.33 -0.14 <0.0001 
2h-PG (mmol/l) 3 608 -0.57 0.25 -1.05 -0.09 0.021 
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Figure 5. Fasting plasma glucose change (mmol/l) in overweight or obese at risk 
of diabetes 
 
The data input of the meta-analyses performed are provided in the Appendix 2 
and the graphical representation of all analyses are presented in Appendix 3. 
 
Discussion 
The global rise in obesity prevalence continues to be a threat to people’s health. 
Although health policies have aimed to raise public awareness to prevent obesity, 
its increasing prevalence implies that successful solutions have not been yet 
identified. The present systematic review provides new information on the 
effectiveness of lifestyle interventions by assessing the mid- to long-term effects 
on weight and cardiovascular risk profile in overweight and obese people. Our 
findings suggest that - on an average follow-up time of three years - lifestyle 
interventions reduce significantly body weight and cardiovascular risk factors in 
overweight and obese people. To estimate whether these results are of clinical 
relevance we searched the medical literature for studies that have linked the 
intermediate physiological endpoints i.e. HbA1c, FPG, with hard outcomes such 
as reduced incidence of diabetes, reduced cardiovascular events and morbidity, 
and reduced mortality risk.  
Several individual studies in obese people designed to prevent diabetes 
(DPP 2002, Lindstrom 2003) demonstrated that lifestyle intervention was 
associated to a 58% reduction in the incidence of diabetes in a three years 
program compared with a control group. A large trial (UKPDS 34) specifically 
designed to address the hypothesis that glucose lowering therapies may reduce 
the risk for cardiovascular morbidity or mortality in overweight individuals with 
type 2 diabetes, demonstrated that relatively small reductions in HbA1c (<1%) 
were associated with reduced microvascular complications. It has been estimated 
that each 1% reduction in HbA1c level was associated with a 14% reduction in 
the incidence of fatal and nonfatal myocardial infarction and 37% reduction in the 
microvascular complications (Stratton 2000). In our study, lifestyle intervention 
reduced HbA1c by 0.5% more compared to standard care in overweight people; 
however, the difference between groups was not significant. This may be partially 
explained by the small number of studies reporting HbA1c as a reported outcome 
and, in addition, our main analysis was not stratified for individuals with high risk 
for developing type 2 diabetes.  
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Observational analyses using data from a large clinical trial (UKPDS 61) 
demonstrated that individuals with intermediate FPG values (7.8 to 10 mmol/l) 
compared with individuals with low FPG values (<7.8 mmol/l) had a significantly 
lower risk of diabetes related deaths and myocardial infarction. In our analysis, 
lifestyle intervention reduced significantly FPG in overweight subjects but not in 
obese subjects. However, when the analysis was performed in obese people at 
risk of developing diabetes, lifestyle intervention significantly reduced FPG (see 
Figure 5).  
Our analysis showed a significantly greater decrease in waist 
circumference in the lifestyle intervention group in comparison to standard care. It 
has been documented that waist circumference is more closely correlated with 
the volume of visceral adipose tissue than the waist-to-hip ratio or total body fat 
mass (Despres 1993, Lemieux 1996). It may be hypothesized that a greater loss 
of visceral adipose tissue, as reflected indirectly by the observed decrease in 
waist circumference, contributed to the improvement in glycemic status 
(significant decrease in 2h-PG and FPG) in the lifestyle intervention group.  
Central obesity, which is measured as increased waist circumference, is also an 
important component of atherogenic dyslipidemia, which has been identified as 
predictor of the metabolic syndrome and plays a major role in the pathogenesis of 
cardiovascular disease (Vinik 2005). 
Evidence from epidemiological studies and clinical trials indicate that 
dyslipidemia is one of the most important modifiable risk factors for coronary heart 
disease (Ferdinand 2004, Meagher 2004). Dyslipidemia is generally characterized 
by increased fasting concentrations of TC, LDL and TG, in conjunction with 
decreased concentrations of HDL (NCEP 2001). Thus, decreasing TC, LDL, TG 
and increasing HDL represent an important clinical target (Pyorala 1997). For 
example, analyzing the data from the Scandinavian Simvastatin Survival Study, 
the authors estimated that each additional 1% reduction in LDL would generate a 
1.7% reduction in the risk of major coronary events (Pedersen 1998). In our study 
lifestyle intervention was associated with a significant decrease in TG, TC and 
LDL and an increase in HDL in overweight people, as well as with a decrease in 
TG and TC in obese people. When a subgroup analysis was performed in 
overweight people with cardiovascular risk factors, the difference in means 
between lifestyles intervention and standard care was not significantly different 
with respect to TG and HDL. The observed results pointed in the expected 
direction but showed no statistically significant difference. A possible explanation 
for these small changes is the fact that the control group often showed moderate 
weight loss and TG reductions, minimizing between-group differences. 
The association between obesity and cardiovascular disease is well 
established and up to 60% of overweight and obese patients are hypertensive 
(Dentali 2005). Cardiovascular complications may, to a large extent, be prevented 
by lowering blood pressure in patients at risk of developing cardiovascular 
disease. The Heart Outcome Prevention Study showed that a decrease in systolic 
blood pressure of 2-3 mmHg in patients with diabetes and one other risk factor for 
cardiovascular morbidity was associated with a 25% reduction in risk of 
myocardial infarction, stroke, or cardiovascular death (Gerstein 2002).  Another 
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major trial (UKPDS 38) compared tight with less tight blood pressure control i.e. 
mean 144/82 mmHg versus 154/87 mmHg. The tight blood pressure control 
demonstrated considerable benefits reducing heart failure by 56%, stroke by 44% 
and combined myocardial infarction, sudden death, stroke, and peripheral 
vascular disease by 34%. According to our analysis, lifestyle intervention reduced 
significantly systolic and diastolic blood pressure in overweight and obese people. 
The present study established the mid- to long-term effectiveness of 
lifestyle intervention in overweight and obese people by combining the beneficial 
effects on body weight and cardiovascular risk factors at distal follow-up. The 
actual lifestyle intervention in all evaluated studies included dietary counseling 
and physical exercise and lasted from one to six years including an average 
follow-up time of three years. The question now arise weather the observed 
beneficial effects of lifestyle interventions are maintained over lifetime. Such 
information is presently not available. However, the extended follow-up of the 
Finish Diabetes Prevention Program (Lindstrom 2006) which lasted seven years 
resulted in sustained lifestyle changes and a reduction in diabetes incidence that 
was maintained long after the lifestyle counseling had stopped. The study 
reported a 43% reduction in the relative risk from developing diabetes related to 
the success in achieving the intervention goals of weight loss, reduced intake of 
total and saturated fat, increased intake of dietary fibre and increased physical 
activity. Nevertheless, continued research in overweight and obese people is 
required to evaluate the effect of lifestyle interventions over lifetime. 
Our analysis has several limitations. We may not have identified all 
relevant literature on this topic given the large applicability of lifestyle 
interventions in obesity related diseases. However, our search strategies of 
literature identification was comprehensive, capturing many of the published 
studies on lifestyle intervention in overweight and obese people independent of 
the associated co-morbidities. We cannot exclude the possibility of publication 
bias i.e. small studies with positive results are more likely to be published 
although the funnel plot suggests no such publication bias. Our results are limited 
by the poor quality of data reported on the outcome evaluated i.e. BMI, HDL, LDL, 
HbA1c, as well as the lack of subgroup analysis on different patient population i.e. 
gender difference, stratification according to different co-morbid conditions. We 
also observed qualitative and quantitative heterogeneity across studies on sample 
size, study population, and types of lifestyle intervention.  
Questions may arise whether a lifestyle program could accomplish 
equivalent beneficial effects in different countries and ethnically diverse 
populations. Socio-cultural factors can influence the efficacy of lifestyle program 
in different countries, young or older adults, men or women, and the presence of 
different co-morbidities. Evidence based on the studies selected for the present 
review strongly suggest that lifestyle intervention programs performed in different 
countries that target overweight and obese people with different co-morbidities 
are effective in reducing weight and cardiovascular risk factors. However, further 
research should adapt lifestyle interventions for the need of each patient 
population taking into consideration different dietary and physical activity 
background. 
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Conclusion 
In summary, the results of the present systematic literature review suggest that 
lifestyle intervention is efficacious in the mid- to long-term prevention and 
treatment of obesity leading to a significant reduction in weight and cardiovascular 
risk factors.  Lifestyle intervention can be considered an effective prevention tool 
that can be applied across different disease areas including obesity, diabetes and 
cardiovascular disease with beneficial effects maintained for more than three 
years. 
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Appendix 1. Lifestyle intervention components 
 
Author,  
year Lifestyle intervention description - Prevention of obesity studies 
Anderssen 
1996 
The dietary counseling focused on a reduction in total caloric intake, 
increase intake of fish and a reduction in the intake of saturated fat. 
Physical exercise program consisted in endurance exercise such as 
aerobic, circuit training, fast walking/jogging, intensity of training being 
at the level of 60-80% of each participant’s heart rate measured by the 
treadmill test. 
Burke  
2005 
The nutrition component promoted a diet low in fat (<30% energy from 
total fat; <10% energy from saturated fat), high in fruits and vegetables, 
low in salt and sugar, and recommended at least four fish meals per 
week. Participants were encouraged to accumulate at least 30 min of 
moderate-intensity physical activity on most days and to increase 
incidental activity. The program encouraged self-directed change in 
behavior with a focus on barriers to change, costs and benefits of a 
healthy lifestyle, goal setting and time management. 
Carr  
2005 
Isocaloric diet consisted of <30% of total calories as fat (<7% as 
saturated fat), 55% as carbohydrate, and the balance as protein, giving 
<200 mg cholesterol daily. Exercise session consisted in endurance 
exercise that involved one hour of walking or jogging on a treadmill 
three times a week, with a goal of exercising at 70% of heart rate 
reserve. 
Dyson  
1997 
Dietary advice on limiting total fat intake and increasing consumption of 
unrefined carbohydrate and dietary fiber. The exercise program 
encouraged continuous rhythmic movements involving the large muscle 
groups (e.g. swimming, cycling, brisk walking, skipping, jogging and 
low-impact aerobics). Subjects were seen by a dietitian and fitness 
instructor every three months and were required to complete food and 
exercise diaries. 
He  
2000 
Dietary counseling on sodium reduction focused on shopping, cooking, 
and food selection behaviors aimed at reducing the intake of calories 
and sodium. Weight loss is encouraged by an increase in the caloric 
expenditure, primarily by walking at a brisk pace for 45 minutes, 4 to 5 
times per week. 
Kastarinen 
2002 
Counseling sessions and behavior modification methods targeting 
weight reduction, reduction in salt, alcohol and saturated fat 
consumption, as well as increase in leisure-time physical activity. 
Ketola  
2001 
Individual multifactorial intervention program was tailored for each 
patient according to the risk factor status and needs of the patients. 
These include booklets of healthy lifestyle habits, individual dietary 
counseling by a nurse or dietician, joining a weight reduction group, and 
group or individual physiotherapy program. 
 
 
Appendix 1 27 
 
Author,  
year Lifestyle intervention description - Prevention of obesity studies 
Liao 
2002 
Dietary prescription included an isocaloric diet comprising 30% of total 
calories as fat (7% as saturated fat) 55% as carbohydrate, the balance 
as protein, and <200 mg cholesterol daily. Subjects performed 
endurance exercise (walk/jog) on a treadmill three times a week for 1 
hour at each session. Initially exercise was designed to attain 50% of 
heart rate reserve. The exercise was gradually increased at 2-week 
intervals over a period of 3 months until subjects were exercising at a 
goal of 70% of heart rate reserve.  
Mensink 
2003 
Dietary counseling consisted of carbohydrate intake of at least 55% of 
total energy intake, total fat intake of <30 to 35% energy intake, 
saturated fatty acids <10% of energy intake, a cholesterol intake of 
<33mg/MJ, protein intake of 10-15% of energy intake and an intake of 
dietary fiber of at least 3 g/MJ. Subjects were encouraged to increase 
their physical activity (walking, cycling, swimming) to at least 30 
minutes of moderate physical activity a day for at least 5 days a week.  
Pan  
1997 
Individual goals were set for total calorie consumption and for daily 
quantities of cereals, vegetables, meat, milk, and oils. Patients received 
physician counseling concerning daily food intake. Patients were 
encouraged to increase the amount of their leisure time physical 
exercise by at lease 1 unit/day and by 2 units/day if possible for those 
<50 years of age with no evidence of cardiovascular disease or arthritis. 
Activities required for one unit of exercise: mild activity 30 minutes (slow 
walking, shopping, housecleaning), moderate activity 20 minutes (faster 
walking, cycling, ballroom dancing), and strenuous activity 10 minutes 
(slow running, climbing stairs, playing volleyball).  
Stefanick  
1998 
Dietary recommendations to use less than 30% total fat, less than 7% 
saturated fat, and less than 200mg of cholesterol per day. Participants 
were given goals on engaging in aerobic activity equivalent to at least 
16 km of brisk walking or jogging each week. 
Trento  
2001 
Participants were given educational objectives to reach desirable body 
weight, learn to shop for food, and increase physical activity. 
Simkin-
Silverman 
2003 
Counseling was provided on reducing total fat, saturated fat, 
cholesterol, and integrating alternative lipid lowering dietary strategies 
(e.g. increasing soy protein, fruits vegetables and fiber) into the 
participant’s meal plan. Participants were asked to increase their 
physical activity expenditure to the level of 1000 to 1500 kcal/week (e.g 
brisk walking 10-15 miles). 
DPP 2005 
The goals of the lifestyle intervention were to achieve and maintain a 
weight reduction of at least 7% of initial body weight through 
consumption of a healthy low-calorie, low-fat diet and to engage in 
physical activity of moderate intensity such as brisk walking for at least 
150 min/week. 
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Esposito 
2005 
Participants received detailed advice on reducing dietary calories, 
personal goal setting, and self-monitoring. The mean caloric intake goal 
was set at 1300 kcal/d for the first year and 1500 kcal/d for the second 
year. The recommended composition of the dietary regimen was 50% 
to 60% carbohydrates, 15% to 20% proteins, less than 30% total fat, 
less than 10% saturated fat, 10% to 15% to monosaturated fat, 5% to 
8% polyunsaturated fat, and 18 g of fiber per 1000 kcal. Participants 
received individual guidance on increasing physical activity, mainly 
walking, but also with swimming and aerobic ball games.  
Harvey-
Berino 2006 
The weight loss treatment program focused on the modification of 
eating and exercise habits through the use of behavioral strategies and 
self-management skills. Subjects were given prescribed menus, grocery 
lists, and recipes specific to their dietary condition. Calorie goals were 
formulated to represent a 500 kcal/d restriction from baseline levels. 
Jeffery  
1995 
Standard behavior therapy including instruction on diet, exercise, and 
behavior modification technique. Dietary goals were assigned at 1000 
or 1500 kcal per day depending on initial body weight.  Exercise 
recommendations were to walk or bike 5 days per week, beginning with 
a weekly goal of 250 kcal per week and gradually increasing to 1000 
kcal per week. 
Lindahl 
 1999 
The diet recommendation included approximately 20% of energy from 
fat and with high fibre content. The recommended portion size was 
calculated to give a daily energy intake of 1800 kcal in men and 1500 
kcal in women. Aerobic physical exercise of low to moderate intensity 
was performed daily for 2.5 hours, e.g. brisk walks, gymnastics, cycling 
and swimming.  
Linström 
2003 
Lifestyle intervention goals were weight reduction > 5%, moderate 
intensity physical activity > 30 min/day, dietary fat < 30% of total 
energy, saturated fat < 10% of total energy, and fiber > 15 g/1000 kcal. 
Messier 
2004 
The goal of the dietary intervention was to produce and maintain an 
average weight loss of 5% during the 18-month intervention period. 
Participants were provided with an aerobic exercise prescription that 
included walking within a heart range of 50-75% of heart rate reserve. 
Behavior change was facilitated using self-regulatory skills. 
Moore 2003 
A management model that consisted in training on the clinical benefit of 
weight loss and effective treatment options, including reduction of 
dietary energy intake and increased physical activity. 
Narayan 
1998 
The aims of the nutrition intervention were to reduce fat and alcohol and 
increase fibre intake. The goal of the activity intervention was to 
increase energy expenditure by 700-1000 kcal per week though 
physical activity (waking, water aerobics, softball, volleyball). 
Sbrocco 
1999 
Behavioral choice treatment encouraged subjects to eat in moderation, 
to engage in pleasure activities besides eating such as regular 
exercise. 
 
 
Appendix 1 29 
 
Author,  
year Lifestyle intervention description - Prevention of obesity studies 
Stevens 
2001 
The dietary intervention focused on reducing caloric intake by 
decreasing consumption of excess fat, sugar and alcohol. The physical 
activity goal was to gradually increase activity to 30 to 45 minutes per 
day, four to five days per week.  Exercise intensity was moderate (40% 
to 55% of heart rate reserve) and consisted in brisk walking. Specific 
behavior change techniques included self-monitoring (food diaries and 
graphs of minutes of physical activity per day), setting explicit short 
term goals and developing specific action plans to achieve those 
objectives.  
Tate  
2003 
Internet behavioral e-counseling consisted in advice on diet and 
physical exercise. Subjects were instructed to report calorie and fat 
intake, exercise energy expenditure and received weekly e-mail 
behavioral counseling and feedback from a counselor. 
 
Wylie-Rosett 
2001 
 
Cognitive behavioral approach to target lifestyle and behavior 
modifications. The intervention included: a workbook, a computer and 
staff consultation.  
Whelton 
1998 
Participants were advised on ways to change eating patterns and 
increase physical activity. The goal for weight loss was achieving and 
maintaining a weight loss of 4.5 kg or greater.  
Wing  
1999 
Subjects were asked to follow an 800-1000 kcal/day diet, with 20% of 
calories as fat. Meal plans and shopping lists specific to the calorie and 
fat goals were distributed weekly. Subjects were encouraged to 
gradually increase their physical activity to 1500 kcal/week through 
activities such as brisk walking completed 5 days each week and to 
monitor their exercise daily throughout the program. 
Wolf  
2004 
Goals of the intervention were modest weight loss (5% of initial weight) 
and dietary intake as well as increase physical activity. 
Yeh  
2003 
Skill based intervention included counseling on meal planning, dinning 
out, food label reading, recipe modification, and physical activity. 
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Appendix 3. Meta-analyses figures 
 
 
1. Meta-analysis prevention of obesity 
 
 
 
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Carr 2005 -2.000 1.272 1.617 -4.493 0.493 -1.573 0.116
Liao 2002 -2.100 0.236 0.056 -2.563 -1.637 -8.885 0.000
Mensink 2003ab -2.500 0.919 0.844 -4.301 -0.699 -2.721 0.007
-2.121 0.225 0.051 -2.562 -1.679 -9.415 0.000
-5.00 -2.50 0.00 2.50 5.00
Favours Lifestyle Favours Standard Care
Figure 3. Meta-analysis waist circumference change (cm) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Andersen 1996 -2.160 0.220 0.048 -2.591 -1.729 -9.818 0.000
Liao 2002 -0.900 0.053 0.003 -1.003 -0.797 -17.135 0.000
Mensink 2003ab -0.800 0.290 0.084 -1.369 -0.231 -2.757 0.006
Pan 1997 -0.700 0.369 0.136 -1.423 0.023 -1.898 0.058
Simkin-Silverman 2003 -0.910 0.168 0.028 -1.240 -0.580 -5.402 0.000
-1.110 0.229 0.052 -1.559 -0.661 -4.846 0.000
-3.00 -1.50 0.00 1.50 3.00
Favours Lifestyle Favours Standard Care
Figure 2. Meta-analysis BMI change (kg/m2) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Burke 2005 -2.500 0.721 0.520 -3.914 -1.086 -3.465 0.001
Carr 2005 -2.400 0.699 0.489 -3.771 -1.029 -3.431 0.001
Dyson 1997 -0.200 0.835 0.697 -1.836 1.436 -0.240 0.811
He 1999 0.400 1.286 1.655 -2.121 2.921 0.311 0.756
Kastarinen 2002 -1.200 0.423 0.179 -2.028 -0.372 -2.839 0.005
Ketola 2001 -1.300 0.858 0.736 -2.981 0.381 -1.516 0.130
Liao 2002 -2.500 0.145 0.021 -2.784 -2.216 -17.237 0.000
Mensink 2003ab -2.300 0.842 0.709 -3.951 -0.649 -2.731 0.006
Simkin-Silverman 2003 -2.500 0.556 0.309 -3.590 -1.410 -4.494 0.000
Stefanick 1998_Female -3.900 0.845 0.715 -5.557 -2.243 -4.614 0.000
Stefanick 1998_Male -4.700 0.732 0.535 -6.134 -3.266 -6.423 0.000
Trento 2002 -1.700 1.031 1.063 -3.721 0.321 -1.649 0.099
-2.185 0.316 0.100 -2.805 -1.565 -6.907 0.000
-7.00 -3.50 0.00 3.50 7.00
Favours Lifestyle Favours Standard Care
Figure 1. Meta-analysis weight change (kg) in overweight people
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Anderssen 1996 -8.000 2.316 5.364 -12.539 -3.461 -3.454 0.001
Burke 2005 -2.000 1.780 3.167 -5.488 1.488 -1.124 0.261
Dyson 1997 -2.000 1.807 3.266 -5.542 1.542 -1.107 0.268
He 1999 -1.700 2.655 7.048 -6.903 3.503 -0.640 0.522
Kastarinen 2002 -2.000 1.171 1.372 -4.296 0.296 -1.707 0.088
Ketola 2001 -0.700 2.082 4.335 -4.781 3.381 -0.336 0.737
Simkim-Silverman 2003 -0.300 1.126 1.269 -2.508 1.908 -0.266 0.790
Stefanick 1998 _Male -3.300 1.518 2.305 -6.276 -0.324 -2.173 0.030
Stefanick 1998_Female -0.700 1.706 2.911 -4.044 2.644 -0.410 0.682
Trento 2002 -4.000 2.400 5.760 -8.704 0.704 -1.667 0.096
-2.083 0.608 0.370 -3.275 -0.891 -3.426 0.001
-13.00 -6.50 0.00 6.50 13.00
Favours Lifestyle Favours Standard Care
Figure 4. Meta-analysis systolic blood pressure change (mmHg) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Anderssen 1996 -6.100 1.766 3.118 -9.561 -2.639 -3.455 0.001
Burke 2005 -2.000 1.163 1.353 -4.280 0.280 -1.720 0.086
Dyson 1997 -0.010 1.181 1.395 -2.325 2.305 -0.008 0.993
He 1999 -1.300 1.624 2.638 -4.484 1.884 -0.800 0.424
Kastarinen 2002 -1.100 0.662 0.438 -2.398 0.198 -1.661 0.097
Ketola 2001 1.100 1.355 1.837 -1.557 3.757 0.812 0.417
Simkin-Silverman 2003 -0.700 0.736 0.542 -2.143 0.743 -0.951 0.342
Stefanick 1998_ Female -2.100 1.131 1.280 -4.317 0.117 -1.856 0.063
Stefanick 1998_Male -4.800 1.312 1.722 -7.372 -2.228 -3.658 0.000
Trento 2002 -0.800 1.569 2.460 -3.874 2.274 -0.510 0.610
-1.592 0.552 0.304 -2.673 -0.511 -2.886 0.004
-10.00 -5.00 0.00 5.00 10.00
Favours Lifestyle Favours Standard Care
Figure 5. Meta-analysis diastolic blood pressure change (mmHg) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Andersen 1996 -0.600 0.165 0.027 -0.923 -0.277 -3.638 0.000
Dyson 1997 0.000 0.155 0.024 -0.303 0.303 0.000 1.000
Kastarinen 2002 -0.100 0.081 0.007 -0.258 0.058 -1.238 0.216
Ketola 2001 -0.260 0.176 0.031 -0.606 0.086 -1.474 0.140
Mensink 2003 -0.100 0.141 0.020 -0.375 0.175 -0.711 0.477
Stefanick 1998_Female -0.420 0.112 0.013 -0.639 -0.201 -3.751 0.000
Stefanick 1998_Male -0.430 0.111 0.012 -0.648 -0.212 -3.860 0.000
Trento 2002 -0.200 0.204 0.042 -0.600 0.200 -0.980 0.327
-0.262 0.073 0.005 -0.406 -0.119 -3.582 0.000
-1.00 -0.50 0.00 0.50 1.00
Favours Lifestyle Favours Standard Care
Figure 6. Meta-analysis total cholesterol change (mmol/l) in overweight people
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Anderssen 1996 0.180 0.181 0.033 -0.175 0.535 0.995 0.320
Dyson 1997 -0.010 0.042 0.002 -0.091 0.071 -0.241 0.810
Kastarinen 1997 0.030 0.022 0.000 -0.013 0.073 1.383 0.167
Mensink 2003ab 0.010 0.033 0.001 -0.054 0.074 0.304 0.761
Simkin-Silverman 2003 -0.020 0.026 0.001 -0.070 0.030 -0.778 0.437
Stefanick 1998_Female -0.060 0.035 0.001 -0.129 0.009 -1.706 0.088
Stefanick 1998_Male 0.020 0.026 0.001 -0.031 0.071 0.768 0.443
Trento 2002 0.100 0.055 0.003 -0.007 0.207 1.825 0.068
0.007 0.014 0.000 -0.022 0.035 0.468 0.640
-0.60 -0.30 0.00 0.30 0.60
Favours Standard Care Favours Lifestyle
Figure 7. Meta-analysis high density lipoprotein cholesterol change (mmol/l) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Dyson 1997 0.100 0.106 0.011 -0.108 0.308 0.944 0.345
Kastarinen 2002 -0.150 0.055 0.003 -0.258 -0.042 -2.710 0.007
Mensink 2003ab 0.000 0.139 0.019 -0.272 0.272 0.000 1.000
Simkin-Silverman 2003 -0.140 0.066 0.004 -0.269 -0.011 -2.133 0.033
Stefanick 1998_Female -0.310 0.107 0.012 -0.520 -0.100 -2.888 0.004
Stefanick 1998_Male -0.400 0.103 0.011 -0.603 -0.197 -3.866 0.000
-0.155 0.063 0.004 -0.278 -0.032 -2.478 0.013
-0.70 -0.35 0.00 0.35 0.70
Favours Lifestyle Favours Standard Care
Figure 8. Meta-analysis low density lipoprotein cholesterol change (mmol/l) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Anderssen 1996 -0.890 0.226 0.051 -1.333 -0.447 -3.941 0.000
Dyson 1997 -0.140 0.137 0.019 -0.409 0.129 -1.019 0.308
Kastarinen 2002 0.000 0.072 0.005 -0.141 0.141 0.000 1.000
Mensink 2003ab -0.550 0.171 0.029 -0.886 -0.214 -3.211 0.001
Simkin-Silverman 2003 -0.130 0.085 0.007 -0.297 0.037 -1.527 0.127
Stefanick 1998_Female -0.140 0.111 0.012 -0.358 0.078 -1.261 0.207
Stefanick 1998_Male -0.180 0.164 0.027 -0.501 0.141 -1.100 0.271
Trento 2002 -0.260 0.181 0.033 -0.616 0.096 -1.433 0.152
-0.230 0.078 0.006 -0.383 -0.076 -2.925 0.003
-1.50 -0.75 0.00 0.75 1.50
Favours Lifestyle Favours Standard Care
Figure 9. Meta-analysis triglyceride change (mmol/l) in overweight people
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Dyson 1997 0.000 0.109 0.012 -0.213 0.213 0.000 1.000
Mensink 2003ab 0.100 0.141 0.020 -0.175 0.375 0.711 0.477
Trento 2002 -1.600 0.144 0.021 -1.882 -1.318 -11.140 0.000
-0.498 0.521 0.271 -1.519 0.523 -0.956 0.339
-2.00 -1.00 0.00 1.00 2.00
Favours Lifestyle Favours Standard Care
Figure 10. Meta-analysis HbA1c change (%) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Carr 2005 -0.110 0.115 0.013 -0.336 0.116 -0.953 0.341
Dyson 1997 0.100 0.283 0.080 -0.455 0.655 0.353 0.724
Mensink 2003ab -0.300 0.088 0.008 -0.472 -0.128 -3.412 0.001
Pan 1997 -0.590 0.310 0.096 -1.198 0.018 -1.902 0.057
Stefanick 1998_Female -0.290 0.155 0.024 -0.593 0.013 -1.876 0.061
Stefanick 1998_Male -0.220 0.111 0.012 -0.437 -0.003 -1.990 0.047
Trento 2002 -1.300 0.374 0.140 -2.033 -0.567 -3.474 0.001
-0.278 0.088 0.008 -0.450 -0.107 -3.180 0.001
-2.30 -1.15 0.00 1.15 2.30
Favours Lifestyle Favours Standard Care
Figure 11. Meta-analysis fasting plasma glucose change (mmol/l) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Mensink 2003ab -1.200 0.428 0.183 -2.039 -0.361 -2.804 0.005
Stefanick 1998_Female -0.340 0.339 0.115 -1.004 0.324 -1.003 0.316
Stefanick 1998_Male -0.520 0.332 0.111 -1.172 0.132 -1.564 0.118
-0.627 0.239 0.057 -1.095 -0.160 -2.629 0.009
-2.30 -1.15 0.00 1.15 2.30
Favours Lifestyle Favours Standard Care
Figure 12. Meta-analysis 2-hour plasma glucose change (mmol/l) in overweight people
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1.1. Sensitivity analysis prevention of obesity high quality studies 
 
 
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Mensink 2003ab -2.300 0.842 0.709 -3.951 -0.649 -2.731 0.006
Simkin-Silverman 2003 -2.500 0.556 0.309 -3.590 -1.410 -4.494 0.000
Stefanick 1998_Female -3.900 0.845 0.715 -5.557 -2.243 -4.614 0.000
Stefanick 1998_Male -4.700 0.732 0.535 -6.134 -3.266 -6.423 0.000
Trento 2002 -1.700 1.031 1.063 -3.721 0.321 -1.649 0.099
-3.072 0.539 0.291 -4.129 -2.015 -5.696 0.000
-7.00 -3.50 0.00 3.50 7.00
Favours Lifestyle Favours Standard Care
Figure 13. Sensitivity analysis weight change (kg) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Simkin-Silverman 2003 -0.300 1.126 1.269 -2.508 1.908 -0.266 0.790
Stefanick 1998_Female -0.700 1.706 2.911 -4.044 2.644 -0.410 0.682
Stefanick 1998_Male -3.300 1.518 2.305 -6.276 -0.324 -2.173 0.030
Trento 2002 -4.000 2.400 5.760 -8.704 0.704 -1.667 0.096
-1.623 0.888 0.789 -3.364 0.118 -1.827 0.068
-9.00 -4.50 0.00 4.50 9.00
Favours Lifestyle Favours Standard Care
Figure 14. Sensitivity analysis systolic blood pressure change (mmHg) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Simkin-Silverman 2003 -0.700 0.736 0.542 -2.143 0.743 -0.951 0.342
Stefanick 1998_Female -2.100 1.131 1.280 -4.317 0.117 -1.856 0.063
Stefanick 1998_Male -4.800 1.312 1.722 -7.372 -2.228 -3.658 0.000
Trento 2002 -0.800 1.569 2.460 -3.874 2.274 -0.510 0.610
-2.005 0.925 0.856 -3.818 -0.191 -2.167 0.030
-8.00 -4.00 0.00 4.00 8.00
Favours Lifestyle Favours Standard Care
Figure 15. Sensitivity analysis diastolic blood pressure change (mmHg) in overweight people
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Mensink 2003ab -0.100 0.141 0.020 -0.375 0.175 -0.711 0.477
Stefanick 1998_Female -0.420 0.112 0.013 -0.639 -0.201 -3.751 0.000
Stefanick 1998_Male -0.430 0.111 0.012 -0.648 -0.212 -3.860 0.000
Trento 2002 -0.200 0.204 0.042 -0.600 0.200 -0.980 0.327
-0.318 0.083 0.007 -0.480 -0.156 -3.852 0.000
-1.00 -0.50 0.00 0.50 1.00
Favours Lifestyle Favours Standard Care
Figure 16. Sensitivity analysis total cholesterol change (mmol/l) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Mensink 2003ab 0.010 0.033 0.001 -0.054 0.074 0.304 0.761
Simkin-Silverman 2003 -0.020 0.026 0.001 -0.070 0.030 -0.778 0.437
Stefanick 1998_Female -0.060 0.035 0.001 -0.129 0.009 -1.706 0.088
Stefanick 1998_Male 0.020 0.026 0.001 -0.031 0.071 0.768 0.443
Trento 2002 0.100 0.055 0.003 -0.007 0.207 1.825 0.068
0.001 0.020 0.000 -0.038 0.040 0.050 0.960
-0.25 -0.13 0.00 0.13 0.25
Favours Standard Care Favours Lifestyle
Figure 17. Sensitivity analysis high density lipoprotein cholesterol change (mmol/l) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Mensink 2003ab 0.000 0.139 0.019 -0.272 0.272 0.000 1.000
Simkin-Silverman 2003 -0.140 0.066 0.004 -0.269 -0.011 -2.133 0.033
Stefanick 1998_Female -0.310 0.107 0.012 -0.520 -0.100 -2.888 0.004
Stefanick 1998_Male -0.400 0.103 0.011 -0.603 -0.197 -3.866 0.000
-0.219 0.080 0.006 -0.376 -0.062 -2.737 0.006
-1.00 -0.50 0.00 0.50 1.00
Favours Lifestyle Favours Standard Care
Figure 18. Sensitivity analysis low density lipoprotein cholesterol change (mmol/l) in overweight people
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Mensink 2003ab -0.550 0.171 0.029 -0.886 -0.214 -3.211 0.001
Simkin-Silverman 2003 -0.130 0.085 0.007 -0.297 0.037 -1.527 0.127
Stefanick 1998_Female -0.140 0.111 0.012 -0.358 0.078 -1.261 0.207
Stefanick 1998_Male -0.180 0.164 0.027 -0.501 0.141 -1.100 0.271
Trento 2002 -0.260 0.181 0.033 -0.616 0.096 -1.433 0.152
-0.210 0.067 0.005 -0.342 -0.078 -3.113 0.002
-1.00 -0.50 0.00 0.50 1.00
Favours Lifestyle Favours Standard Care
Figure 19. Sensitivity analysis triglyceride change (mmol/l) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Mensink 2003ab 0.100 0.141 0.020 -0.175 0.375 0.711 0.477
Trento 2002 -1.600 0.144 0.021 -1.882 -1.318 -11.140 0.000
-0.750 0.850 0.722 -2.416 0.916 -0.882 0.378
-3.00 -1.50 0.00 1.50 3.00
Favours Lifestyle Favours Standard Care
Figure 20. Sensitivity analysis HbA1c change (%) in overweight people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Mensink 2003ab -0.300 0.088 0.008 -0.472 -0.128 -3.412 0.001
Stefanick 1998_Female -0.290 0.155 0.024 -0.593 0.013 -1.876 0.061
Stefanick 1998_Male -0.220 0.111 0.012 -0.437 -0.003 -1.990 0.047
Trento 2002 -1.300 0.374 0.140 -2.033 -0.567 -3.474 0.001
-0.349 0.114 0.013 -0.573 -0.126 -3.063 0.002
-2.00 -1.00 0.00 1.00 2.00
Favours Lifestyle Favours Standard Care
Figure 21. Sensitivity analysis fasting plasma glucose change (mmol/l) in overweight people
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1.2. Subgroup analysis overweight people with cardiovascular risk factors 
 
 
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Burke 2005 -2.500 0.721 0.520 -3.914 -1.086 -3.465 0.001
He 1999 0.400 1.286 1.655 -2.121 2.921 0.311 0.756
Kastarinen 2002 -1.200 0.423 0.179 -2.028 -0.372 -2.839 0.005
Ketola 2001 -1.300 0.858 0.736 -2.981 0.381 -1.516 0.130
Stefanick 1998_Female -3.900 0.845 0.715 -5.557 -2.243 -4.614 0.000
Stefanick 1998_Male -4.700 0.732 0.535 -6.134 -3.266 -6.423 0.000
-2.296 0.703 0.494 -3.674 -0.919 -3.267 0.001
-7.00 -3.50 0.00 3.50 7.00
Favours Lifestyle Favours Standard Care
Figure 22. Subgroup analysis weight change (kg) in overweight with cardiovascular risks
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Anderssen 1996 -8.000 2.316 5.364 -12.539 -3.461 -3.454 0.001
Burke 2005 -2.000 1.780 3.167 -5.488 1.488 -1.124 0.261
He 1999 -1.700 2.655 7.048 -6.903 3.503 -0.640 0.522
Kastarinen 2002 -2.000 1.171 1.372 -4.296 0.296 -1.707 0.088
Ketola 2001 -0.700 2.082 4.335 -4.781 3.381 -0.336 0.737
Stefanick 1998_Female -0.700 1.706 2.911 -4.044 2.644 -0.410 0.682
Stefanick 1998_Male -3.300 1.518 2.305 -6.276 -0.324 -2.173 0.030
-2.431 0.778 0.605 -3.955 -0.907 -3.126 0.002
-13.00 -6.50 0.00 6.50 13.00
Favours Lifestyle Favours Standard Care
Figure 23. Subgroup analysis systolic blood pressure change (mmHg) in overweight with cardiovascular risks
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Anderssen 1996 -6.100 1.766 3.118 -9.561 -2.639 -3.455 0.001
Burke 2005 -2.000 1.163 1.353 -4.280 0.280 -1.720 0.086
He 1999 -1.300 1.624 2.638 -4.484 1.884 -0.800 0.424
Kastarinen 2002 -1.100 0.662 0.438 -2.398 0.198 -1.661 0.097
Ketola 2001 1.100 1.355 1.837 -1.557 3.757 0.812 0.417
Stefanick 1998_Female -2.100 1.131 1.280 -4.317 0.117 -1.856 0.063
Stefanick 1998_Male -4.800 1.312 1.722 -7.372 -2.228 -3.658 0.000
-2.156 0.770 0.593 -3.665 -0.646 -2.798 0.005
-10.00 -5.00 0.00 5.00 10.00
Favours Lifestyle Favours Standard Care
Figure 24. Subgroup analysis diastolic blood pressure change (mmHg) in overweight with cardiovascular risks
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Andersen 1996 -0.600 0.165 0.027 -0.923 -0.277 -3.638 0.000
Kastarinen 2002 -0.100 0.081 0.007 -0.258 0.058 -1.238 0.216
Ketola 2001 -0.260 0.176 0.031 -0.606 0.086 -1.474 0.140
Stefanick 1998_Female -0.420 0.112 0.013 -0.639 -0.201 -3.751 0.000
Stefanick 1998_Male -0.430 0.111 0.012 -0.648 -0.212 -3.860 0.000
-0.346 0.094 0.009 -0.531 -0.161 -3.661 0.000
-1.00 -0.50 0.00 0.50 1.00
Favours Lifestyle Favours Standard Care
Figure 25. Subgroup analysis total cholesterol change (mmol/l) in overweight with cardiovascular risks
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Anderssen 1996 -0.890 0.226 0.051 -1.333 -0.447 -3.941 0.000
Kastarinen 2002 0.000 0.072 0.005 -0.141 0.141 0.000 1.000
Stefanick 1998_Female -0.140 0.111 0.012 -0.358 0.078 -1.261 0.207
Stefanick 1998_Male -0.180 0.164 0.027 -0.501 0.141 -1.100 0.271
-0.242 0.141 0.020 -0.519 0.036 -1.709 0.087
-1.50 -0.75 0.00 0.75 1.50
Favours Lifestyle Favours Standard Care
Figure 26. Subgroup analysis triglyceride change (mmol/l) in overweight with cardiovascular risks
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Anderssen 1996 0.180 0.181 0.033 -0.175 0.535 0.995 0.320
Kastarinen 1997 0.030 0.022 0.000 -0.013 0.073 1.383 0.167
Stefanick 1998_Female -0.060 0.035 0.001 -0.129 0.009 -1.706 0.088
Stefanick 1998_Male 0.020 0.026 0.001 -0.031 0.071 0.768 0.443
0.006 0.024 0.001 -0.041 0.053 0.256 0.798
-0.25 -0.13 0.00 0.13 0.25
Favours Standard Care Favours Lifestyle
Figure 27. Subgroup analysis high density lipoprotein change (mmol/l) in overweight with cardiovascular risks
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Kastarinen 2002 -0.150 0.055 0.003 -0.258 -0.042 -2.710 0.007
Stefanick 1998_Female -0.310 0.107 0.012 -0.520 -0.100 -2.888 0.004
Stefanick 1998_Male -0.400 0.103 0.011 -0.603 -0.197 -3.866 0.000
-0.267 0.082 0.007 -0.428 -0.106 -3.254 0.001
-1.00 -0.50 0.00 0.50 1.00
Favours Lifestyle Favours Standard Care
Figure 28. Subgroup analysis low density lipoprotein change (mmol/l) in overweight with cardiovascular risks
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2. Meta-analysis treatment of obesity 
 
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -5.500 0.109 0.012 -5.715 -5.285 -50.248 0.000
Esposito 2003 -11.000 1.515 2.295 -13.969 -8.031 -7.261 0.000
Lindahl 1999 -4.900 0.329 0.109 -5.546 -4.254 -14.873 0.000
Lindstrom 2003 -2.600 0.504 0.254 -3.588 -1.612 -5.155 0.000
Messier 2004 -4.100 0.816 0.665 -5.699 -2.501 -5.026 0.000
Moore 2003 1.300 1.578 2.490 -1.793 4.393 0.824 0.410
Narayan 1998 -1.700 1.346 1.812 -4.338 0.938 -1.263 0.207
Stevens 2001 -2.000 0.338 0.114 -2.662 -1.338 -5.919 0.000
Whelton 1998 -4.940 0.780 0.609 -6.469 -3.411 -6.333 0.000
Wing 1998 -2.200 1.706 2.910 -5.543 1.143 -1.290 0.197
Wolf 2004 -3.000 1.210 1.464 -5.371 -0.629 -2.480 0.013
Yeh 2003 0.500 1.550 2.402 -2.538 3.538 0.323 0.747
-3.487 0.620 0.384 -4.702 -2.272 -5.624 0.000
-14.00 -7.00 0.00 7.00 14.00
Favours Lifestyle Favours Standard Care
Figure 29. Meta-analysis weight change (kg) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -2.270 0.085 0.007 -2.436 -2.104 -26.783 0.000
Esposito 2003 -4.200 1.111 1.234 -6.377 -2.023 -3.781 0.000
Lindahl 1999 -1.800 0.118 0.014 -2.032 -1.568 -15.222 0.000
Lindstrom 2003 -1.000 0.187 0.035 -1.367 -0.633 -5.338 0.000
Moore 2003 0.100 0.534 0.286 -0.948 1.148 0.187 0.852
Wing 1998 -0.700 0.617 0.381 -1.909 0.509 -1.134 0.257
Yeh 2003 0.090 0.749 0.561 -1.378 1.558 0.120 0.904
-1.329 0.308 0.095 -1.933 -0.724 -4.310 0.000
-7.00 -3.50 0.00 3.50 7.00
Favours Lifestyle Favours Standard Care
Figure 30. Meta-analysis BMI change (kg/m2) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -2.700 0.707 0.500 -4.086 -1.314 -3.818 0.000
Lindahl 1999 -6.200 1.564 2.445 -9.265 -3.135 -3.965 0.000
Lindstrom 2003 -4.000 1.270 1.612 -6.488 -1.512 -3.151 0.002
Narayan 1998 1.900 2.677 7.168 -3.348 7.148 0.710 0.478
Stevens 2001 -1.400 0.533 0.284 -2.445 -0.355 -2.625 0.009
Wing 1998 -3.300 3.429 11.759 -10.021 3.421 -0.962 0.336
-2.781 0.816 0.667 -4.381 -1.180 -3.406 0.001
-10.00 -5.00 0.00 5.00 10.00
Favours Lifestyle Favours Standard Care
Figure 31. Meta-analysis systolic blood pressure change (mmHg) in obese people
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -1.940 0.424 0.180 -2.771 -1.109 -4.573 0.000
Lindahl 1999 -2.400 1.320 1.742 -4.987 0.187 -1.818 0.069
Lindstrom 2003 -2.000 0.788 0.621 -3.544 -0.456 -2.538 0.011
Narayan 1998 2.000 1.750 3.062 -1.430 5.430 1.143 0.253
Stevens 2001 -0.800 0.419 0.175 -1.620 0.020 -1.911 0.056
Wing 1998 -2.200 2.357 5.557 -6.820 2.420 -0.933 0.351
-1.417 0.433 0.188 -2.266 -0.569 -3.273 0.001
-8.00 -4.00 0.00 4.00 8.00
Favours Lifestyle Favours Standard Care
Figure 32. Meta-analysis diastolic blood pressure change (mmHg) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Esposito 2003 -0.100 0.104 0.011 -0.303 0.103 -0.966 0.334
Lindahl 1999 -0.150 0.158 0.025 -0.460 0.160 -0.947 0.344
Lindstrom 2003 -0.200 0.082 0.007 -0.361 -0.039 -2.432 0.015
Narayan 1998 0.100 0.228 0.052 -0.346 0.546 0.439 0.661
Wing 1998 -0.090 0.153 0.023 -0.389 0.209 -0.590 0.555
-0.136 0.054 0.003 -0.242 -0.031 -2.527 0.011
-0.50 -0.25 0.00 0.25 0.50
Favours Lifestyle Favours Standard Care
Figure 33. Meta-analysis total cholesterol change (mmol/l) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab 0.025 0.012 0.000 0.001 0.049 2.004 0.045
Esposito 2003 0.100 0.027 0.001 0.048 0.152 3.772 0.000
Lindstrom 2003 0.030 0.019 0.000 -0.007 0.067 1.596 0.110
Wing 1998 -0.020 0.057 0.003 -0.131 0.091 -0.352 0.725
0.040 0.018 0.000 0.004 0.076 2.193 0.028
-0.25 -0.13 0.00 0.13 0.25
Favours Standard Care Favours Lifestyle
Figure 34. Meta-analysis high density lipoprotein cholesterol change (mmol/l) in obese people
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -0.166 0.041 0.002 -0.247 -0.085 -4.019 0.000
Lindahl 1999 -0.070 0.157 0.025 -0.378 0.238 -0.446 0.656
Lindstrom 2003 -0.100 0.067 0.005 -0.232 0.032 -1.484 0.138
Wing 1998 -0.800 0.313 0.098 -1.413 -0.187 -2.560 0.010
-0.153 0.060 0.004 -0.272 -0.035 -2.540 0.011
-1.50 -0.75 0.00 0.75 1.50
Favours Lifestyle Favours Standard Care
Figure 35. Meta-analysis triglyceride change (mmol/l) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -0.300 0.028 0.001 -0.356 -0.244 -10.565 0.000
Lindahl 1999 -0.190 0.124 0.015 -0.433 0.053 -1.531 0.126
Lindstrom 2003 -0.100 0.067 0.005 -0.232 0.032 -1.485 0.138
Narayan 1998 0.000 0.285 0.081 -0.558 0.558 0.000 1.000
Wing 1998 0.300 0.244 0.060 -0.178 0.778 1.229 0.219
-0.146 0.083 0.007 -0.309 0.017 -1.759 0.079
-1.00 -0.50 0.00 0.50 1.00
Favours Lifestyle Favours Standard Care
Figure 36. Meta-analysis fasting plasma glucose change (mmol/l) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Lindahl 1999 -0.380 0.290 0.084 -0.949 0.189 -1.309 0.191
Lindstrom 2003 -0.600 0.183 0.033 -0.958 -0.242 -3.286 0.001
-0.538 0.155 0.024 -0.841 -0.235 -3.478 0.001
-1.00 -0.50 0.00 0.50 1.00
Favours Lifestyle Favours Standard Care
Figure 37. Meta-analysis 2-hour plasma glucose change (mmol/l) in obese people
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Lindstrom 2003 -0.200 0.058 0.003 -0.313 -0.087 -3.465 0.001
Wing 1998 0.140 0.201 0.040 -0.254 0.534 0.696 0.486
-0.085 0.161 0.026 -0.400 0.231 -0.525 0.599
-1.00 -0.50 0.00 0.50 1.00
Favours Lifestyle Favours Standard Care
Figure 37a. Meta-analysis HbA1c change (%) in obese people
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2.1. Sensitivity analysis treatment of obesity high quality studies 
 
 
 
 
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -5.500 0.109 0.012 -5.715 -5.285 -50.248 0.000
Esposito 2003 -11.000 1.515 2.295 -13.969 -8.031 -7.261 0.000
Lindstrom 2003 -2.600 0.504 0.254 -3.588 -1.612 -5.155 0.000
Whelton 1998 -4.940 0.780 0.609 -6.469 -3.411 -6.333 0.000
Wing 1998 -2.200 1.706 2.910 -5.543 1.143 -1.290 0.197
-5.086 0.970 0.942 -6.989 -3.184 -5.241 0.000
-14.00 -7.00 0.00 7.00 14.00
Favours Lifestyle Favours Standard Care
Figure 38. Sensitivity analysis weight change (kg) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -2.270 0.085 0.007 -2.436 -2.104 -26.783 0.000
Esposito 2003 -4.200 1.111 1.234 -6.377 -2.023 -3.781 0.000
Lindstrom 2003 -1.000 0.187 0.035 -1.367 -0.633 -5.338 0.000
Wing 1998 -0.700 0.617 0.381 -1.909 0.509 -1.134 0.257
-1.769 0.521 0.271 -2.790 -0.749 -3.398 0.001
-7.00 -3.50 0.00 3.50 7.00
Favours Lifestyle Favours Standard Care
Figure 39. Sensitivity analysis BMI change (kg/m2) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -2.700 0.707 0.500 -4.086 -1.314 -3.818 0.000
Lindstrom 2003 -4.000 1.270 1.612 -6.488 -1.512 -3.151 0.002
Wing 1998 -3.300 3.429 11.759 -10.021 3.421 -0.962 0.336
-3.017 0.608 0.370 -4.209 -1.825 -4.962 0.000
-10.00 -5.00 0.00 5.00 10.00
Favours Lifestyle Favours Standard Care
Figure 40. Sensitivity analysis systolic blood pressure change (mmHg) in obese people
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -1.940 0.424 0.180 -2.771 -1.109 -4.573 0.000
Lindstrom 2003 -2.000 0.788 0.621 -3.544 -0.456 -2.538 0.011
Wing 1998 -2.200 2.357 5.557 -6.820 2.420 -0.933 0.351
-1.960 0.369 0.136 -2.683 -1.236 -5.312 0.000
-8.00 -4.00 0.00 4.00 8.00
Favours Lifestyle Favours Standard Care
Figure 41. Sensitivity analysis diastolic blood pressure change (mmHg) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Esposito 2003 -0.100 0.104 0.011 -0.303 0.103 -0.966 0.334
Lindstrom 2003 -0.200 0.082 0.007 -0.361 -0.039 -2.432 0.015
Wing 1998 -0.090 0.153 0.023 -0.389 0.209 -0.590 0.555
-0.151 0.059 0.004 -0.267 -0.034 -2.538 0.011
-0.50 -0.25 0.00 0.25 0.50
Favours Lifestyle Favours Standard Care
Figure 42. Sensitivity analysis total cholesterol change (mmol/l) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab 0.025 0.012 0.000 0.001 0.049 2.004 0.045
Esposito 2003 0.100 0.027 0.001 0.048 0.152 3.772 0.000
Lindstrom 2003 0.030 0.019 0.000 -0.007 0.067 1.596 0.110
Wing 1998 -0.020 0.057 0.003 -0.131 0.091 -0.352 0.725
0.040 0.018 0.000 0.004 0.076 2.193 0.028
-0.25 -0.13 0.00 0.13 0.25
Favours Standard Care Favours Lifestyle
Figure 43. Sensitivity analysis high density lipoprotein cholesterol change (mmol/l) in obese people
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -0.166 0.041 0.002 -0.247 -0.085 -4.019 0.000
Lindstrom 2003 -0.100 0.067 0.005 -0.232 0.032 -1.484 0.138
Wing 1998 -0.800 0.313 0.098 -1.413 -0.187 -2.560 0.010
-0.172 0.075 0.006 -0.319 -0.025 -2.293 0.022
-2.00 -1.00 0.00 1.00 2.00
Favours Lifestyle Favours Standard Care
Figure 44. Sensitivity analysis triglyceride change (mmol/l) in obese people
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -0.300 0.028 0.001 -0.356 -0.244 -10.565 0.000
Lindstrom 2003 -0.100 0.067 0.005 -0.232 0.032 -1.485 0.138
Wing 1998 0.300 0.244 0.060 -0.178 0.778 1.229 0.219
-0.132 0.112 0.013 -0.353 0.088 -1.180 0.238
-1.00 -0.50 0.00 0.50 1.00
Favours Lifestyle Favours Standard Care
Figure 45. Sensitivity analysis fasting plasma glucose change (mmol/l) in obese people
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2.2. Subgroup analysis overweight/obese at risk of diabetes 
 
 
 
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Carr 2005 -2.400 0.499 0.249 -3.378 -1.422 -4.810 0.000
DPP 2005ab -5.500 0.109 0.012 -5.715 -5.285 -50.248 0.000
Dyson 1997 -0.200 0.835 0.697 -1.836 1.436 -0.240 0.811
Liao  2002 -2.500 0.145 0.021 -2.784 -2.216 -17.237 0.000
Lindahl 1999 -4.900 0.329 0.109 -5.546 -4.254 -14.873 0.000
Lindstrom 2003 -2.600 0.592 0.351 -3.761 -1.439 -4.390 0.000
Mensink 2003ab -2.300 0.842 0.709 -3.951 -0.649 -2.731 0.006
Wing 1998 -2.200 1.706 2.910 -5.543 1.143 -1.290 0.197
-2.933 0.723 0.522 -4.349 -1.516 -4.058 0.000
-6.00 -3.00 0.00 3.00 6.00
Favours Lifestyle Favours Standard Care
Figure 46. Subgroup analysis weight change (kg) in overweight/obese at risk of diabetes
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -2.270 0.085 0.007 -2.436 -2.104 -26.783 0.000
Liao 2002 -0.900 0.053 0.003 -1.003 -0.797 -17.135 0.000
Lindahl 1999 -1.800 0.118 0.014 -2.032 -1.568 -15.222 0.000
Lindstrom 2003 -1.000 0.220 0.048 -1.431 -0.569 -4.549 0.000
Mensink 2003ab -0.800 0.290 0.084 -1.369 -0.231 -2.757 0.006
Wing 1998 -0.700 0.617 0.381 -1.909 0.509 -1.134 0.257
-1.294 0.332 0.110 -1.944 -0.644 -3.902 0.000
-2.50 -1.25 0.00 1.25 2.50
Favours Lifestyle Favours Standard Care
Figure 47. Subgroup analysis BMI change (kg/m2) in overweight/obese at risk of diabetes
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -2.700 0.707 0.500 -4.086 -1.314 -3.818 0.000
Dyson 1997 -2.000 1.736 3.015 -5.403 1.403 -1.152 0.249
Lindahl 1999 -6.200 1.564 2.445 -9.265 -3.135 -3.965 0.000
Lindstrom 2003 -4.000 1.290 1.663 -6.527 -1.473 -3.102 0.002
Wing 1998 -3.300 3.429 11.759 -10.021 3.421 -0.962 0.336
-3.454 0.677 0.458 -4.781 -2.127 -5.103 0.000
-11.00 -5.50 0.00 5.50 11.00
Favours Lifestyle Favours Standard Care
Figure 48. Subgroup analysis systolic blood pressure change (mmHg) in overweight/obese at risk of diabetes
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -1.940 0.424 0.180 -2.771 -1.109 -4.573 0.000
Dyson 1997 -0.100 1.181 1.395 -2.415 2.215 -0.085 0.933
Lindahl 1999 -2.400 1.320 1.742 -4.987 0.187 -1.818 0.069
Lindstrom 2003 -2.000 0.800 0.640 -3.568 -0.432 -2.499 0.012
Wing 1998 -2.200 2.357 5.557 -6.820 2.420 -0.933 0.351
-1.834 0.341 0.116 -2.502 -1.165 -5.374 0.000
-7.00 -3.50 0.00 3.50 7.00
Favours Lifestyle Favours Standard Care
Figure 49. Subgroup analysis diatolic blood pressure change (mmHg) in overweight/obese at risk of diabetes
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Dyson 1997 0.000 0.155 0.024 -0.303 0.303 0.000 1.000
Lindahl 1999 -0.150 0.158 0.025 -0.460 0.160 -0.947 0.344
Lindstrom 2003 -0.200 0.094 0.009 -0.385 -0.015 -2.123 0.034
Mensink 2003ab -0.100 0.141 0.020 -0.375 0.175 -0.711 0.477
Wing 1998 -0.090 0.153 0.023 -0.389 0.209 -0.590 0.555
-0.130 0.059 0.003 -0.246 -0.015 -2.207 0.027
-0.50 -0.25 0.00 0.25 0.50
Favours Lifestyle Favours Standard Care
Figure 50. Subgroup analysis total cholesterol change (mmol/l) in overweight/obese at risk of diabetes
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab 0.025 0.012 0.000 0.001 0.049 2.004 0.045
Dyson 1997 -0.010 0.042 0.002 -0.091 0.071 -0.241 0.810
Lindstrom 2003 0.030 0.022 0.000 -0.013 0.073 1.380 0.168
Mensink 2003ab 0.010 0.033 0.001 -0.054 0.074 0.304 0.761
Wing 1998 -0.020 0.057 0.003 -0.131 0.091 -0.352 0.725
0.021 0.010 0.000 0.002 0.041 2.175 0.030
-0.25 -0.13 0.00 0.13 0.25
Favours Standard Care Favours Lifestyle
Figure 51. Subgroup analysis high density lipoprotein change (mmol/l) in overweight/obese at risk of diabetes
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Dyson 1997 0.000 0.109 0.012 -0.213 0.213 0.000 1.000
Lindstrom 2003 -0.200 0.067 0.005 -0.332 -0.068 -2.974 0.003
Mensink 2003ab 0.100 0.141 0.020 -0.175 0.375 0.711 0.477
Wing 1998 0.140 0.201 0.040 -0.254 0.534 0.696 0.486
-0.035 0.087 0.008 -0.205 0.135 -0.404 0.686
-1.00 -0.50 0.00 0.50 1.00
Favours Lifesyle Favours Standard Care
Figure 54. Subgroup analysis HbA1c change (%) in overweight/obese at risk of diabetes
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -0.166 0.041 0.002 -0.247 -0.085 -4.019 0.000
Dyson 1997 -0.140 0.137 0.019 -0.409 0.129 -1.019 0.308
Lindahl 1999 -0.070 0.157 0.025 -0.378 0.238 -0.446 0.656
Lindstrom 2003 -0.100 0.082 0.007 -0.260 0.060 -1.225 0.220
Mensink 2003ab -0.550 0.171 0.029 -0.886 -0.214 -3.211 0.001
Wing 1998 -0.800 0.313 0.098 -1.413 -0.187 -2.560 0.010
-0.202 0.067 0.004 -0.333 -0.071 -3.025 0.002
-1.50 -0.75 0.00 0.75 1.50
Favours Lifesyle Favours Standard Care
Figure 53. Subgroup analysis triglyceride change (mmol/l) in overweight/obese at risk of diabetes
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Dyson 1997 0.100 0.106 0.011 -0.108 0.308 0.944 0.345
Mensink 2003ab -0.150 0.089 0.008 -0.325 0.025 -1.683 0.092
Wing 1998 -0.100 0.157 0.025 -0.407 0.207 -0.638 0.524
-0.050 0.084 0.007 -0.215 0.116 -0.590 0.555
-0.50 -0.25 0.00 0.25 0.50
Favours Lifesyle Favours Standard Care
Figure 52. Subgroup analysis low density lipoprotein change (mmol/l) in overweight/obese at risk of diabetes
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Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DPP 2005ab -0.300 0.028 0.001 -0.356 -0.244 -10.565 0.000
Dyson 1997 0.100 0.283 0.080 -0.455 0.655 0.353 0.724
Lindahl 1999 -0.190 0.124 0.015 -0.433 0.053 -1.531 0.126
Lindstrom 2003 -0.100 0.078 0.006 -0.254 0.054 -1.275 0.202
Mensink 2003ab -0.300 0.088 0.008 -0.472 -0.128 -3.412 0.001
Wing 1998 -0.300 0.244 0.060 -0.778 0.178 -1.229 0.219
-0.234 0.048 0.002 -0.328 -0.139 -4.853 0.000
-1.00 -0.50 0.00 0.50 1.00
Favours Lifesyle Favours Standard Care
Figure 55. Subgroup analysis fasting plasma glucose change (mmol/l) in overweight/obese at risk of diabetes
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Lindahl 1999 -0.380 0.290 0.084 -0.949 0.189 -1.309 0.191
Lindstrom 2003 -0.400 0.256 0.065 -0.901 0.101 -1.565 0.118
Mensink 2003ab -1.400 0.521 0.271 -2.421 -0.379 -2.687 0.007
-0.567 0.245 0.060 -1.048 -0.087 -2.316 0.021
-3.00 -1.50 0.00 1.50 3.00
Favours Lifesyle Favours Standard Care
Figure 56. Subgroup analysis 2-hour plasma glucose change (mmol/l) in overweight/obese at risk of diabetes
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Chapter 3 
 
 
 
Regulatory Requirements: 
Validation of Electronic Data Capture 
 of Quality of Life Instruments 
 
 
 
Summary 
Traditionally, health-related quality of life research has predominately been 
conducted with the use of paper-and-pencil questionnaires.  However, as 
computers become more prevalent, a greater number of studies are utilizing 
electronic data in clinical trials setting. Regulatory agencies require from health 
technology manufacturers to provide evidence of the validity of the quality of life 
instruments in the electronic format as compared to paper version. The aims of 
the present chapter was to assess the comparability, reliability, and subject 
acceptability of electronic data capture (EDC) versions of Irritable Bowel 
Syndrome – Quality of Life (IBS-QOL), EuroQol (EQ-5D) and Work Productivity 
and Activity Impairment (WPAI:IBS) instruments. Comparability of EDC and paper 
questionnaires was evaluated in 72 subjects with IBS who completed a baseline 
EDC or paper questionnaire, a crossover questionnaire 24 hours later, and a 
retest of the crossover version at 1 week.  The EDC version was presented on a 
hand-held device.  Comparability of scores was assessed using paired t-test 
statistics, intraclass correlation coefficients (ICC) and tests for internal 
consistency (Cronbach’s alpha). No significant differences were found between 
scores obtained by paper questionnaire and EDC at the baseline and crossover 
assessments.  ICCs between baseline and crossover assessments ranged from 
0.83 to 0.96 for the IBS-QOL scores, 0.82 to 0.96 for the WPAI:IBS scores, and 
0.77 to 0.82 for the EQ-5D.  Internal consistency was comparable for the two data 
collection methods for the IBS-QOL overall score (0.96) and subscales and the 
EQ-5D Index (0.70 vs. 0.74). Ease of use was comparable for the two modes of 
administration, but more patients preferred EDC (47.2%) than the paper 
questionnaire (23.6%). In summary, EDC versions of the IBS-QOL, EQ-5D, and 
WPAI:IBS are comparable to paper questionnaires in terms of internal 
consistency, and test-retest reliability, and have a greater patient acceptability. 
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Introduction 
Patient-reported outcomes in clinical studies have generally been obtained by 
self-administered paper questionnaires.  Electronic data capture (EDC) with hand-
held or desktop computers is an alternative mode of data collection that offers 
many potential benefits over paper questionnaires, including customization of 
questions depending on a prior response, automatic date and time stamping, and 
immediate data entry that eliminates the possibility of subsequent entry errors.  
Several recent studies have found that patient-reported outcome data collected 
with EDC are psychometrically comparable to data collected by the standard 
paper mode, in terms of validity and reliability, and that EDC has high 
acceptance, and is generally preferred over the paper mode by the majority of 
subjects (Bushnell 2003, Drummond 1995, Pouwer 1998, Kleinman 2001, Bliven 
2001, Caro 2001).   
The validity and acceptability of EDC in studies of patients with irritable 
bowel syndrome (IBS) have not been investigated. Questionnaires useful for 
assessing outcomes in IBS studies include validated disease-specific quality of 
life and work productivity questionnaires, as well as general health questionnaires 
or utility measures for valuing IBS decrements relative to other diseases.  The IBS 
Quality of Life Questionnaire (IBS-QOL) is an IBS-specific measure with 
established internal consistency, test-retest reliability and validity (Patrick 1998, 
Drossman 2000).  The Work Productivity and Activity Impairment Questionnaire 
has been validated for IBS (WPAI:IBS) (Reilly 2004), as well as for other 
diseases, such as allergies (Reilly 1996), gastroesophageal reflux disease 
(Wahlqvist 2002) and chronic hand dermatitis (Reilly 2003).  The validity and 
reliability of the EuroQol (EQ-5D) (Kind 1996), a general health measure, has 
been established in several diseases, including inflammatory bowel disease 
(Konig 2002), rheumatoid arthritis (Hurst 1997), AIDS (Wu 2002), and IBS 
(Bushnell 2006).  The objectives of this study were to test the equivalence of the 
EDC versions of the IBS-QOL, WPAI:IBS and EQ-5D with the paper versions of 
these questionnaires in IBS patients, and to assess respondent acceptability of 
the EDC format to determine if EDC would be a valid and appropriate 
methodology for obtaining patient-reported outcomes in IBS studies.  
 
Methods  
 
Subject Enrollment and Study Design 
This was a randomized crossover study designed to test the effect of mode of 
questionnaire administration (paper vs. EDC) on patient-reported outcomes.  The 
study was conducted at two USA sites (Seattle, Washington and Rockford, 
Illinois) with recruitment through general advertisement.  Patients aged 18 years 
or above who met Rome II diagnostic criteria for IBS (Drossman 2000) and 
signed informed consent were eligible to participate.  Patients were randomized in 
equal numbers to the two sequences of questionnaire administration; efforts were 
made to recruit patients who were diverse as to gender and type of IBS 
(constipation predominant, diarrhea predominant and alternating). The study 
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consisted of the completion of a baseline questionnaire (paper or EDC), a 
crossover questionnaire within 24 hours, and a retest of the crossover 
questionnaire seven days later, i.e. a sequence of either paper-EDC-EDC or 
EDC-paper-paper (See Figure 1).   
  A hand-held electronic device with entry by stylus was used for EDC.  
One question was displayed per screen and once a response was entered the 
next item automatically appeared. There was an option to return to review or 
change a previous question and all questions required a response. There were 
minor formatting differences between the paper questionnaire and EDC, e.g. in 
fonts and bolding, but the questions themselves were essentially identical in both 
presentations.  All paper questionnaires and EDC were completed at the study 
site (research facility in Seattle and clinical setting in Rockford).   
 
Figure 1. Study design, electronic data capture (EDC) 
 
Additional information was obtained by paper questionnaire throughout the course 
of the study.  Prior to randomization, all qualified patients completed questions 
about demographics, IBS characteristics and other health information.  Following 
administration of the baseline and crossover questionnaires patients completed 
questions about the acceptability of the administration mode just completed, and 
at the crossover assessment, questions about preferences for the mode of 
administration.  At baseline, symptom severity was rated and at the retest visit, 
patients completed a question assessing the global rating of change in overall 
quality of life. All patients enrolled completed the study. Patients were 
compensated for their participation. 
 
Outcomes Questionnaires 
The IBS-QOL is a 34-item condition-specific instrument that assesses overall 
quality of life and 8 domains (dysphoria, interference with activity, body image, 
health worry, food avoidance, social reactions, sexual and relationships).  Each 
item has a five-point Likert response scale that assesses how much the item 
Baseline paper 
Crosover paper Crossover EDC 
Baseline EDC 
Retest paper Retest EDC 
24 hours 
1 week 1 week 
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describes the respondent during the past month (not at all, slightly, moderately, 
quite a bit, and extremely or a great deal).  Items scores are summed to derive 
the overall score and eight subscales; scores are transformed to a 0 to100 scale 
ranging from 0 (poor quality of life) to 100 (maximum quality of life).   
The WPAI:IBS asks questions about the effect of IBS symptoms, for 
example abdominal discomfort, abdominal pain, bloating, constipation, and 
diarrhea on ability to work and perform regular daily activities during the past 
seven days.  It consists of six items: employment status; hours missed due to 
IBS; hours missed for other reasons; hours worked; lost work productivity and 
daily activity impairment due to IBS.  Four scores are calculated: absenteeism 
(work time missed), presenteeism (impairment while at work), overall work 
productivity loss (absenteeism + presenteeism) and daily activity impairment.  
Scores are expressed as percentages, with higher scores indicating more 
productivity loss.  
The EQ-5D consists of a 5-item descriptive system and the EQ Visual 
Analog Scale (VAS).  The descriptive system records the level of self-reported 
problems on each of the dimensions of the classification (mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression) on the day the questionnaire is 
completed.  Health states defined by the descriptive system can be converted into 
a weighted health state index by applying scores elicited from general population 
samples.  Respondents describe their own health status that day using a 20cm 
VAS, ranging from 0, worst imaginable health state, to 100, best imaginable 
health state.   
 
Additional Measures 
The Short Form 36-Item Health Survey (SF-36) (Ware 1993) is a generic 
measure of functional status and well-being. It contains 36 questions that 
measure health across eight dimensions and two summary measures: the 
physical component (PCS) and the mental component (MCS).  Scores within a 
dimension are reported on a scale from 0 to 100, where higher scores indicate 
‘good health’ and 0 indicates ‘poor health’.  Items with a recall period refer to the 
last 4 weeks. 
Respondent acceptability of the two modes of administration was 
assessed with questions regarding ease of reading, ease in changing response 
and difficulty using the two formats. Responses were scored on 10 cm VAS, from 
0, not at all easy (difficult) to 100, extremely easy (difficult).  Preference for 
administration mode was assessed by asking which method was easier to use 
and which method was preferred.  Severity of IBS symptoms during the past 7 
days was assessed using a 0- to 10-point numerical scale ranging from no 
symptoms (0) to very severe symptoms (10).  At the final retest visit, patients 
rated the global change in their overall quality of life as “A lot better”, “Somewhat 
better”, "About the same", "Somewhat worse”, or "A lot worse".   
 
Statistical Methods 
Comparability of the two modes of administration was evaluated by testing 
differences in scores between the baseline and crossover assessments with 
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Student’s t-test and the intraclass correlation coefficient (ICC).  The ICC is the 
preferred measure of strength of association for determining stability of scores 
over time because it corrects for lack of independence between measurement 
intervals (Deyo 1991).  The ICC ranges between 0.00 and 1.00, and the minimal 
acceptable level is 0.70 (SACMOT 2002). 
Cronbach’s alpha was used to determine if the items within the scaled 
questionnaires, i.e. IBS-QOL and EQ-5D, had the same degree of association in 
the two modes of administration at the baseline assessment.  A minimum 
correlation of 0.70 is necessary to support internal consistency and alpha values 
between 0.85 and 0.95 are preferred (Cronbach 1951). An alpha value of 0.95 
has been previously reported for the IBS-QOL total sore (Patrick 1998). Internal 
reliability does not apply to the IBS:IBS or EQ-5D because these scores are 
single items.   
Test-retest reliability was assessed using the ICC to compare the 
relationship between the crossover assessment and the retest assessments for 
the two modes of administration.  The test-retest analysis was restricted to 
subjects rating their overall quality of life “about the same” on the global rating of 
change item at the retest visit. Previously reported ICC values for IBS-QOL total 
score was 0.86 (Patrick 1998).  
For each mode of administration, the relationship between IBS-QOL, EQ-
5D, and WPAI:IBS component scores and the physical and mental summary 
scores of the SF-36 was assessed using Pearson correlation coefficients, and the 
magnitude of the coefficients was compared across mode of administration. 
Discriminant validity of the scores from the two modes of administration (pooled 
from baseline and crossover for paper and for EDC) was compared relative to IBS 
symptom severity.  An examination of responses to the symptom severity 
question indicated that they could be categorized as low (0-5), middle (6-7) or 
high (8-10) to permit a sufficient sample size in each category. Differences in 
mean scores between severity categories were tested with analysis of variance 
(ANOVA).  
Acceptability of the two modes of administration was evaluated with 
descriptive statistics.  Differences between the ease of administration of the two 
modes were assessed with Student’s paired t-test.   
Results for work productivity scores apply only to employed patients and 
are limited by the small sample size.  All analyses were conducted using SPSS 
(SPSS 1999).  A p-value <0.05 was required for significance using two-sided 
hypothesis tests; no p-value adjustments were made for the analysis of multiple 
endpoints.    
 
Results 
Table 1 shows the characteristics of the population by initial mode of 
questionnaire administration.  Patients had a mean age of 46.2 years and were 
predominately female (86.1%); 69.4% were currently employed.  All IBS types 
were represented: 25% of patients had IBS with constipation, 33.3% of patients 
had IBS with diarrhea, and 41.7% had alternating IBS.  Compared to patients 
randomized to the paper-first group, the EDC-first group tended to be younger 
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(42.4 vs. 48.5 years), female (91.4% vs.81.1%), and less likely to have a college 
degree (18.9% vs. 34.3%).  The EDC-first group was more likely to have IBS with 
diarrhea (40% vs. 27%) and have a shorter IBS duration (13.0 vs. 16.9 years).  
Employment rates were comparable.    
Table 1 Characteristics of the population by mode of initial administration 
 Initial administration, Mean (+ s.d.) or percentage 
Characteristic EDC  (n=37) 
Paper 
(n=35) 
Total  
(n=72) 
Age (years) 
[range] 
42.4 (13.7) 
[21-72] 
48.5 (14.2) 
[21-83] 
46.2 (13.5) 
[21-83] 
Gender (female, %) 81.1 91.4 86.1 
Highest level of school (%) 
High school graduate or less 
Some college/2-yr degree 
4-year college graduate 
 
21.6 
59.5 
18.9 
 
28.6 
37.1 
34.3 
 
25.0 
48.6 
26.4 
Length of time with IBS symptoms 
(years) 13.0 (9.5) 16.9 (15.2) 14.8 (12.6) 
Type of IBS (%) 
Constipation 
Diarrhea 
Alternating 
 
20.0 
40.0 
40.0 
 
29.7 
27.0 
43.2 
 
25.0 
33.3 
41.7 
Currently Employed (%) 70.3 68.6 69.4 
EDC, Electronic Data Capture; IBS, Irritable Bowel Syndrome; s.d., standard deviation 
 
Table 2a and 2b show the mean scores for the baseline and crossover 
assessments by mode of initial questionnaire administration.  There were no 
significant differences between the baseline and crossover scores for subjects in 
either administration group.  ICC statistics were above 0.70 for each IBS-QOL, 
EQ-5D and WPAI measure for both sequences of administration.  
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Table 3 shows the results of the internal consistency evaluation of the IBS-QOL 
and the EQ-5D index at baseline and test-retest reliability of these two measures 
and the EQ-5D VAS and WPAI:IBS.  Internal consistency was comparable for 
both modes of administration of the IBS-QOL and the EQ-5D; both questionnaires 
and modes of administration demonstrated internal consistency with alpha values 
all above 0.70, with the exception of the Relationship domain of the IBS-QOL 
EDC which was 0.69.   Among stable subjects, retest statistics (ICC) were 
comparable between the EDC and paper versions of the IBS-QOL, with all 
correlations above 0.88, and for the EDC and paper versions of the EQ-5D, with 
all correlations above 0.73.  The analysis of the reliability of the WPAI:IBS was 
limited by the small sample of stable employed patients in the paper and EDC 
groups (n= 15 and 13, respectively).  However, all correlations were above 0.75, 
except for absenteeism, which was 0.68.      
 
Table 3. Internal consistency and test-retest reliability of the questionnaires by 
mode of administration 
Internal  
Consistency a Test-Retest Reliability 
b  
Paper 
(n=35) 
EDC 
(n=37) 
Paper (vs 
paper) (n=20) 
EDC (vs EDC)   
(n=20) 
IBS-QOL 
 Overall 
 Dysphoria 
 Interference with 
activity 
 Body image 
 Health worry 
 Food avoidance 
 Social reactions 
 Sexual 
 Relationships 
 
0.96 
0.94 
0.82 
 
0.79 
0.74 
0.83 
0.84 
0.75 
0.77 
 
0.96 
0.95 
0.89 
 
0.72 
0.79 
0.88 
0.80 
0.77 
0.69 
 
0.99 
0.99 
0.93 
 
0.93 
0.94 
0.95 
0.91 
0.92 
0.94 
 
0.95 
0.93 
0.96 
 
0.95 
0.88 
0.90 
0.90 
0.94 
0.92 
EQ-5D Index 
EQ-5D VAS  
0.74 
NA 
0.70 
NA 
0.77 
0.82 
0.75 
0.73 
WPAI:IBS   
 Absenteeism 
 Presenteeism 
 Work Productivity 
Loss 
 Daily Activity 
Impairment  
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
 
NA 
0.68 (n=15) 
0.75 (n=15) 
0.84 (n=15) 
 
0.90 (n=20) 
0.93 (n=13) 
0.97 (n=13) 
0.98 (n=13) 
 
0.83 (n=20) 
a As measured by Chronbach’s alpha using baseline administration; b As measured by the 
intraclass correlation coeficient using the crossover and retest assessment at 1 week 
(includes only those patients reporting no change on the global rating of change at 1 week 
retest. EDC, Electronic Data Capture; NA, not applicable; VAS, Visial Analog Scale; 
WPAI:IBS, Work Productivity Activity Impairement questionaire – Irritable Bowel Syndrome 
version 
 
Table 4 shows the correlation coefficients between the IBS-QOL, EQ-5D and 
WPAI:IBS component scores and the SF-36 physical and mental summary 
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scores.  The correlation coefficients were generally comparable for the two modes 
of administration. 
 
Table 4. Concurrence of correlation coefficients between the paper and electronic 
modes 
SF-36  Physical 
Component Summary
SF-36  Mental Component  
Summary 
 
Paper 
(n = 72) 
EDC  
(n = 72) 
Paper  
(n = 72) 
EDC  
(n = 72) 
IBS-QOL    
 Overall 0.40 a 0.36 a 0.47 a 0.46 a 
 Dysphoria  0.49 a 0.45 a 0.51 a 0.50 a 
 Interference with Activity  0.36 a 0.30 a 0.37 a 0.40 a 
 Body Image  0.21 0.23 0.32 a 0.34 a 
 Health Worry  0.32 a 0.35 a 0.43 a 0.44 a 
 Food Avoidance  0.33 a 0.24 a 0.34 a 0.34 a 
 Social Reaction  0.19 0.17 0.29 a 0.33 a 
 Sexual  0.22 0.19 0.32 a 0.24 a 
 Relationships  0.22 0.26 a 0.31 a 0.27 a 
EQ-5D     
 VAS 0.55 a 0.60 a 0.54 a 0.45 a 
 Index 0.63 a 0.60 a 0.32 a 0.47 a 
WPAI:IBS     
 Absenteeismb 0.04 0.07 -0.33 a -0.41 a 
 Presenteeismc -0.33 a -0.22 -0.35 a -0.46 a 
 Work Productivity Lossb -0.24 -0.17 -0.39 a -0.49 a 
 Daily Activity Impairment  -0.60 a -0.43 a -0.34 a -0.40 a 
a Pearson Correlation is significant at the ≤ 0.05 level (2-tailed) b (n=49 paper, n=48 EDC), 
c (n=50 paper, n=48 EDC); EDC, electronic data capture; IBS-QOL,  Irritable Bowel 
Syndrome-Quality of Life; VAS, Viasual Analog Scale; WPAI:IBS, Work Productivity 
Activity Impairement questionaire – Irritable Bowel Syndrome version 
 
Table 5 shows the mean IBS-QOL, WPAI:IBS, and EQ-5D scores for the two 
modes of administration  (pooled baseline and crossover) by level of disease 
severity.  For the paper version, there were significant differences for all 
measures by severity category (p values 0.03 to <0.0001), with higher severity 
scores associated with higher impairment.  Each of the summary scores was 
markedly different at each level of symptom severity, with the exception of the 
EQ-5D index which had comparable scores for the low and middle severity 
groups (0.78 and 0.75).  For EDC, there were significant differences by level of 
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severity for the IBS-QOL overall score (p< 0.002) and the WPAI:IBS activity 
impairment score (p<0.0001).  Again, the EQ-5D index scores did not differentiate 
the low and middle symptom severity groups (0.70 for both).  While the trend for 
the WPAI:IBS overall work productivity loss score indicated that higher symptom 
severity was associated with higher impairment (21.2%, 37.2% and 40.5% for the 
low, middle and high severity groups, respectively), the differences were not 
significant.   
 
Table 5. IBS-QOL, EQ-5D and WPAI:IBS summary scores by symptom severity 
and mode of questionnaire administration.   
IBS symptom 
severity  
Overall 
IBS-QOL 
EQ-5D  
VAS 
Overall work 
productivity loss
Activity 
Impairment 
Paper Questionnaire (pooled baseline and crossover) 
Low (0-5) Mean 77.0 0.78 19.9 21.7 
 N 24 24 18 24 
Middle (6-7) Mean 67.3 0.75 39.6 40.9 
 N 32 32 21 32 
High (8-10) Mean 54.5 0.55 41.5 53.1 
 N 16 16 10 16 
Total Mean 67.7 0.72 32.7 37.2 
 N 72 72 49 72 
P value  P=0.001 P=0.006 P=0.03 P<0.0001 
EDC administration (pooled baseline and crossover) 
Low (0-5) Mean 78.5 0.70 21.2 21.7 
 N 24 24 18 24 
Middle (6-7) Mean 67.5 0.70 37.2 38.8 
 N 32 32 20 32 
High (8-10) Mean 56.3 0.58 40.5 51.9 
 N 16 16 10 16 
Total Mean 68.7 0.67 31.9 36.0 
 N 72 72 48 72 
P value  P=0.002 P=0.29 P=0.10 P<0.0001 
EDC, electronic data capture; IBS-QOL,  Irritable Bowel Syndrome-Quality of Life; VAS, 
Viasual Analog Scale; WPAI:IBS, Work Productivity Activity Impairement questionaire – 
Irritable Bowel Syndrome version 
 
Table 6 shows ease of use for the two modes of administration by initial mode of 
administration.  Both versions were rated easy to read, regardless of which mode 
was administered first, with mean scores ranging from 87.9 to 91.8 out of a 
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possible high score of 100.  Patients reported it was significantly easier to go back 
and change answers on the EDC version than in the paper version, regardless of 
whether paper or EDC was administered first (p values 0.004 and 0.001), but 
there were no significant differences in difficulty using the two administration 
modes. 
 
Table 6. Ease of using the paper questionnaire and electronic data capture (EDC) 
by mode of first administration. 
   Paper first mean 
(+ standard deviation) 
[Range] n=35 
EDC first mean (+ standard 
deviation) 
[Range]n=37 
 Paper EDC Paper EDC 
How easy was the diary 
to read 
Not at all easy (0) – 
Extremely easy (100) 
90.7 (8.1) 
[72 – 100] 
87.9 (17.1) 
[26 – 100] 
91.8 (11.8) 
[47 – 100] 
91.2 (11.3) 
[47 – 100] 
How easy was it to go 
back and change 
answers? 
Not at all easy (0) – 
Extremely easy (100) 
77.9 (26.6) a 
[10 – 100] 
92.3 (9.1) 
[64 – 100] 
73.1 (35.8) a 
[0 – 100] 
93.5 (14.8) 
[9 – 100] 
How difficult was it to use 
this diary? 
Not at all difficult (0)  – 
Extremely difficult (100) 
10.1 (19.5) 
[0 – 82] 
9.1 (18.2) 
[0 – 94] 
13.5 (26.2) 
[0 – 100] 
5.9 (10.4) 
[0 –47] 
a P ≤ 0.004 by Student’s paired t-test 
 
Table 7 shows the preference for the two modes of administration.  Overall, 
47.2% of the patients thought the EDC version was easier to use; 23.6% thought 
the paper questionnaire was easier to use and 29.2% thought there was no 
difference between methods.  If the patients were to participate in another study, 
half would prefer EDC, 13.9% would prefer paper questionnaires and 36.1% 
would have no preference.  Missing data was negligible for both modes of 
administration. 
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Table 7. Preference for mode of administration by mode of first administration 
 Paper first, n = 35 EDC first, n = 37 Total 
Method easier to use 
 Paper and 
pencil 
 Computer 
 No difference 
 
5 (14.3%) 
 
19 (54.3%) 
11 (31.4%) 
 
12 (32.4%) 
 
15 (40.5%) 
10 (27.0%) 
 
17 (23.6%) 
 
34 (47.2%) 
21 (29.2%) 
Preferred method in 
future study 
 Paper and 
pencil 
 Computer 
 No difference 
 
5 (14.3%) 
 
18 (51.4%) 
12 (34.3%) 
 
5 (13.5%) 
 
18 (48.6%) 
14 (37.8%) 
 
10 (13.9%) 
 
36 (50.0%) 
26 (36.1%) 
 
Discussion   
Electronic data capture is increasingly being used to collect patient-reported 
outcomes data in clinical studies.  We tested three previously validated 
questionnaires (IBS-QOL, WPAI:IBS, EQ-5D) to determine if the EDC versions of 
these questionnaires were comparable to the paper versions and acceptable to 
subjects, and therefore suitable for use in IBS studies.   
We found no significant differences between the scores obtained by 
paper questionnaire and EDC and no pattern of results emerged that would 
suggest that one mode of administration was better than the other in terms of its 
psychometric properties. Scores from both modes of administration had 
comparable correlations with SF-36 measures of physical and mental well-being. 
Scores obtained by both paper questionnaire and EDC demonstrated internal 
consistency, test-retest reliability, and validity, as measured by the relationship of 
scores to symptom severity. The one exception was the EQ-5D Visual Analog 
Scale that did not differentiate the low and middle symptom severity groups in 
either mode of administration. This is not surprising considering that this is a 
general health measure for a single day and the criterion for discriminant validity 
was IBS symptom severity for the past 7 days.  Acceptability of both modes of 
administration was high, but patients reported the EDC mode was significantly 
easier for going back and changing a response, and more patients preferred EDC 
over the paper questionnaire.    
Our subjects were selected to be representative of IBS patients in terms 
of sex and type of IBS, but our results are limited by the small sample size, 
particularly among the employed (n = 49) in the investigation of WPAI:IBS work 
productivity measures. Consequently, although we failed to demonstrate 
statistically significant differences between the two modes of administration, there 
may be differences that we were unable to detect. For example, we note that 
impairement as measured by the IBS-QOL and WPAI:IBS domain scores 
uniformly decreased from baseline to the 24-hour crossover assessment, 
regardless of mode of administration, whereas the EQ-5D scores were generally 
higher when obtained by paper questionaire, regardless of whether paper was 
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administrated first or second. Investigation of these differences was outside the 
scope of the planned anaysis and warrant additional investigation. 
Another limitation of our findings is that they may not reflect the 
application of the two modes of administration in the typical clinical setting, in 
terms of missing information. Because subjects could not skip an entry in EDC 
and the site coordinators rigorously reviwed missing information from subjects, 
missing information was not found in either mode of administration. In other 
settings, paper questionnaires have had higher rates of missing information 
relative to EDC (Johannes 2000, Ryan 2002, Palermo 2004), so the advantage of 
EDC in this study may be understated. 
Despite the study’s limitations, the findings of comparability between the 
two modes of administration are consistent with the growing body of research in a 
variety of diseases, populations, and settings that has shown EDC to be 
comparable to paper questionaires. 
 
Conclusion 
Electronic data capture versions of the IBS-QOL, EQ-5D, and WPAI:IBS are 
generally comparable to paper questionnaires and demonstrate internal 
consistency, test-retest reliability, and subject acceptability; discriminant validity of 
the questionnaires by the two modes of administration is comparable.   
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Decision Analytic Model  
of Management Strategies  
for Paget’s Disease of Bone 
 
 
 
Summary 
Bisphosphonates (BP) are the treatment of choice in Paget’s disease of bone 
(PDB). As more potent BP are becoming available, it is important to assess the 
costs and effects of comparative BP therapy in order determine the optimal way 
patients with PDB should be managed. The aim of the present chapter is to 
estimate the cost-effectiveness of a new BP, zoledronic acid 5mg (ZOL), 
administered as a single 15 minutes intravenous infusion compared to risedronate 
(RIS) administered orally 30mg/day for 2 months in the treatment of PDB. A 
Markov model was developed to estimate costs and effects of ZOL versus RIS 
over a period of two years. The model consists of four half-year cycles and four 
possible health states, i.e. response, non-response, relapse, no relapse. As 
measure of effectiveness, time in response was used, with response defined as 
normalized serum alkaline phosphatase level. Probabilities and time to 
maintaining response were derived from clinical trial data. Resource use and unit 
cost estimates for the United Kingdom (UK) were based on databases, published 
literature and expert panel, and include direct costs of treatment and follow-up. 
Costs and effects were discounted by 3.5%. The analysis was performed from a 
National Health System (NHS) perspective and societal perspective in the UK. An 
extensive probabilistic sensitivity analysis was performed to address uncertainty. 
This study showed that on average, patients receiving ZOL will maintain response 
for 5.9 months longer than patients receiving RIS. Additionally, from the societal 
perspective over two years, the cost savings of ZOL versus RIS was £182 and 
from the NHS perspective, the cost savings amounted to £195. The key driver of 
cost-effectiveness in the model was the number of re-treatments required over 
two years. The average number of treatments per year was estimated at 0.59 in 
the ZOL group and 0.93 in the RIS group. When taking uncertainty into account, 
all simulated outcomes indicated that ZOL is both cost-saving and more effective. 
In conclusion, when compared to the standard therapy RIS, ZOL is the dominant 
strategy in the management of PDB due to superior effectiveness and lower cost. 
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Introduction 
Paget’s disease of bone (PDB) known also as osteitis deformans is the second 
most common metabolic bone disease in the UK after osteoporosis, affecting up 
to 5% of those aged 55 years and over. Epidemiological studies undertaken over 
the last 30 years have suggested high prevalence rates of PDB in Britain, with 
somewhat lower rates in Australia, North America and parts of Western Europe 
(van Staa 2002).  
PDB is a chronic skeletal disorder characterized by localized areas of 
increased bone remodeling, bone hypertrophy and abnormal bone structure 
(Paget 1877). PDB can affect one or more bones within the skeleton.  Prevalent 
signs and symptoms of PDB are skeletal deformity and bone pain. Complications 
of PDB can involve bone (deformity, pathological fracture, neoplastic 
degeneration), joints (secondary osteoarthritis), the nervous system (deafness, 
spinal cord compression), and the vascular system (steal syndrome) (Kanis 
1998).  
There has been a dramatic change in the therapeutic approach to 
patients with PDB over the last 40 years. In the 1960s, only symptomatic therapy 
could be given, with control of pain the main objective. Analgesics and 
nonsteroidal anti-inflammatory drugs were the most commonly used agents. From 
1968 onwards, antiosteoclastic agents became available, including calcitonin, 
plicamycin (mithramycin) and etidronate, a first-generation bisphosphonate (BP) 
(Devogelaer 2002). Limitations of these agents, especially potentially deleterious 
effects on bone mineralization with etidronate, paved the way for increasingly 
potent second- and third-generation of nitrogen containing bisphosphonates, 
including clodronate (clodronic acid), pamidronate, alendronate, RIS and recently 
ZA. With the newer BPs, long-term remission of pagetic lesions, as well as 
prevention of long-term complications in both symptomatic and asymptomatic 
patients may be expected (Devogelaer 2002). 
Biochemical markers of bone turnover have been used for many years in 
the diagnosis and monitoring of treatment for PDB (Delmas 1997). All clinical 
studies of BP in PDB have been short term and have used total serum alkaline 
phosphatase (total ALP), the key biochemical marker of bone turnover as the 
primary endpoint. It is believed that suppression of ALP can reduce the risk and 
prevent progression of complications of the PDB. 
As more potent BPs are becoming available, it is important to assess the 
long-term costs and effects of comparative BP therapy in order determine the 
optimal treatment for patients with PDB. The increased potency and longer 
duration of action of newer BP could compensate for their marginally increased 
cost compared with older BP. This study describes an evaluation of the cost-
effectiveness model of two years’ treatment with either ZOL or RIS for PDB 
patients from societal and NHS perspective in the UK. 
 
Methods 
A cost-effectiveness analysis (CEA) was performed to compare the costs and 
effects of ZOL treatment, a single 5 mg infusion over 15 minutes, and RIS 
treatment, 30 mg/day orally given for two months, in patients with PDB over two 
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years. The CEA was based on the pooled analysis of the two identical registration 
clinical trials of ZOL versus RIS in PDB patients, published literature and expert 
panel (Reid 2005, Hosking 2007). Given the small number of observations 
beyond two years follow-up, a time horizon of two years was chosen. 
The analysis was performed from two perspectives, the societal and NHS 
perspective in UK. The NHS perspective is usually required by NICE in their 
technology appraisals (NICE 2004). Additionally, we included the societal 
perspective, limited to direct costs. Indirect costs due to production losses were 
not included since the prevalence of PDB increases with age, (Eekhoff 2004) and 
occur mostly in people over 55 years old. Patients in the two clinical trials had a 
mean age of 70.8 years in the ZOL group and 70.0 years in the RIS group (see 
Table 1) (Reid 2005). A discount rate of 3.5% was used for costs and effects in 
the second year, according to NICE guidelines (NICE 2004).   
The clinical studies have been described in detail elsewhere and we 
summarize the main characteristics relevant to the present study here (Reid 
2005). The main patients’ characteristics are provided in Table 1.  
 
Table1. Patient characteristics  
 ZOL RIS 
Number of patients 176 171 
Sex – Male (%) 68.1 67.4 
Age (years) Mean (SD) 70.8 (9.82) 70.0 (10.73) 
Age – ≥65 years (%)  74.7 73.7 
Baseline ALP (U/L) Mean (SD) 427.8 (320.99) 425.3 (312.05) 
 
The primary efficacy variable of the clinical studies was the proportion of patients 
who achieved therapeutic response. Therapeutic response was defined as a 
reduction of at least 75% from baseline in total serum alkaline phosphatase (total 
ALP) excess (difference between measured level and midpoint of the normal 
range) or normalization of ALP at the end of six months. A secondary efficacy 
variable was normalization of ALP, i.e. return of ALP to within the normal range. 
The normal range of ALP for male and female between the age of 20 and 58 
years is 31-110 U/L whereas for male and female above 59 years of age the 
normal range is 35-115 U/L. Note that the ALP-normalized patients form a sub-
sample of the patients with a therapeutic response.  
Both outcome measures have their own rates for response and relapse, 
and time-to-response. The results of the pooled studies showed statistically 
significant superiority of ZOL for the proportion of patients who were therapeutic 
responders at 6 months (96%) compared to RIS (74%, p<0.001). The proportion 
of patients with ALP normalization was statistically superior with 5 mg ZOL (89%) 
to that with RIS (58%, p<0.001).  Additionally, the time to therapeutic response 
differed significantly, 62.8 days in the ZOL group and 110 days in the RIS group 
(p<0.001). The time to normalization was 92 days in the ZOL group and 136 days 
in the RIS group [p < 0.001] (Reid 2005).  
Patients who met the definition of therapeutic response at the end of the 
core study (at six months), were asked to participate in an extended observation 
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study (Hosking 2007). In this extended observation period patients were followed-
up every six months to measure ALP until levels returned to within 20% of 
baseline or up to the cutoff date of 30-Sep-2004 whichever came first. A partial 
disease relapse was defined in the clinical protocol as an increase in ALP of at 
least 50% from the ALP measurement at month 6 and at least 1.25 times the 
upper normal limit. With up to 18 months follow-up after the end of the core study 
(24 months overall), 99% of patients in the ZOL group and 70% of patients in the 
RIS group had had no partial disease relapse. For patients who were normalized 
at 6 months, these percentages were 100% and 76%, respectively. Table 2 
presents the results of the extension trial for patients who were normalized at 6 
months.  
 
Table 2. Relapse rate estimates 
Follow-up 
interval (days) 
No of 
events 
No of patients at risk 
(adjusted for censoring) 
Probability relapse during 
6-month interval 
ZOL 
<182 0 141.5 0% 
182 – 364 0 132 0% 
364 - 546 0 117.5 0% 
RIS 
<182 2 89.5 2% 
182 – 364 9 84.5 11% 
364 - 546 9 68.5 13% 
 
A Markov model was developed to estimate costs and effects of ZOL versus RIS 
over a period of two years (see Figure 1). The model consists of four half-year 
cycles and four possible health states: ‘responder’, ‘non-responder’, ‘relapse’ and 
‘no relapse’. At the end of every six-month period, ALP measurement is 
performed and used to classify patients in to one of the four health states. This 
means that the physician does not know whether a patient is a responder or had 
a relapse until the end of the six-month period. Response in the CEA was defined 
as normalization of ALP. The cycle length of the model was chosen to coincide 
with the frequency of follow-up visits in daily practice. 
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Figure 1. Graphical presentation of the model, ZOL treatment arm 
 6 months 6 months 6 months 6 months 
 Period 1 Period 2 Period 3 Period 4 
            
          No relapse 
       No relapse   
        Relapse 
            
    No relapse    Responders 
  ZOL   Relapse ZOL  
 Responders     Non-responders 
          
        ZOL  No relapse 
       Responders   
        Relapse 
            
    Relapse  ZOL  Responders 
Arm  
ZOL     Non-responders ZOL  
        Non-responders 
            
            
          No-relapse 
       No relapse   
        Relapse 
     ZOL       
    Responders    Responders 
     Relapse ZOL  
        Non-responders 
  ZOL          
 Non-responders         
      ZOL  No-relapse 
     ZOL  Responders  
    Non-responders  Relapse 
         
        ZOL  Responders 
       Non-responders ZOL  
        Non-responders 
            
 
At the end of period 1, patients in ‘non-responder’ health status receive another 
course of treatment with ZOL or RIS, depending on treatment group, whereas 
patients in ‘responder’ health status continue to stay in response. After another 
six months (period 2), a further ALP measurement is performed and patients in 
‘non-responder’ health status are classified again as either a ‘responder’ or a 
‘non-responder’ to the second course of BP therapy. Based on ALP level at the 
end of period 2, patients who are in ’responder` status are either classified as ‘no-
relapse’ or ‘relapse’. After period 3 and 4, the same algorithm applies; thus, a 
maximum of four treatment courses can be given. 
It was assumed that patients who were in ‘non-response’ or ‘relapse’ 
health status start another course of the same treatment (i.e. no cross-over 
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occur). These re-treatments did not occur in the clinical studies, as this was not 
part of the protocol. However, in daily practice, patients whose ALP levels go 
above the upper limit of the normal range will be re-treated, as will patients who 
do not respond to the first treatment. 
Outcome was expressed as time maintaining response over the 2-year 
period, with response defined as ALP normalization. To determine time 
maintaining response we used data from the clinical studies on time to 
therapeutic response, so in the first period after treatment, time maintaining 
response is 6 months minus time to response. In a period with no response the 
time maintaining response is 0, in a period with no relapse this is 6 months, and in 
the period where relapse occurs, we assumed this takes place (on average) 
halfway through the cycle, giving a time in response of 3 months. 
All estimates of probabilities that were used in the model are presented in 
Table 3. In the ZOL group, no relapses occurred. Since a true relapse rate of zero 
seems unlikely, we have assumed a small non-zero percentage, i.e. 1% per 6 
months. 
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The clinical study only provided estimates for the rate of response to the first 
treatment course. The probability of response after an initial non-response was 
derived from the sub-sample of patients in the trials who had previously used BP 
since it has been suggested that patients treated for PDB may gradually become 
resistant to BP therapy (Selby 2002, Johnston 1980). In the trials, the RIS group 
that had previously used BP had a response rate of 46%, 21% lower than for the 
whole group. This response rate was assumed to be a good proxy for the 
probability of response in the period after non-response. The model assumed that 
the same reduction of 21% would apply to the ZOL group, i.e. a response rate of 
71% was used for patients who did not respond to the first cycle of ZOL. 
Complications of PDB (e.g. deformity, pathological fracture, deafness, 
etc) are not included in the model as they were not captured in the clinical trials 
and precise data could not be taken from literature. 
 
Costs 
No cost data was collected in the clinical studies. Instead, resource use has here 
been estimated based on literature and clinical experts in the UK. The following 
assumptions were made in the model: 
1. PDB in the UK is treated both by specialists and general practitioners 
(GPs). Given the specificity of the two types of drug administration, we 
assumed that half of the patients taking oral medication visit a GP and 
half visit a specialist, whereas all patients that receive an infusion visit a 
specialist. 
2. Oral BPs are poorly absorbed from the gastrointestinal tract causing 
upper gastrointestinal side effects, such as heartburn and dyspepsia 
(Kelly 1997). In the model, it is assumed that 15% of patients taking oral 
BP will manifest upper gastrointestinal side effects (Siris 2003) and are 
therefore treated with a proton pump inhibitor (PPI), i.e. omeprazole 
generic, for 2 months. 
3. It has been suggested that intravenously administered BP could induce 
an acute febrile reaction, so called ‘flu like syndrome’ (FLS) (Langston 
2004). In the model, it is assumed (based on the trial data) that 11% of 
the patients receiving intravenously BP manifested an acute febrile 
reaction (CZOL 2004) and are therefore treated with analgesics, 
paracetamol, for 3 days. 
4. Non-responders to BP treatment are considered more severe cases and 
are therefore treated with analgesics (ibuprofen) for 1 month on average 
to relieve the osteoarthritis pain caused by misshapen bones. 
5. Concomitant intake of calcium and vitamin D is recommended during BP 
treatment. In concordance with product labeling, (EMEA 2007) the model 
assumed 10 days of calcium and vitamin D intake for ZOL and 2 months 
for RIS. 
Resource use was defined for all four health states: ‘response’, ‘non-response’, 
‘relapse’, ‘no relapse’, over a period of 6 months. The costs of extra medication, 
e.g. omeprazole, paracetamol, ibuprofen, calcium and vitamin D are those of 
generic products in the UK (EMIMS 2005). A summary of resource use for each 
health state is presented in Table 4.  
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Estimates of UK unit costs for each health care service were derived from 
nationally representative data sources (Netten 2005). Costs were calculated to 
cover medical procedures performed in a two years time frame for patients with 
PDB and include direct costs of treatment and follow-up. The analysis was 
performed from societal and NHS perspectives in the UK. When the societal 
perspective is applied the cost of prescription and of patient travel expenses to 
hospital and GPs are added to the analysis. A summary of unit costs is provided 
in Table 5. In Table 4, the resource use is combined with the unit costs to arrive at 
a cost estimate for each health state. 
 
Table 5. Unit Costs  
Cost breakdown Unit Cost (£) 
Drug Acquisition  
Zoledronic acid 
Risedronate (EMIMS 2005)  
 
Per cycle 
Per cycle 
 
305.62 
305.62 
Infusion  
Nurse time (Netten 2005)  
Medical equipment for infusion* (NHS 2004)  
 
Per hour 
Per 
administration 
 
34 
5 
General Practitioner visit (Netten 2005)  Per visit 28 
Specialist visit (Netten 2005)  Per visit 29 
Analgesics (ibuprofen, paracetamol generic) (EMIMS 
2005) Per month 2 
Proton Pump Inhibitor, omeprazole generic (EMIMS 
2005) Per month 8 
ALP measurement (NHS 2004) Per unit 7 
Calcium Vitamin D generic (EMIMS 2005) Per day 0.15 
Patient travel expenses to GP (Netten 2005) Per visist 7 
Patient travel expenses to hospital*  Per vistit 18 
Prescription oral medication (Netten 2005) Per prescription 5 
* Personal communication and data on file Manchester Royal Infirmary 
 
Sensitivity analysis 
To investigate the impact of assumptions made during the analysis and to test the 
robustness of results given variation in the data input, a probabilistic sensitivity 
analysis was performed (Briggs 2000). Probabilistic sensitivity analysis involves 
specifying distributions for input variables in the model allowing the joint effect of 
input uncertainty to be assessed. Within our model there are two main categories 
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of variables: model probabilities related to the four health states which have a 
beta distribution and variables relating to the level of resources consumption with 
their associated unit cost which have a normal distribution. The parameters of all 
beta distributions were derived from the point estimate of the probability and the 
sample size. The standard deviations of the normal distributions (for the cost 
estimates per health state) were based on the assumption that limits of the 95% 
confidence interval are the mean ± 20%. This margin for costs reflects the 
uncertainty about the resource use in each health state. Having specified 
distributions for the relevant variables, the probabilistic sensitivity analysis was 
undertaken by randomly sampling from each of the distributions and calculating 
the expected costs and expected time in response for that combination of input 
values. This process formed a single replication of the model results, and a total 
of 2500 replications were performed in order to examine the distribution of the 
resulting costs and effects. A summary of the point estimates of variables, and 
their 95% confidence interval used in the probabilistic sensitivity analysis are 
presented in Table 3. 
 
Results 
Table 6 presents the results. From a societal perspective, it was estimated that 
over two years the costs in the ZOL group were lower (£590) than in the RIS 
group (£773) leading to savings of £182, after discounting. Also, in the ZOL group 
the time maintaining response was 5.9 months higher (ZOL 19.5 months, RIS 
13.6 months). Thus, ZOL is the dominant treatment. The average (discounted) 
cost per year was estimated at £295 for ZOL and £386 for RIS, while the average 
number of treatments per year was estimated at 0.59 in the ZOL group and 0.93 
in the RIS group.  
When the NHS perspective was taken into consideration, patient travel 
expenses and prescription costs were excluded. This led to a slightly higher cost 
savings of £195, after discounting. The average cost per year was now estimated 
at £260 for ZOL and £357 for RIS. 
In both perspectives, costs for ZOL are about 3% higher than RIS in the 
first 6 months, while they are about 45% lower in the subsequent three periods. 
 
Table 6. Model Outcomes  
 
Costs (£) 
Societal 
perspective 
Costs (£) 
NHS perspective 
Effects 
(ALP normalized 
months) Time 
ZOL RIS ZOL RIS ZOL RIS 
Period 1 381 368 363 350 2.7 0.9 
Period 2 88 181 70 167 5.5 3.7 
Period 3 66 123 48 109 5.8 4.9 
Period 4 59 109 41 95 5.9 4.7 
Total (2 years) 594 780 522 721 19.9 13.9 
Total discounted 590 773 519 714 19.5 13.6 
 Difference £183 Difference £195 Difference 5.9 
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Sensitivity analysis 
The results of the 2500 replications of the probabilistic sensitivity analysis are 
presented on the cost-effectiveness plane in Figure 2. The plane is divided into 
four quadrants indicating four possible situations in relation to the additional costs 
and additional health outcome effects of ZOL compared to RIS. The graph shows 
that all the simulated values are in the South-East quadrant, indicating that ZOL is 
the dominant strategy with both increased time in response and a reduction in 
costs. 
  
Figure 2. Joint distribution of cost and effects on the cost-effectiveness plane 
 
 
Discussion 
The current study shows that treatment of PDB with ZOL instead of RIS is more 
effective and cost-saving, even when taking uncertainties into account. These 
savings are estimated at about £190 per patient over a period of two years, which 
is a decrease of 24%. The measure of effectiveness used in this study was 
maintaining ALP normalization. A possible final outcome would be complications 
of PDB. However, unlike measures such as fracture rate in osteoporosis, the 
symptoms and complications of PDB are either rare (fracture) or difficult to 
measure/quantify in randomized controlled trials (warmth, nerve entrapment, 
osteoarthritis in weight-bearing joints) (Drake 2001). Currently, the aim of PDB 
therapy is to achieve normalization of biochemical markers of bone turnover, in 
particular serum alkaline phosphatase, in order to obtain full remission. This 
objective aims at controlling the activity of the disease and preventing 
complications (Delmas 1997, Selby 2002, Drake 2000, Jacobs 1999, Rousiere 
2003). Therefore, ALP was taken as an adequate and relevant intermediate 
outcome in this study. However, the complications of PDB may be expected to 
have a high economic impact and thus further research in PDB is needed, to 
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explore the long term-effects of BP therapy on complications of PDB. Recently, a 
large multicentre trial (PRISM) has been set up in the UK to address the effects of 
the anti-Pagetic treatment on symptoms, complications, as well as ALP level in 
PDB (PRISM 2005). Until such information is available, using an intermediate 
measure of effectiveness is necessary.  
In the clinical studies, no economic data was gathered. Furthermore, little 
is known about resource use of patients with PDB. In this study, we relied on 
literature and expert panels in order to estimate resource use. This is clearly a 
source of uncertainty, but we expect this uncertainty to be limited, as the 
management of PDB patients is rather straightforward. By using margins of 
plus/minus 20% in the sensitivity analysis, we addressed the uncertainty, and it 
did not have an impact on the outcome of the study. 
This study has a limited time frame, which is based on the availability of 
data. The number of patients observed in the extension trial between after 18 
months is rather small, as the follow-up duration was intended to be 18 months. 
However, based on the small group of patients observed between 18 and 30 
months (at 18 months 111 patients at risk in the ZOL group and 55 in the RIS 
group, at 30 months 52 and 23 at risk, respectively) it seems reasonable to 
assume that the difference between the relapse rates observed in the first 2 years 
will continue to increase over time, leading to increased cost savings and time in 
response associated with ZOL. Thus, the current time frame may be assumed to 
lead to a conservative estimate of the cost-effectiveness of ZOL. 
One major issue with the use of oral BP that was not addressed in this 
study is compliance with the dosing regimen. Although there are no studies 
specifically designed to study compliance, several clinical studies have reported 
data on it (Conte 2004). These show that non-compliance is a serious problem in 
long-term treatment with oral BP for osteoporosis and bone metastasis from 
advanced cancer (Conte 2004). It can be assumed that the compliance with oral 
therapy outside the controlled conditions of a clinical trial is even worse. As ZOL 
is given once by infusion, this problem occurs only in the RIS group, where 
patients are required to take the drug orally daily for 2 months. Non-compliance 
can result in a decreased response in the RIS group. Disregarding this issue 
means that a conservative estimate of cost-effectiveness has been made. 
In conclusion, we found that ZOL is a more cost-effective treatment in 
management of PDB with superior effectiveness and lower cost, when compared 
with the oral standard therapy RIS. Thus, ZOL will most likely be the preferred 
treatment in the long-term management strategies of PDB, both from an 
economical and a patient convenience point of view. 
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Chapter 5 
 
 
 
Probabilistic Cost-Effectiveness Model  
of Lifestyle Intervention in the 
Prevention and Treatment of Obesity 
 
 
 
 
Summary 
The use of decision-analytic modeling in health technology assessments has 
increased exponentially in recent years. Mathematical modeling is used widely in 
economic evaluations of medical interventions. Models represent an important 
analytic framework to generate estimates of cost-effectiveness based on a 
synthesis of available data and explicit representation of uncertainty. The aim of 
the present chapter was to develop a decision analytic model that quantifies the 
lifetime health and economic consequences of preventing and treating obesity 
with lifestyle intervention in Switzerland. A Markov model was developed 
comparing lifestyle intervention and standard care in overweight and obese 
people. Changes in weight and cardiovascular risk factors over time are modeled 
from reduction in body mass index (BMI), systolic blood pressure, total cholesterol 
and high density lipoprotein cholesterol in three-year active treatment period 
based on data from meta-analysis. A probabilistic sensitivity analysis is 
performed. Three groups of people are followed in the analysis: overweight 
subjects (BMI 27 kg/m2), borderline subjects (BMI 30 kg/m2) and moderate obese 
subjects (BMI 33 kg/m2). The cost-effectiveness of interventions is compared 
using incremental costs, incremental effects: life-years, quality adjusted life-years, 
and the cost-effectiveness ratio. Lifestyle intervention results in increased survival 
duration and quality of life over lifetime. Compared with standard care, the 
average incremental cost of lifestyle intervention is lower in borderline subjects 
and moderate obese subjects and higher in overweight subjects. Lifestyle 
intervention dominates standard care being less costly and more effective in 
borderline female subjects’ aged 35 to 55 years, borderline male subjects’ aged 
25 to 60 years, moderate obese female subjects’ aged 45 years and moderate 
obese male subjects’ aged 55 years. In conclusion, our economic analysis 
suggests that lifestyle intervention is cost-effective in the long-term prevention 
and treatment of obesity.   
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Introduction 
Obesity has become one of the most common medical problems due to an 
explosive increase in the number of people affected by the disease. Obesity is 
associated with numerous co-morbidities such as cardiovascular disease, 
diabetes, and hypertension, certain cancers and sleep apnoea (Poirier 2006). 
Several different treatments are available for the management of obesity: non-
pharmacological interventions (e.g. dietary interventions, physical exercise, 
lifestyle interventions, etc.), pharmacological interventions (e.g. sibutramine, 
orlistat, etc.), alternative medicine (e.g. acupuncture, hypnotherapy, etc.) and in 
the case of morbid obesity, surgical treatments (e.g. gastric bypass, gastroplasty, 
etc). In the latest years a specific interest is focused on prevention strategies that 
aim to stop the progression of overweight to obesity and the occurrence of obesity 
complications (World Health Organization 2000).   
The economic burden of obesity is substantial. In Switzerland, obesity 
related expenditures are estimated to a total CHF 2691 million, or almost 2.3-
3.5% of total health care spending (Schmid 2005). The top five co-morbidities 
responsible for the increased costs associated with overweight and obesity are 
hypertension, hypercholesterolemia, diabetes mellitus, stroke and coronary heart 
disease (Neilson 2005). Thus, the economic costs of obesity represent a sizeable 
issue for the Swiss healthcare system. The increasing burden on the budgets of 
health care providers has resulted in considerable interest in assessing new and 
existing treatments for their clinical effectiveness and cost-effectiveness. Such an 
assessment enables decisions to be made on the allocation of limited healthcare 
resources while ensuring that any additional cost is justified by the additional 
benefits (Neumann 2005). Among several treatments available, lifestyle 
interventions have been documented to lead safely to improvements in metabolic 
abnormalities such as increased body weight, dyslipidemia, elevated blood 
pressure and glucose control that are linked to the development of obesity, 
diabetes, and cardiovascular disease (Pritchett 2005). Lifestyle programs are 
multi-factorial interventions that are designed for each patient or group of patients 
according to their risk factor status and include promotion of healthy lifestyle 
habits, dietary counseling, physical exercise training and behavioral change 
targets. 
The aim of the present study is to develop a decision analytic model to 
quantify the lifetime health and economic consequences of preventing and 
treating obesity with lifestyle intervention in Switzerland. 
 
Methods 
A Markov decision model (Sonnenberg 1993) was developed to evaluate the 
lifetime effect of a three-year lifestyle intervention compared with standard care in 
overweight and obese people. Seven states are modeled: ‘normal’, if patients are 
overweight with body mass index (BMI) 25 to 29.9 kg/m2 or obese with BMI ≥ 30 
kg/m2 and free of complications, ‘hypertension’ if patients are overweight or obese 
and developed hypertension (systolic blood pressure greater than 140 mmHg and 
diastolic blood pressure greater than 90 mmHg, JNC 1997), 
‘hypercholesterolemia’ if patients are overweight or obese and developed 
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hypercholesterolemia (total serum cholesterol ≥ 6.2 mmol/l, EP 2001), ‘diabetes’ if 
patients are overweight or obese and developed type 2 diabetes (fasting glucose 
of at least 7.8 mmol/l or 2-hour glucose of at least 11.1 mmol/l, Alberti 1998), 
‘stroke’, if patients are overweight or obese and developed stroke, ‘coronary heart 
disease’ if patients are overweight or obese and developed coronary heart 
disease and ‘death’: patients can die and enter this point at any time in the model. 
A diagrammatic representation of the Markov model is presented in Fig.1. 
 
Figure 1. Markov model diagram 
Stroke
Death
Coronary heart 
disease
Normal
Hypertension Diabetes Hyper-cholesterolemia
 
 
Following the lifestyle intervention patients enter into the model in the normal 
health state. The cycle length is one year. At the end of each one-year period, 
proportions of the cohort can move from one disease state to another or stay in 
the same disease state. The transition probabilities are based on the disease 
progression with age, sex, BMI and cycle number. The model is run over a period 
of 60 years to estimate the lifetime costs and effects of the intervention. Patients 
entering the model have a minimum age of 25 years. The model runs until 
subjects reach the age of 85 years considering that the average life expectancy in 
Switzerland is 77.3 years for men and 82.8 years for women (World Health 
Organization 2005). 
Because of the complexity of the interrelationship between the degree of 
overweight/obesity and the five obesity-related complications, we made several 
assumptions. It is assumed that those diseases for which obesity is a risk factor 
are not interconnected and therefore are not counted as an additive effect on the 
lifetime health and costs in the model. For simplicity, the possibility of having 
concomitant diabetes, hypertension and hypercholesterolemia is not incorporated 
into the model. One reason for excluding the correlation between the existing co-
morbidities is the absence of prevalence data for Swiss population. This 
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assumption is most probably underestimating the burden associated with obesity 
co-morbidities. 
A hypothetical cohort of 10000 subjects overweight or obese receives a 
lifestyle program or standard care intervention for a period of three years. The 
components of lifestyle intervention are regular physical activity and healthy 
eating, including diets rich in fruits and vegetables. In our model, lifestyle 
intervention is adapted from Finish Diabetes Prevention Study (Lindström 2005) 
and consist in detailed dietary recommendations: to limit the total intake of fat to 
less than 30% of energy consumed and of saturated fat to less than 10%, and to 
increase fibre to at least 15g/1000 kcal as well as advice about specific food 
types, and asked to undertake moderate exercise for at least 30 minutes per day. 
Lifestyle intervention group members attended dietitian sessions and supervised 
exercise sessions during the first three years. For overweight people, standard 
care consists in no intervention whereas for obese people standard care consists 
in basic dietary counseling and physical exercise sessions (see cost description 
section). Treatment effect is modeled as a reduction in BMI, systolic blood 
pressure, total cholesterol, and high density lipoprotein cholesterol based on data 
obtained in three-year active treatment. It is assumed that the effect of lifestyle 
intervention on cardiovascular risk factors and weight loss is maintained up to six 
years, thereafter subjects start to regain weight linear for a period of four years 
i.e. after ten years weight loss went back to the initial weight.  This assumption is 
sustained by the extended follow-up of the Finnish Diabetes Prevention Study 
(Lindstrom 2006) which lasted 7 years and resulted in sustained lifestyle changes 
that were maintained after the individual lifestyle counselling stopped. The study 
reported a 43% reduction in the relative risk related to the success in achieving 
the intervention goals of weight loss, reduced intake of total and saturated fat, 
increased intake of dietary fibre and increased physical activity. In the cost-
effectiveness model, we assume that all patients developing hypertension, 
diabetes and hypercholesterolemia are diagnosed and treated. We also assumed 
that patients remain in those states once they have entered, unless they develop 
cardiovascular disease or die.  
 
Parameter estimates and data sources 
We estimate our model using data from a variety of secondary sources, which we 
will describe in detail. The correlation between BMI and annual risk of developing 
hypertension, diabetes, and hypercholesterolemia is calculated based on two 
large American prospective, epidemiological studies: the Nurses Health Study 
and the Health Professional Follow-up Study, both summarized by Field et al. 
2001 (Table 1). Intermediate values of BMI have been interpolated using the 
polynomial function.  
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Table 1. Estimated yearly risk of obesity complications 
BMI Normal to Diabetes  (%) 
Normal to Hypertension 
(%) 
Normal to Hyper-
cholesterolemia  (%) 
 Male Female Male Female Male Female 
22 1.16 0.96 1.65 1.75 5.13 6.27 
23 1.46 1.28 1.84 1.92 5.32 6.42 
24 1.82 1.63 2.03 2.08 5.47 6.52 
25 2.24 1.99 2.23 2.23 5.58 6.55 
26 2.69 2.37 2.44 2.36 5.66 6.51 
27 3.17 2.75 2.63 2.48 5.70 6.42 
28 3.67 3.14 2.83 2.59 5.72 6.29 
29 4.19 3.52 3.02 2.70 5.72 6.13 
30 4.71 3.90 3.19 2.79 5.71 5.97 
31 5.22 4.27 3.35 2.87 5.69 5.84 
32 5.71 4.62 3.50 2.94 5.66 5.77 
33 6.18 4.95 3.62 3.00 5.64 5.80 
34 6.61 5.25 3.73 3.06 5.63 5.97 
35 7.00 5.52 3.80 3.11 5.63 6.34 
36 7.33 5.76 3.85 3.14 5.65 6.95 
37 7.61 5.95 3.87 3.18 5.69 7.87 
38 7.80 6.10 3.86 3.20 5.76 9.17 
39 7.92 6.20 3.80 3.22 5.87 9.17 
40 7.95 6.24 3.71 3.23 6.01 9.17 
 
The risk of complications has been adjusted according to age, sex and 
prevalence of hypertension, diabetes and hypercholesterolemia (Table 2) based 
on the information provided by the Swiss health survey (SFSO 2006).  
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Table 2. Yearly probability of developing obesity co-morbidities in Switzerland by 
age and sex 
Hypertension  
(%) 
Diabetes  
(%) 
Hypercholesterolemia  
(%) Age 
group 
Male Female Male Female Male Female 
25-34 1.6 0.6 0.7 0.1 0.8 0.5 
35-44 3.6 2.2 0.9 0.8 4.4 1.5 
45-54 7.7 7.4 2.1 1.9 8.1 5.2 
55-64 18.5 18 6.9 3.1 14.4 11.7 
65-74 27 26.5 8.1 5.8 16.6 15.3 
75+ 25 33.2 11.2 8.5 15.3 15.0 
 
The mean BMI by age and gender is taken from World Health Organization 
country profile (2005) and Monica Project (Mähönen 2000) and presented in 
Table 3. 
 
Table 3. Mean BMI of the Swiss population by age and gender 
Body Mass Index 
Age group 
Male Female 
25-34 24.6 24 
35-44 26.2 24.5 
45-54 27.7 25.6 
55-64 27.8 27.1 
65-74 28 27 
75+ 28 27 
 
The risk of developing coronary heart disease and stroke from ‘normal’, 
‘hypertension’, ‘diabetes’, ‘hypercholesterolemia’ states are based on a risk 
equation from the Framingham cohort study (Anderson 1990). Risk factors are 
age, sex, systolic blood pressure, total cholesterol, high density lipoprotein 
cholesterol, presence of diabetes and smoking status. Data on systolic blood 
pressure, total cholesterol and high density lipoprotein of the Swiss population are 
obtained from Monica Project (Mähönen 2000). The mean systolic blood pressure 
increases with age in both men and women, rising from 127 mmHg in men aged 
25-35 years to 145 mmHg in men aged 75 years and over, and from 115 to 144 
mmHg in women. The mean blood cholesterol levels increases with age with a 
slight decrease in the oldest age group. The Framingam equation data input is 
presented in Table 4. The Framingam equations applied in the model for stroke 
and coronary heart disease are presented in the Appendix. 
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Table 4. Framingham equation input 
Variable Unit Normal Hypertension Diabetes Hyper-cholesterolemia 
Age Years Range (25-85) 
Range  
(25-85) 
Range  
(25-85) 
Range  
(25-85) 
Sex Male / Female M / F M / F M / F M / F 
SBP mmHg Range (115-147)
Range  
(169-183) 
Range (115-
147) 
Range  
(115-147) 
TC mmol/l Range (5.3-6.4) 
Range  
(5.3-6.4) 
Range  
(5.3-6.4) 
Range  
(6.5-8.5) 
HDL mmol/l Range (1.1-1.4) 
Range  
(1.1-1.4) 
Range  
(1.1-1.4) 
Range 
(0.75-0.9) 
Smoking Yes / No N N N N 
Diabetes Yes / No N N Y N 
Left 
ventricular 
hypertrophy 
Yes / No N N N N 
 
Mortality rates of overweight and obese subjects in the normal health state are 
assumed to be equivalent to those observed in the general population although 
there are studies that explored the relationship between BMI and the risk of death 
(Fontaine 2003, McGee 2005). Obesity and overweight in adults are found to be 
associated with large decreases in life expectancy and increases in early 
mortality. However, we decided not to include these increased mortality risks 
because there is a danger of double counting if the elevated mortality risks are 
combined with associated complication mortality rates. Age and gender specific 
mortality data is obtained from Swiss Federal Statistical Office (2006): overall 
mortality data (Table 5) and disease specific according to International 
Classification of Diseases (ICD-10 codes): I10-I15 Hypertensive disease (Table 
6), I20-I25 Ischemic heart disease (Table 7), I60-I69 Cerebrovascular disease 
(Table 8) and E10-E14 Diabetes mellitus (Table 9). The yearly probability of 
diabetes, hypertension, coronary heart disease and stroke are obtained from the 
actual number of deaths and disease prevalence rates in Switzerland (SFSO 
2006).  
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Table 5. Overall mortality data (excluding ICD-10: I10-I25, I20-I25, I60-I69, E10-
E14) 
Sex Age range Actual population Actual death Yearly probability of death (%) 
Male 25-34 504703 381 0.08 
Female 25-34 510907 190 0.04 
Male 35-44 616872 721 0.12 
Female 35-44 609610 403 0.07 
Male 45-54 512754 1388 0.27 
Female 45-54 506602 857 0.17 
Male 55-64 421426 2808 0.66 
Female 55-64 430819 1741 0.40 
Male 65-74 272748 4435 1.61 
Female 65-74 327097 2941 0.90 
Male 75-84 156349 6676 4.1 
Female 75-84 246640 6391 2.56 
Male 85+ 42600 5080 11.25 
Female 85+ 103343 9771 9.03 
 
Table 6. Hypertensive disease (Ht) mortality (ICD-10:I10-I15) 
Sex Age range 
Actual 
population 
Prev. Ht 
(%) 
Population 
with Ht 
Actual 
death Ht 
Yearly 
prob. of 
death Ht 
(%) 
Male 25-34 504703 3.0 15141 0 0.00 
Female 25-34 510907 1.7 8685 0 0.00 
Male 35-44 616872 5.7 35162 4 0.01 
Female 35-44 609610 3.1 18898 0 0.00 
Male 45-54 512754 12.4 63582 15 0.02 
Female 45-54 506602 10.0 50660 9 0.02 
Male 55-64 421426 25.1 105778 51 0.05 
Female 55-64 430819 24.5 105551 18 0.02 
Male 65-74 272748 37.6 102553 107 0.10 
Female 65-74 327097 35.2 115138 67 0.06 
Male 75-84 156349 35.0 54722 248 0.45 
Female 75-84 246640 43.4 107042 337 0.31 
Male 85+ 42600 35.0 14910 292 1.94 
Female 85+ 103343 43.4 44851 885 1.95 
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Table 7. Diabetes mellitus (Dm) mortality (ICD-10:E10-E14) 
Sex Age range 
Actual 
population 
Prev. 
Dm (%) 
Population 
with Dm 
Actual 
death 
Dm 
Yearly prob. 
% of death 
Dm 
Male 25-34 504703 0.7 3533 1 0.03 
Female 25-34 510907 0.3 1533 1 0.07 
Male 35-44 616872 1.4 8636 4 0.05 
Female 35-44 609610 1.0 6096 3 0.05 
Male 45-54 512754 2.8 14357 28 0.19 
Female 45-54 506602 2.6 13172 14 0.11 
Male 55-64 421426 8.3 34978 76 0.22 
Female 55-64 430819 4.0 17233 25 0.14 
Male 65-74 272748 9.5 25911 176 0.68 
Female 65-74 327097 6.8 22243 96 0.43 
Male 75-84 156349 13.4 20951 292 1.38 
Female 75-84 246640 9.5 23431 418 1.77 
Male 85+ 42600 13.4 5708 971 15.68 
Female 85+ 103343 9.5 9818 504 5.01 
 
Table 8. Coronary heart disease (CHD) mortality (ICD-10:I20-I25) 
Sex Age range 
Actual 
population 
Prev. 
CHD 
(%) 
Population 
with CHD 
Actual 
death 
CHD 
Yearly prob. 
(%) of death 
CHD  
Male 25-34 504703 0.4 2019 11 0.54 
Female 25-34 510907 0.3 1533 0 0.00 
Male 35-44 616872 0.9 5552 64 1.15 
Female 35-44 609610 0.4 2438 16 0.65 
Male 45-54 512754 3.5 17946 205 1.14 
Female 45-54 506602 2.0 10132 43 0.42 
Male 55-64 421426 11.1 46778 459 0.98 
Female 55-64 430819 5.9 25418 103 0.40 
Male 65-74 272748 21.5 58641 891 1.51 
Female 65-74 327097 9.7 31728 376 1.18 
Male 75-84 156349 26.4 41276 1781 4.22 
Female 75-84 246640 18.4 45382 1398 3.03 
Male 85+ 42600 26.4 11246 1577 13.10 
Female 85+ 103343 18.4 19015 3050 14.85 
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Table 9. Stroke mortality (ICD-10:I60-I69) 
Sex Age range 
Actual 
population 
Prev. 
Stroke 
(%) 
Population 
with Stroke 
Actual 
death 
Stroke 
Yearly prob. 
(%) of death 
Stroke 
Male 25-34 504703 0.4 2019 5 0.25 
Female 25-34 510907 0.3 1533 5 0.33 
Male 35-44 616872 0.3 1851 7 0.38 
Female 35-44 609610 0.6 3658 20 0.55 
Male 45-54 512754 1.2 6153 42 0.68 
Female 45-54 506602 0.9 4559 31 0.68 
Male 55-64 421426 2.2 9271 78 0.84 
Female 55-64 430819 2.5 10770 61 0.56 
Male 65-74 272748 7.6 20729 240 1.15 
Female 65-74 327097 5.4 17663 224 1.26 
Male 75-84 156349 13.3 20794 731 3.45 
Female 75-84 246640 8.9 21951 895 4.00 
Male 85+ 42600 13.3 5666 651 10.87 
Female 85+ 103343 8.9 9198 1588 15.89 
 
Data on the effectiveness of lifestyle intervention is obtained using meta-analysis 
technique (Saint 1999) of the randomized controlled trials performed in 
overweight and obese people. The aim of the meta-analysis is to combine the 
long-term effects of lifestyle intervention on weight and cardiovascular risk factors 
in overweight and obese people from several studies. The lifestyle intervention in 
all evaluated studies consisted in dietary counseling and physical exercise 
sessions and lasted from one to six years with an average follow-up time of three 
years. A summary of the meta-analyses results on the outcomes of interest is 
presented in Table 10. Effects are combined using a random effects model. The 
summary outcome measure calculated is the difference in means between 
lifestyle intervention and standard care. The pooled estimates of effect size are 
obtained using Comprehensive Meta-Analysis software (CMA 2005).  
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Table 10. Meta-analysis results 
 Outcome N studies N  DM SE 95% CI p-Value 
BMI 
(kg/m2) 5 926 -1.11 0.23 -1.56, -0.66 <0.0001 
SBP 
(mmol/l) 9 2239 -2.08 0.61 -3.28, -0.89 0.001 
TC 
(mmol/l) 7 1516 -0.26 0.07 -0.41, -0.12 <0.0001 O
ve
rw
ei
gh
t 
HDL 
(mmol/l) 7 1875 0.01 0.01 -0.22, 0.04 0.640 
BMI 
(kg/m2) 7 3522 -1.33 0.31 -1.93, -0.72 <0.0001 
SBP 
(mmol/l) 6 4182 -2.78 0.82 -4.38, -1.18 0.001 
TC 
(mmol/l) 5 893 -0.14 0.05 -0.24, 0.03 0.011 
O
be
se
 
HDL 
(mmol/l) 4 2778 0.04 0.02 0.004, 0.08 0.028 
N, number; DM, difference in means; SE, standard error; CI, confidence intervals 
 
Utility score represent the strength of patient preferences for their own health on a 
scale from 0.0 (death) to 1.0 (perfect health). Three published sources of utilities 
are used: utilities for overweight and obese people (Macran 2004), utilities 
changes due to decreases in BMI (Hakim 2002) and utilities associated with the 
complications of obesity (Jia 2005). The utilities associated with overweight and 
obese people are presented in Table 11 and the utilities associated with obesity 
complications are presented in Table 12. 
 
Table 11. Utilities for overweight and obese people 
Overweight Obese 
Age group 
Male Female Male Female 
25-34 0.92 0.91 0.89 0.88 
35-44 0.89 0.86 0.89 0.82 
45-54 0.86 0.83 0.84 0.83 
55-64 0.81 0.78 0.72 0.74 
65-74 0.81 0.76 0.78 0.71 
75+ 0.77 0.73 0.76 0.68 
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Table 12. Utilities associated with obesity complications 
Health state Disutility due to co-morbidities 
Utility gain for 1 unit 
BMI reduction 
Normal - 0.017 
Hypertension -0.053 0.015 
Diabetes -0.042 0.029 
Hypercholesterolemia -0.030 0.015 
Coronary heart disease -0.083 0.017 
Stroke -0.080 0.017 
 
The data on resource used by subjects receiving lifestyle intervention or standard 
care are taken from Finnish Diabetes Prevention Study (Lindström 2005) and 
adapted for Switzerland. For lifestyle intervention, seven dietitian visits are 
assumed in the first year, and four visits per year thereafter. Based on the unit 
cost of the health care calculated for Switzerland, the dietician cost per visit is 
estimated at CHF 64 (Tarmed 2006). The same price is assumed for physical 
exercise which is done in group sessions of 20 people for one hour. The group 
attended four sessions per month in the first year and two sessions per month 
during the subsequent year. The total estimated costs of lifestyle intervention are 
CHF 602 per person in the first year and CHF 333 per person per subsequent 
year. In the standard control group, costs are assumed zero in overweight people. 
For obese the standard care consists in three dietitian visit in the first year, and 
one visit per year thereafter and the equivalent of two exercise sessions per 
month in the first year and one session per month during the subsequent year. 
The obesity medication costs are not taken into consideration in the standard 
therapy of obesity given that there are not chronic medications, i.e. the European 
prescribing guidelines state that the duration of treatment with orlistat should not 
be longer than two years (EMEA 1998). Thus, a conservative estimate is 
preferred. The total estimated costs of standard care intervention in obese 
subjects are CHF 369 per person in the first year and CHF 102 per person per 
subsequent year. 
The costs of obesity complications are taken from published literature and 
adjusted to 2006 Swiss prices (CHF) using the consumer price index (SNB 2006). 
This included the average direct and indirect cost of the disease. A summary of 
the cost components and source of data is provided in Table 13. 
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Table 13. Cost components 
Component Cost (CHF)a Reference 
Lifestyle intervention in 
overweight/obeseb 1268 
Lindstrom 2005 adapted for 
Switzerland 
Standard intervention in obeseb 573 Lindstrom 2005 adapted for Switzerland 
Hypertension 1653 Schmid 2005 
Type 2 diabetes 2890 Schmitt-Koopmann 2004 
Hypercholesterolemia 1245 Schmid 2005 
Coronary heart disease 6242 Schmid 2005 
Stroke 11495 Schmitt-Koopmann 2004 
a Cost per person per year adjusted for 2006 prices; b Cost of three years intervention 
 
Cost-effectiveness analysis 
In order to assess the effect of lifestyle interventions in the prevention and 
treatment of obesity, we defined three groups of people that are followed 
throughout the analysis: overweight group, borderline group and moderate obese 
group. The subjects in the overweight group have a BMI of 27 kg/m2 selected 
from the overweight range of BMI 25 to 29.9 kg/m2, the subjects from the 
moderate obese group have a BMI of 33 kg/m2 selected from the moderate 
obesity range BMI 30 to 35 kg/m2 and the subjects from the borderline group have 
a BMI of 30 kg/m2 representing people who are at the upper limit of overweight 
and lower limit of obesity. For each group of people: overweight, borderline and 
moderate obese, the results are presented as difference between lifestyle and 
standard care intervention in mean costs, life-years (LY) and quality adjusted life-
years (QALY). A subgroup analysis was performed in overweight subjects, 
borderline subjects and moderate obese subjects on different age groups (e.g. 
25, 35, 45, 55 years) and gender to allow for a direct comparison among patient 
populations. Half cycle correction is applied to life expectancy calculations 
assuming that the transition will take place half way through a cycle.  
The cost-effectiveness of interventions is compared using the incremental 
cost-effectiveness ratio, defined as difference in costs (CL-CS) divided by 
difference in effects (EL-ES). Given the chronic nature of the diseases 
incorporated in the model, a lower value of LY compared to QALY is expected. 
Our model comparatively calculates the incremental cost-effectiveness ratio as 
cost per LY in a cost-effectiveness analysis and as cost per QALY in a cost-utility 
analysis. Incremental costs were reported in Swiss Francs (CHF) and Euro (€) to 
allow for an international comparison (exchange rate 1 CHF = 0.607158 €, May 9, 
2007). The analysis is performed from a society perspective. Future costs and 
effects are presented undiscounted and discounted at 3% rate. The model is 
developed using Microsoft Excel Software. 
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Sensitivity analysis 
A probabilistic sensitivity analysis (Briggs 2000) is carried out to investigate the 
robustness of the data input including the baseline risks of transitioning to obesity-
complications, the lifestyle and standard care intervention effects, the utility 
values, the costs of complications, and the costs of interventions. In order to 
propagate uncertainty in our model, distributions are assigned to all model 
parameters that are estimated with uncertainty. The distributional forms of the 
model parameters are: normal distribution for the costs of interventions and 
cardiovascular risk factors, gamma distribution for the costs of obesity 
complications and beta distribution for utility scores. Values are drawn at random 
from the specified distributions using a random number generator for the chosen 
parameter. Monte Carlo simulation was used to propagate these distributions 
through the model by recalculating the results over a large number of iterations. 
The results of running the probabilistic sensitivity analysis by randomly sampling 
from the parameter distributions are presented on the cost-effectiveness plane 
(Briggs 1998) and cost-effectiveness acceptability curve (Fenwick 2004).  
 
Results 
The average difference in costs and effects between lifestyle intervention and 
standard care is presented in Table 14. The lifestyle intervention resulted in 
increased survival and improved quality of life, equivalent to a difference of 0.05 
LY and 0.33 QALY per person per year gained over lifetime. Compared with 
standard care, the average incremental cost of lifestyle intervention is lower in the 
borderline group (female CHF -281, male CHF -384) and the moderate obese 
group (female CHF -65, male CHF -176) and higher in the overweight group 
(female CHF 216, male CHF 124) when probabilistic results are undiscounted. 
When future costs and effects are discounted at 3% rate, lifestyle intervention has 
lower costs than standard care in borderline male subjects (CHF -99). In the 
borderline group, the lifetime incremental cost per LY is estimated in female at 
CHF -15000 (€ -9107) per LY and male at CHF -13933 (€ -8460) per LY when 
results are undiscounted. When 3% discount rate is applied, incremental cost-
effectiveness ratio is CHF 1700 (€ 1032) per LY in borderline female subjects and 
CHF -11200 (€ -6800) per LY in borderline male subjects. Lifetime incremental 
cost per QALY in the borderline group is estimated in female at CHF -969 (€ -588) 
per QALY and male at CHF -1200 (€ -729) per QALY when results are 
undiscounted. When discounting is applied, incremental cost-effectiveness ratio is 
CHF 64 (€ 39) per QALY in borderline female subjects and CHF -354 (€ -215) per 
QALY in borderline male subjects.  
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Table 14. Incremental costs and effects per person per year 
Overweight b Borderline b Moderate Obese b 
 Sex Average a 
0 % 3 % 0 % 3 % 0 % 3 % 
Cost, CHF 234 510 -161 80 18 207 
Cost, € 142 310 -98 49 11 126 
LY 0.02 0.01 0.02 0.01 0.02 0.01 
F 
QALY 0.27 0.23 0.29 0.25 0.29 0.26 
Cost, CHF 156 405 -260 -6 -70 127 
Cost, € 95 246 -158 -4 -43 77 
LY 0.03 0.01 0.03 0.01 0.02 0.01 
D
et
er
m
in
is
tic
 
M 
QALY 0.29 0.25 0.32 0.28 0.33 0.29 
Cost, CHF 216 490 -281 16 -65 145 
Cost, € 131 298 -171 10 -39 88 
LY 0.02 0.01 0.05 0.01 0.02 0.01 
F 
QALY 0.26 0.23 0.29 0.25 0.30 0.26 
Cost, CHF 124 384 -384 -99 -176 44 
Cost, € 75 233 -233 -60 -107 27 
LY 0.03 0.01 0.03 0.01 0.03 0.01 
P
ro
ba
bi
lis
tic
 
M 
QALY 0.30 0.25 0.32 0.28 0.30 0.29 
  a Difference between lifestyle and standard intervention, average from age 25 to 65 years; 
b Lifetime results are presented undiscounted (0%) and discounted (3%) 
 
Subgroup analysis is conducted on different age groups (Table 15). The bolded 
cells show the dominant intervention strategies whose lifestyle intervention has 
lower costs and a higher health effect compared with standard intervention. The 
subgroup analysis estimates that lifestyle intervention dominates standard care in 
overweight female subjects aged 45 years, overweight male subjects aged 25 
years, borderline female subjects aged 30 to 65 yeas, overweight male subjects 
aged 25 to 65, moderate obese female subjects aged 35 to 60 and moderate 
obese male subjects aged 25 to 60 years, when results are undiscounted. When 
discounting is applied to future costs and effects, lifestyle intervention dominates 
standard care in borderline female subjects aged 35 to 55 years, borderline male 
subjects aged 25 to 60 years, moderate obese female subjects aged 45 years 
and obese male subjects aged 55 years. 
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Table 15. Incremental cost-effectiveness ratio per person per year 
Age 25a Age 35 a Age 45 a Age 55 a 
 S
ex
 
ICER 
0% 3% 0% 3% 0% 3% 0% 3% 
CHF/
QALY 4515 6286 95 2352 -419 1131 508 1366 F 
CHF/
LY 76734 295863 834 45551 -4311 23126 7278 33482 
CHF/
QALY -374 1854 395 2014 324 1457 237 914 O
ve
rw
ei
gh
t 
M 
CHF/
LY -2840 34291 3006 30934 3054 24473 2787 17149 
CHF/
QALY 1534 3023 -2945 -1630 -2000 -785 -898 -173 F 
CHF/
LY 27510 142619 -19380 -6050 -22053 -17106 -13032 -4250 
CHF/
QALY -2560 -781 -283 -331 -1373 -523 -1027 -508 Bo
rd
er
lin
e 
M 
CHF/
LY -19496 -14886 -14196 -52927 -14158 -9595 -13282 -10417 
CHF/
QALY 1973 3180 -982 -753 -1026 -88 -355 173 F 
CHF/
LY 39925 171544 -11287 10019 -14496 -2426 -6670 5481 
CHF/
QALY -1453 3 395 276 -741 9 -502 -69 
O
be
se
 
M 
CHF/
LY -12657 58 -7373 5580 -8912 185 -8048 -1745 
a Lifetime probabilistic results are presented undiscounted (0%) and discounted (3%) 
 
To reflect the uncertainty in the estimates, Figure 2 presents a scatter plot of the 
mean differences in costs and QALY gained between lifestyle and standard care, 
derived from the Monte Carlo simulation, in borderline people. The x- and y-axis 
divide the graph into four separate quadrants, which represent the following 
scenarios for lifestyle versus standard care (clockwise from the top right): (a) 
more effective and more costly; (b) more effective and less costly; (c) less 
effective and less costly, and (d) less effective and more costly. The high 
concentration of points in quadrant (a) and (b) indicate that lifestyle intervention is 
more effective than standard care. For example in borderline the majority of the 
replicates lie in the quadrant (b), where lifestyle dominates standard care, 78% 
simulations of the lifestyle intervention are cost-effective relative to standard care 
(Figure 2). However, the dispersion of points above and below the x-axis, 
indicates that there is some uncertainty about whether this gain in QALY is 
achieved at a lower or higher cost than standard care. If the gain in QALY is 
achieved at a higher cost, then the critical issue that determines whether lifestyle 
intervention is cost-effective is how much (if any) the decision maker is willing to 
pay for an additional unit gain in health outcome. 
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Figure 2. Scatter plot of the difference in mean costs and effects between lifestyle 
and standard care intervention 
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Figure 3 illustrates the cost-effectiveness acceptability curves for lifestyle com-
pared to standard care intervention in borderline group. The curves indicate the 
probability of lifestyle intervention being more cost-effective than the standard 
care for a range of potential maximum amounts a decision maker is willing to pay 
for an additional unit of health gained. We carried out the analysis for a range of 
values for the society willingness to pay for an additional unit of health gain. When 
the decision-maker is unwilling to pay anything additional for a health gain the 
probability that lifestyle intervention is cost-effective is 5% in the overweight 
group, 78% in the borderline group (Figure 3.) and 47% in the moderate obese 
group. If the decision-maker is willing to pay CHF 500 per QALY gained, the 
probability of the lifestyle intervention being cost-effective increases to 12% in 
overweight subjects, 95% in borderline subjects (Figure 3) and 75 % in moderate 
obese subjects. Furthermore, if the decision-maker is willing to pay CHF 1000 per 
QALY gained, the probability of the lifestyle intervention being cost-effective 
increase further to 35 % in overweight subjects, 99 % in borderline subjects 
(Figure 3) and 92 % in moderate obese subjects. 
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Figure 3. Cost-effectiveness acceptability curves lifestyle versus standard care 
intervention 
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Figure 4 and Figure 5 present the cost-effectiveness acceptability curves in 
borderline subjects for different age groups in female and male. Overall, the cost-
effectiveness for men is greater than for women. Lifestyle intervention is more 
cost-effective in female aged 35 to 55 years and male aged 25 to 55 years 
compared to other age groups. 
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Figure 4. Cost-effectiveness acceptability curves of lifestyle intervention in female 
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Figure 5. Cost-effectiveness acceptability curves of lifestyle intervention in male 
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Discussion 
We defined based on BMI level three groups of people that are followed thought 
the study: overweight subjects (BMI 27 kg/m2), borderline subjects (BMI 30 kg/m2) 
and moderate obese subjects (BMI 33 kg/m2). For the purpose of this study the 
classification allows us to differentiate prevention from the treatment of obesity 
and to better understand the importance of the transition from overweight to 
obesity reflected in borderline group. 
Using a lifestyle intervention in overweight and obese people, the present 
model tries to quantify several elements of benefit associated with weight loss: 
first, a reduction in the risk of developing diabetes, hypertension, 
hypercholesterolemia and cardiovascular disease, second, an increase in life 
expectancy and quality of life, and third, a reduction in treatment costs by 
reducing the risk of developing obesity complications. In all three groups, 
independent of age, the lifetime effect of three-year lifestyle intervention resulted 
in increased survival and an improved quality of life compared with standard care. 
The difference in cost between lifestyle intervention and standard care is lower in 
borderline subjects and moderate obese subjects and higher in overweight 
subjects. In particular, in borderline people lifestyle intervention dominates 
standard care intervention being less costly and more effective. The majority of 
the costs savings in borderline group are attributable to a decrease in the risk of 
developing obesity complications. Despite the lifestyle interventions incurring 
higher mean costs in the first three years, these additional costs are offset by the 
reduced probability of developing obesity related complications. The subgroup 
analyses differentiate the cost-effectiveness for each age group.  We observed 
some important gender differences. Firstly, the incidence of diabetes is higher in 
men resulting in higher cost saving for men aged 25 to 35 years compared with 
women in the same age group. Secondly, women have a lower mortality rates 
and, as a consequence, higher life expectancy compared to men resulting in 
higher costs associated with obese co-morbidities. Thirdly, investigations have 
suggested that weight gain during and after menopause may contribute more to 
cardiovascular disease than actual weight prior to menopause and that weight 
loss and increase physical activity may mitigate some of the cardiovascular risk 
factors i.e. high cholesterol, insulin resistance (Carels 2004, Matthews 1989). 
These observations are consistent with our findings that weight loss with lifestyle 
intervention is more cost-effective in women aged 45-55 years due to a decrease 
in the cardiovascular risk factors compared with standard care intervention. 
The current analysis suggests that borderline people who are at the upper 
limit of overweight and lower limit of obesity benefit the most from a lifestyle 
intervention lasting for three years. The lifetime effect of a lifestyle intervention is 
reflected in lower costs and higher effects. This may be considered a critical point 
in the prevention of obesity. It has been suggested that reducing the risk factors 
that diseases have in common may prove to be an efficient prevention strategy 
(Epstein 1983). For example, several risk factors such as obesity, physical 
inactivity, hypertension, hyperglycaemia and hypercholesterolemia predict the 
development of chronic diseases such as diabetes and cardiovascular disease. 
Therefore, a successful preventive program based on lifestyle intervention may 
target several risk factors simultaneously.  
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 One issue of concern in the cost-effectiveness analysis is that societal 
threshold, the maximum willingness to pay for one unit of health gain, is not 
known. It has been suggested that incremental costs of less than CHF 24178 (€ 
14680) per QALY are considered cost-effective representing strong evidence for 
adoption (Laupacis 1992); however, the acceptance value is a subject highly 
debated in the literature. For example, the National Institute for Clinical 
Excellence in the United Kingdom evaluated orlistat and sibutramine for the 
treatment of obesity in adults and determined the cost-effectiveness of orlistat at 
values ranged from CHF 25093 to CHF 110987 per QALY (NICE report 31) and 
of sibutramine at values ranged from CHF 25334 to CHF 72383 per QALY (NICE 
report 22). In Switzerland, the cost-effectiveness of orlistat was estimated at CHF 
22413 (€ 13 608) per QALY (Ruof 2005). The Swiss authorities decided to 
reimburse orlistat in the treatment of diabetic patients with BMI ≥ 28 kg/m2, but 
stipulated that it should be continued beyond six months only in patients who lose 
≥  5 kg of their starting weight or achieve a reduction in HbA1c of  ≥  0.5 % (Ruof 
2005). 
To compare the results of our study with other economic analyses 
performed in overweight and obese people we reviewed the published economic 
literature on lifestyle interventions. An economic analysis was performed in the 
American Diabetes Prevention Program (DPP) in obese people with impaired 
glucose tolerance (Herman 2005). Compared with standard care intervention, 
lifestyle intervention cost CHF 768 more over a lifetime and produce a gain of 
0.57 QALY, resulting in a cost per QALY of approximately CHF 1330 (€ 808). 
Another modelling study performed in the DPP (Eddy 2005) estimate the 30-year 
cost per QALY of lifestyle intervention compared with the control group at CHF 
74953 (€ 45508). The authors suggest that using lifestyle intervention until after a 
person develops diabetes would be more cost-effective (CHF 29619 per QALY). 
In United Kingdom, an economic analysis of lifestyle intervention in obese people 
at risk of diabetes, estimates the 15-year incremental cost per QALY at CHF 
14054 or € 8533 (Avenell 2004). It has been also documented that non-
pharmacological treatments that target severe obesity (BMI > 35 kg/m2) are cost-
effective (Tsai 2005). The fact that certain treatments are cost-effective in high 
risk individuals with severe obesity or associated co-morbidities i.e. diabetes, 
cardiovascular disease does not answer the question of the cost-effectiveness of 
the same interventions for lower risk obese or overweight individuals, whose 
prevention or treatment benefits may also be worth the cost. To answer this 
question, a better understanding of the implications of weight loss and 
improvement of risk factors for long-term health outcomes is necessary in 
overweight and moderate obese people. Policy makers need country specific 
economic data on overweight and obesity to tackle the growing burden of obesity. 
Our cost-effectiveness analysis illustrates from a Swiss perspective the lifetime 
impact of lifestyle intervention in the prevention and treatment of obesity. The 
obtained results provide an argument for organizations and institutions actively 
involved in the field of obesity prevention to justify funds for intensified prevention 
strategies using lifestyle interventions. 
Our analysis also has several limitations. The model could be improved 
by having access to additional Swiss-specific data. So far, epidemiological data 
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such as the correlation between BMI and the risk of complications, obesity related 
mortality data and changes in patient utility for weight loss have not been 
recorded specifically for Switzerland. Further investigations should also take into 
account other important complications of obesity such as metabolic syndrome, 
colorectal cancer, gall bladder disease, sleep apnoea and depression. Our model 
does not take into consideration smoking as a risk factor although it has been 
documented that obese smokers have a decrease in life expectancy compared 
with non-smokers (Sempos 1998). Another limitation of our study consists in the 
estimation of the costs of obesity complications from secondary data sources. In 
our model, the cost of stroke represents the largest value among all 
complications. However, this high cost is confirmed by various costs of illness 
studies performed in Europe (Kolominsky-Rabas 2006, Gerzeli 2005). Overall, 
our model reflects a conservative approach considering that we do not include 
obesity medication, all related obesity complications and correlations between 
diseases incorporated in the model. Although our analysis simplifies the complex 
reality, it provides a first positive estimate on the lifetime impact of lifestyle 
intervention on overweight and obese people in Switzerland.  
 
Conclusion 
In summary, prevention and treatment of obesity must be a priority for heathcare 
decision-makers across Europe giving the rapid increase in prevalence. With the 
aid of a decision analytic model, we synthesised Swiss specific evidence 
available on the outcomes and costs of lifestyle intervention and standard care in 
overweight and obese people. Our economic analysis suggests that lifestyle 
intervention is cost-effective in the long-term prevention and treatment of obesity 
in Switzerland.  
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Appendix  
 
a) Framingham equation - Coronary Heart Disease  
 
From Anderson et al. (1990), the probability of a new case of CHD at period t is 
given by 
 
CHD(t) = [F(t) – F(t – 1)] / [1 – F(t – 1)] 
 
Where 
 
F(t) = 1 – exp (–exp {[ln(t) – μ(t)] / σ(t)})       (the Weibull function) 
 
μ = 15.5305 + 28.4441 × female – 1.4792 x ln[age(t)] – 14.4588 ×          ln[age(t)] 
× female + 1.8515 × ln[age(t)]2 × female – 0.9119 x ln[sbp(t)] – 0.2767 × 
smoker(t) – 0.7181 × ln[totalc(t) / HDL (t)] – 0.1759 × diagnosed diabetic – 0.1999 
× diabetic × female –0.5865 × LVH(t, gender) 
 
ln(σ) = 0.9145 – 0.2784 × μ 
Equation input: 
 Age in years, input female=1, male=0 
 sbp, systolic blood pressure, input range 95-185 mmHg 
 Diabetes, 0=no, 1=yes 
 Smoking, 0=no, 1=yes 
 totalc = total cholesterol level, input range 3.5-10 mmol/l 
 HDL, high density lipoprotein cholesterol level, input range 0.65-2.65 
mmol/l 
 LVH, left ventricular hypertrophy, input 0=no, 1=yes, when 
information not available LVH=0 
 
b) Framingham equation - Stroke 
 
From Anderson et al. (1990), the probability of a new case of Stroke at period t is 
given by  
 
Prob(S[t]) = [F(t) – F(t - 1)] / [1 – F(t - 1)] 
 
 
Where 
 
F(t) = 1 – exp (–exp {[ln(t) – μ(t)] / σ (t)}) (the Weibull function) 
 
μ = 26.5116 + 0.2019 × female – 2.3741 × ln[age(t)]– 2.4643 × ln[sbp(t)] – 0.3914 
smoker(t) – 0.0229 × ln[totalc(t) / HDL (t)] – 0.3087 ×         diagnosed diabetic – 
0.2627 × diabetic × female – 0.2355 × LVH 
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ln(σ) = –0.4312 
 
Equation input: 
 Age in years, input female=1, male=0 
 sbp, systolic blood pressure, input range 95-185 mmHg 
 Diabetes, 0=no, 1=yes 
 Smoking, 0=no, 1=yes 
 totalc = total cholesterol level, input range 3.5-10 mmol/l 
 HDL, high density lipoprotein cholesterol level, input range 0.65-2.65 
mmol/l 
 LVH, left ventricular hypertrophy, input 0=no, 1=yes, when 
information not available LVH=0 
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Chapter 6        
    
 
 
 
 
Direction of Further Research:  
Value of Additional Information  
in Cost-Effectiveness Analysis 
 
 
 
 
 
Summary 
There has been an increasing interest in using value of information analysis in 
medical decision-making, to quantify the uncertainty in decision-making, to 
identify the need for further research and as a tool for sensitivity analysis. The 
aims of the present chapter are to quantify the uncertainty in the cost-
effectiveness of lifestyle intervention versus standard care in overweight and 
obese people and to determine if further research is necessary based on current 
information. Value of information analysis was applied on a probabilistic cost-
effectiveness model to evaluate the uncertainty by calculating the patient 
expected value of perfect information (EVPI), population EVPI and partial EVPI. 
The costs were expressed in Swiss Francs (CHF), price year 2006.  
Results showed that EVPI was higher in overweight than in obese people. The 
maximum population EVPI was CHF 6.8 million in overweight people and CHF 
3.2 million in moderate obese people representing the upper limit on costs 
associated with decision uncertainty. The partial EVPI estimated a higher 
uncertainty in the model parameters such as utilities, body mass index, 
cardiovascular risk factors and systolic blood pressure in overweight and 
moderate obese subjects. In conclusion, the EVPI analysis indicates that there is 
some uncertainty regarding the choice between lifestyle intervention and standard 
care. The parameter EVPI suggests that if further research is commissioned, this 
should focus on the effectiveness of lifestyle intervention on cardiovascular risk 
factors and utilities. 
 Chapter 6 108 
Introduction 
The increasing prevalence of obesity worldwide underlines the pressing need for 
finding effective interventions to tackle the disease and its economic 
consequences. In Switzerland, overweight and obesity account for 37% of the 
population aged over 15 years (Swiss Federal Statistical Office 2006). Obesity is 
associated with a high risk of morbidity, mortality as well as reduced life 
expectancy (Fontaine 2003). The economic burden of obesity is substantial. In 
Switzerland, obesity related expenditures are estimated to have a cost range 
approximately between CHF 2691 million and CHF 3229 million, representing 2.3-
3.5% of total health care expenditures (Schmid 2005).   
The increasing burden on the budget of the Swiss healthcare providers 
resulted in considerable interest in assessing existing treatments for their clinical 
effectiveness and cost-effectiveness. A wide variety of treatments for obesity are 
available including diet, physical exercise, behavioral modification, 
pharmacological treatment and surgery. Among several treatment options, 
lifestyle intervention, including dietary counseling and physical exercise, has been 
documented to lead safely to improvements in metabolic abnormalities such as 
increased body weight, dyslipidemia, elevated blood pressure, and glucose 
control that are linked to the development of obesity, diabetes, and cardiovascular 
disease (Pritchett 2005). 
A decision analytic model was developed to assess the cost-effectiveness 
of lifestyle intervention in overweight and obese people in Switzerland (Galani 
2007). Decision analytic models are extensively used in formal decision-making 
process. One of the requirements for the decision-making is that uncertainty in 
adopting a decision based on cost-effectiveness must be appropriately 
characterized and quantified because this affects the value and the interpretation 
of the model output. Many guidelines for cost-effectiveness analysis recommend 
probabilistic sensitivity analysis to assess uncertainty associated with the model 
parameters (Claxton 2002). Value of information analysis has been suggested as 
a natural methodological extension of the probabilistic sensitivity analysis (Felli 
1999). The analysis quantifies the uncertainty by establishing the value of 
acquiring additional information to inform decision making. The use of value of 
information analysis has been recently encouraged in decision analytic models 
(Claxton 2004, Claxton 2001, Sculpher 2005, Fenwick 2005, Philips 2006). 
The aim of the present study was to apply the value of information 
analysis to assess the uncertainty in the cost-effectiveness of lifestyle intervention 
in overweight and obese people in Switzerland and to determine if further 
research is necessary based on current information.  
 
Methods 
A probabilistic cost-effectiveness model based on Markov process was developed 
to compare the effect of lifestyle intervention with standard care in overweight and 
obese subjects. Seven health states were modeled: ‘normal’, if subjects are 
overweight or obese but free of complications, ‘hypertension’, 
‘hypercholesterolemia’, ‘type 2 diabetes’, ‘stroke’, ‘coronary heart disease’ and 
‘death’. A representation of the Markov model is presented in Figure 1. Subjects 
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enter the model in the normal health state. Three characteristics are selected: 
starting age, starting body mass index (BMI) and gender. Based on BMI subjects 
are classified as overweight if they have a BMI between 25 kg/m2 and 29.9 kg/m2 
or obese if they have a BMI of 30 kg/m2 or over. The cycle length is one year. At 
the end of each one-year, proportions of subjects can move from one disease 
state to another or stay in the same disease state. 
 
Figure 1. Model diagram 
Stroke
Death
Coronary heart 
disease
Normal
Hypertension Diabetes Hyper-cholesterolemia
 
The transition probabilities between cycles are based on the disease progression 
with age, gender, BMI and cycle number. We assumed that all subjects 
developing hypertension, diabetes and hypercholesterolemia are diagnosed and 
treated. Subjects remain in those states once they have entered, unless they 
develop cardiovascular disease or die. The possibility of having concomitant 
diabetes, hypertension and hypercholesterolemia was not incorporated into the 
model. One reason for excluding the correlation between the existing co-
morbidities is the absence of prevalence data for Swiss population. This 
assumption is most probably underestimating the burden associated with obesity 
related co-morbidities. Subjects entering the model had a minimum age of 25 
years and a maximum of 85 years, therefore, the model runs for a period of 60 
years from the age of 25 years, i.e. when a subject enters the model at age of 60 
years, the model will run until he/she will have the age of 85 years. The reason for 
setting the age limit is based on the average life expectancy in Switzerland of 
77.3 years for men and 82.8 for women (World Health Organization 2006). We 
considered that any simulation after the age of 85 years would overestimate the 
costs and the effects. 
A hypothetical cohort of 10000 overweight or obese subjects received a 
lifestyle intervention or standard care intervention for a period of three years. 
Lifestyle intervention consisted of regular physical activity and healthy eating, 
including diets rich in fruits and vegetables. Lifestyle intervention group members 
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attended dietitian sessions and supervised exercise sessions during the first three 
years. Standard care in overweight people consisted in no intervention whereas in 
obese people consisted in basic dietary counseling and physical exercise 
sessions (see cost description). Treatment effect was modeled as a reduction in 
BMI, systolic blood pressure, total cholesterol, and high density lipoprotein 
cholesterol based on data obtained in three-year active treatment. It was 
assumed that the effect of lifestyle intervention on cardiovascular risk factors and 
weight loss is maintained up to six years, thereafter subjects start to regain weight 
linearly for a period of four years, i.e. after ten years weight loss went back to the 
initial weight. This is in line with the assumption used in the economic evaluations 
of weight loss medication (Maetzel 2003, Hertzman 2005) and is based on 
observations from clinical trials (NICE 2007). 
We estimated our model using data from a variety of secondary sources. 
A summary of the data input is presented in Table 1. The correlation between BMI 
and annual risk of developing hypertension, diabetes, and hypercholesterolemia 
was calculated based on two large epidemiological studies: the Nurses Health 
Study and the Health Professional Follow-up Study (Field 2001). Intermediate 
values of BMI have been interpolated using polynomial function. The risk of 
complications had been adjusted according to age, gender and prevalence of 
hypertension, diabetes and hypercholesterolemia based on the information 
provided by the Swiss health survey (Swiss Federal Statistical Office 2006). The 
mean BMI by age and gender of the Swiss population was obtained from 
published literature (World Health Organization 2006, Mähönen 2006). 
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The risk of developing coronary heart disease and stroke from ‘normal’, 
‘hypertension’, ‘diabetes’, ‘hypercholesterolemia’ health states were based on a 
risk equation from the Framingham cohort study (Anderson 2001). The risk fac-
tors were age, gender, systolic blood pressure, total cholesterol, high density 
lipoprotein cholesterol, presence of diabetes and smoking status. Data on systolic 
blood pressure, total cholesterol and high density lipoprotein of the Swiss 
population were obtained from literature (Mähönen 2006). The mean systolic 
blood pressure increased with age in both men and women, rising from 127 
mmHg in men aged 25-35 years to 145 mmHg in men aged 75 years and over, 
and from 115 mmHg to 144 mmHg in women. The mean blood cholesterol levels 
increased with age with a slight decrease in the oldest age group.  
Mortality rates of overweight and obese subjects in the normal health 
state were assumed to be equivalent to those observed in the general population 
although there are studies that explored the relationship between BMI and the risk 
of death (Fontaine 2003, McGee 2005). Obesity and overweight in adults are 
found to be associated with large decreases in life expectancy and increases in 
early mortality. However, we decided not to include these increased mortality 
risks because there is a danger of double counting if the elevated mortality risks 
are combined with associated complication mortality rates. Age and gender 
specific mortality data were obtained from Swiss Federal Statistical Office: overall 
mortality data and disease specific according to International Classification of 
Diseases (ICD-10 codes): I10-I15 Hypertensive disease, I20-I25 Ischemic heart 
disease, I60-I69 Cerebrovascular disease and E10-E14 Diabetes mellitus. The 
yearly probability of developing diabetes, hypertension, coronary heart disease 
and stroke were obtained from the actual number of deaths and disease 
prevalence rates in Switzerland (Swiss Federal Statistical Office 2006).  
Data on the effectiveness of lifestyle intervention was obtained using 
meta-analysis technique (Saint 1999) of the randomized controlled trials 
performed in overweight and obese people. The meta-analysis combined the 
long-term effects of lifestyle intervention on weight and cardiovascular risk factors 
in overweight and obese people from several studies. The lifestyle intervention in 
all evaluated studies consisted in dietary counseling and physical exercise 
sessions and lasted from one to six years with an average follow-up time of three 
years. The summary outcome measure calculated was the difference in means 
between lifestyle intervention and standard care. Effects were combined using a 
random effects model (Table 1).  
Utility score represent the strength of patient preferences for their own 
health on a scale from 0.0 (death) to 1.0 (perfect health). Three published sources 
of utilities were used: utilities for overweight and obese people (Macran 2004), 
utilities changes due to decreases in BMI (Hakim 2002) and utilities associated 
with the complications of obesity (Jia 2005).  
The data on resource used by patients receiving lifestyle intervention or 
standard care were obtained from the Finnish Diabetes Prevention Study 
(Lindström 2005) and adapted for Switzerland. In the lifestyle intervention group 
seven dietitian visits were assumed in the first year, and four visits per year 
thereafter. Based on the unit cost of the health care calculated for Switzerland, 
the dietician cost per visit was estimated at CHF 64 (TARMED 2006). The same 
 Chapter 6 114 
price was assumed for physical exercise which was done in group sessions of 20 
people for one hour. The group attended four sessions per month in the first year 
and two sessions per month during the subsequent year. The total estimated cost 
of lifestyle intervention was CHF 602 per person in the first year and CHF 333 per 
person per subsequent year. In the standard intervention group, costs were 
assumed zero in overweight people. For obese subjects the standard care 
intervention consisted in three dietitian visits in the first year, and one visit per 
year thereafter and the equivalent of two exercise sessions per month in the first 
year and one session per month during the subsequent year. The obesity 
medication costs were not taken into consideration in the standard therapy of 
obesity. Thus, a conservative estimate was preferred. The total estimated cost of 
standard care intervention in obese subjects was CHF 269 per person in the first 
year and CHF 102 per person per subsequent year. 
The costs of obesity complications were obtained from published 
literature and adjusted to 2006 Swiss Francs (CHF) prices using the consumer 
price index (Swiss National Bank 2006). A top down method using a prevalence 
approach has been used to estimate the direct and indirect costs of obesity 
complications. 
We evaluated the cost-effectiveness of lifestyle intervention versus 
standard care intervention using a cost utility analysis. The cost-effectiveness of 
interventions was compared using the incremental costs (CHF), the incremental 
effects (quality adjusted life-years, QALY) and the cost-effectiveness ratio 
(CHF/QALY). In order to assess the effect of lifestyle intervention in overweight 
and obese subjects, we defined two groups of people that were followed 
throughout the analysis: overweight subjects (BMI 28 kg/m2) and moderate obese 
subjects (BMI 33 kg/m2). A subgroup analysis was performed in male and female 
subjects aged 30, 40, 50, and 60 years. 
A probabilistic sensitivity analysis was performed (Briggs 2000). To reflect 
the uncertainty in the model parameters they were incorporated in the model as 
probability distribution. The cardiovascular risk factors data input were 
characterized as normally distributed with standard deviations based on the meta-
analysis results. Utilities score were characterized as beta distributions for two 
reasons: beta distribution takes values between 0 and 1, and it is a continuous 
distribution, which is a desirable property for representing uncertainty. Gamma 
distribution, which is constrained on the interval 0 to positive infinity, was used to 
characterize the costs of obesity complications. Gamma distribution can be highly 
skewed to reflect the skew often found in cost data. We characterized the 
distribution of the costs of interventions as normal with standard deviations equal 
to the standard error, because it cannot take values less than zero and it is 
positively skewed. Monte Carlo simulation was used to propagate these 
distributions through the model by recalculating the results over a large number of 
simulations. The results of running the probabilistic sensitivity analysis by 
randomly sampling from the parameter distributions are presented on the cost-
effectiveness acceptability curve (Fenwick 2004). 
The cost-effectiveness analysis adopted the society perspective. The 
model was developed using Microsoft Excel. 
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Value of information analysis   
Value of information analysis was undertaken for the cost-effectiveness model by 
calculating the patient expected value of perfect information (EVPI) (Claxton 
2001), population EVPI (Sculpher 2005) and the partial EVPI associated with 
model parameters (Brennan 2007). The output from the simulations was used to 
estimate the EVPI. The EVPI for an individual patient was calculated as the 
difference between the expected value of the decision made with perfect 
information and the decision made on the basis of existing evidence (Sculpher 
2005). The population EVPI was obtained using patient EVPI applied to an 
estimated annual incidence of overweight and obesity in Switzerland (Swiss 
Federal Statistical Office 2006). A discount rate of 3% was applied to the 
population size in the EVPI calculation. It was assumed that the information on 
interventions would be valuable for 10 years. We used a conservative assumption 
considering that in 10 years time, advancements in technology could influence the 
development of new interventions able to better tackle obesity and its 
complications. To determine which parameters have the greatest value of 
information and require further research, we looked on following parameters of 
the cost-effectiveness model: cardiovascular risks (body mass index, systolic 
blood pressure, total cholesterol, high density lipoprotein), utilities (overweight 
and obese patient preferences), cost of interventions (lifestyle intervention, 
standard care intervention), cost of complications (diabetes, hypertension, 
hypercholesterolemia, coronary heart disease, stroke). The partial EVPI 
calculated the value of information of the remaining parameters of the model if we 
assumed perfect information for the parameter of interest. The partial EVPI for a 
parameter or group of parameters was the difference between the expected value 
of the decision made with perfect information and the decision made on the basis 
of existing evidence (Sculpher 2005). 
 
Results  
  
Cost-effectiveness results  
Table 2 presents the results of the cost-effectiveness analysis based on current 
evidence. The lifestyle intervention resulted in increased quality of life in 
overweight and obese subjects when results were undiscounted and discounted 
at 3% rate. In overweight and obese people, the difference in quality of life 
between lifestyle intervention and standard care ranged from 0.19 to 0.41 QALY 
(undiscounted) and from 0.16 to 0.37 QALY (discounted) per person per year 
gained over lifetime, depending on gender and age group. Compared with 
standard care intervention, the average incremental cost of lifestyle intervention 
was higher in overweight than in obese subjects, ranging from CHF 510 to CHF 
704 in overweight female subjects and from CHF 402 to CHF 434 in overweight 
male subjects, when results were discounted. When results were undiscounted, 
the lifestyle intervention dominate standard care being less costly and more 
effective in obese female subjects aged 40 to 60 years and obese male subjects 
aged 30 to 60 years.  
 
 Ta
bl
e 
2.
 P
ro
ba
bi
lis
tic
 c
os
t-e
ffe
ct
iv
en
es
s 
re
su
lts
  
 
 
 
Fe
m
al
e 
M
al
e 
 
Ag
e 
U
nd
is
co
un
te
d 
D
is
co
un
te
d 
3%
 
U
nd
is
co
un
te
d 
D
is
co
un
te
d 
3%
 
 
 
C
os
ts
1  
Q
A
LY
1  
IC
E
R
 
C
os
ts
1  
Q
A
LY
1  
IC
E
R
 
C
os
ts
1  
Q
A
LY
1  
IC
E
R
 
C
os
ts
1  
Q
A
LY
1  
IC
E
R
 
30
 
42
7 
0.
19
 
22
66
 
70
4 
0.
16
 
43
58
 
10
4 
0.
24
 
43
7 
43
4 
0.
20
 
21
89
 
40
 
47
 
0.
24
 
19
5 
42
3 
0.
21
 
20
37
 
16
4 
0.
26
 
62
6 
43
8 
0.
22
 
19
59
 
50
 
89
 
0.
30
 
29
8 
38
8 
0.
26
 
15
16
 
18
7 
0.
30
 
61
6 
40
8 
0.
26
 
15
47
 
Overweight 
60
 
33
4 
0.
35
 
95
6 
51
0 
0.
31
 
16
60
 
26
3 
0.
37
 
70
7 
40
2 
0.
32
 
12
37
 
30
 
10
2 
0.
19
 
53
9 
31
0 
0.
16
 
19
22
 
-1
46
 
0.
24
 
D
2  
10
5 
0.
21
 
50
8 
40
 
-1
51
 
0.
25
 
D
2  
10
0 
0.
21
 
46
9 
-1
28
 
0.
29
 
D
2  
98
 
0.
25
 
40
0 
50
 
-1
69
 
0.
33
 
D
2  
55
 
0.
28
 
19
5 
-1
79
 
0.
34
 
D
2  
40
 
0.
30
 
13
3 
Obese 
60
 
-4
3 
0.
38
 
D
2  
11
6 
0.
34
 
34
2 
-1
24
 
0.
41
 
D
2  
27
 
0.
37
 
73
 
1 D
iff
er
en
ce
 b
et
w
ee
n 
lif
es
ty
le
 in
te
rv
en
tio
n 
an
d 
st
an
da
rd
 c
ar
e;
 Q
A
LY
, 
qu
al
ity
 a
dj
us
te
d 
lif
e 
ye
ar
s;
 I
C
E
R
, 
in
cr
em
en
ta
l c
os
t-
ef
fe
ct
iv
en
es
s 
ra
tio
; 
C
os
ts
 a
re
 e
xp
re
ss
ed
 in
 S
w
is
s 
Fr
an
cs
 (
C
H
F)
 y
ea
r 
20
06
; 
2 D
, 
lif
es
ty
le
 in
te
rv
en
tio
n 
do
m
in
at
e 
st
an
da
rd
 
ca
re
 in
te
rv
en
tio
n 
be
in
g 
m
or
e 
ef
fe
ct
iv
e 
an
d 
le
ss
 c
os
tly
  
 
Chapter 6 117 
Figure 2 presents the probability that lifestyle intervention is cost-effective for 
different threshold values in overweight people. Lifestyle intervention had a higher 
probability of being cost-effective in male compared to female subjects from the 
same age group. If the decision-maker is willing to pay CHF 2000 for a unit of 
health gain, lifestyle intervention will have a probability of being cost-effective 
ranging from 48% to 91%, depending on gender and age group with the 
exception of overweight female and male subjects aged 30 years.  
 
Figure 2. Cost-effectiveness acceptability curves of lifestyle intervention in 
overweight subjects (discounted 3%) 
 
 
Figure 3 presents the probability that lifestyle intervention is cost-effective for 
different threshold values in moderate obese people. Lifestyle intervention had a 
higher probability of being cost-effective in moderate obese subjects compared to 
overweight subjects from the same age group. Within moderate obese group, 
lifestyle intervention had a higher probability of being cost-effective in male 
compared with female subjects from the same age group. If the decision-maker is 
willing to pay CHF 2000 for a unit of health gain, lifestyle intervention will have a 
probability of being cost-effective in moderate obese subjects ranging from 52% 
to 100% depending on gender and age group. 
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Figure 3. Cost-effectiveness acceptability curves of lifestyle intervention in obese 
subjects (discounted 3%) 
 
 
Value of information results   
Table 3 presents the patient EVPI for overweight and obese people. The patient 
EVPI reached a maximum at the incremental cost-effectiveness ratio i.e. when we 
are most uncertain about the decision based on current information. A higher 
uncertainty was observed in overweight female subjects aged 30 to 40 years and 
in moderate obese female subjects aged 30 years compared to other age groups.  
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Table 3. Patient expected value of perfect information (EVPI) 
  Age Undiscounted Discounted 3% 
   EVPI (CHF) EVPI (CHF) 
30 133 198 
40 101 103 
50 83 76 Fe
m
al
e 
60 68 48 
30 87 83 
40 87 89 
50 79 67 
O
ve
rw
ei
gh
t 
M
al
e 
60 72 36 
30 80 100 
40 37 73 
50 32 78 Fe
m
al
e 
60 69 64 
30 38 78 
40 40 63 
50 30 72 
O
be
se
 
M
al
e 
60 42 77 
CHF, Swiss Francs (year 2006) 
 
Table 4 presents the populations EVPI for overweight and obese people at 
alternative thresholds values. When results were undiscounted, the population 
EVPI values ranged from zero to CHF 4.1 million in overweight people and from 
zero to CHF 2.2 million in moderate obese people, depending on age, gender and 
threshold value. When results were discounted at 3% rate, the population EVPI 
ranged from zero to CHF 6.8 million in overweight people and from zero to CHF 
3.2 million in moderate obese people, depending on age, gender and threshold 
value.  
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A graphical representation of the population EVPI in overweight people is 
presented for female subjects (Figure 4), and male subjects (Figure 5). The 
population EVPI in overweight female subjects was higher than in overweight 
male subjects reflecting a higher uncertainty. The subgroup analysis in 
overweight people estimated a higher population EVPI in male and female 
subjects aged 30 years compared to other age groups.  
 
Figure 4. Population expected value of perfect information (EVPI) in overweight 
female subjects aged 30 to 60 years (discounted 3%) 
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Figure 5. Population expected value of perfect information (EVPI) in overweight 
male subjects aged 30 to 60 years (discounted 3%) 
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We examined the partial EVPI for five groups of parameters (cardiovascular risks, 
utilities, cost of lifestyle intervention, cost of standard care intervention, cost of 
complications, all costs) and nine individual parameters (BMI, systolic blood 
pressure, total cholesterol, high density lipoprotein cholesterol, cost of 
hypertension, cost of diabetes, cost of hypercholesterolemia, cost of stroke, cost 
of coronary heart disease). Overall, partial EVPI associated with the group of 
parameters and the individual parameters was higher in overweight subjects than 
in moderate obese subjects depending on age and gender, when results were 
discounted. In overweight female subjects, the partial EVPI with the highest 
uncertainty was observed in the utilities of subjects aged 30 years (CHF 4.7 
million, Figure 6), in the BMI of subjects aged 40 years (CHF 1.3 million), and in 
the cost of stroke of subjects aged 30 years (CHF 1.1 million). In overweight male 
subjects, the partial EVPI with the highest uncertainty was observed in the utilities 
of subjects aged 30 years (CHF 2.4 million) and in the BMI of subjects aged 50 
years (CHF 1.5 million). In moderate obese female subjects, the partial EVPI with 
the highest uncertainty was observed in the utilities of subjects aged 30 years 
(CHF 1.3 million) and in the BMI of subjects aged 60 years (CHF 1.3 million, 
Figure 7). In moderate obese male subjects, the partial EVPI with the highest 
uncertainty was observed in the cardiovascular risk factors of subjects aged 50 
years (CHF 3 million), in the BMI of subjects aged 50 years (2.3 million) and in the 
systolic blood pressure of subjects aged 50 years (CHF 1.7 million). 
 
Figure 6. Partial expected value of perfect information (EVPI) in overweight 
female subjects aged 30 to 60 years (discounted 3%) 
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Figure 7. Partial expected value of perfect information (EVPI) in moderate obese 
female subjects aged 30 to 60 years (discounted 3%) 
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Discussion   
Our study demonstrated the application of value of information analysis to 
quantify the uncertainty. We tried to address the following issues: to determine if 
the selection of lifestyle intervention is optimal based on the current information 
available, to assess if it is worth collecting additional information to inform this 
decision in the future and to determine which parameters in the obesity cost-
effectiveness model have the greatest value of information and require further 
research.  
The cost-effectiveness results demonstrated that, based on existing 
evidence, the lifestyle intervention can be regarded as cost-effective only in 
certain situations depending on gender, age group, and threshold value. When no 
discount was applied, the lifestyle intervention dominated standard care in 
moderate obese people being less costly and more effective. When a discount of 
3% was applied, lifestyle intervention was cost-effective at an incremental cost 
per QALY ranging from 1237 to 4358 CHF/QALY in overweight people and from 
73 to 1922 CHF/QALY in moderate obese people, depending on age and gender. 
A recent economic review of non-pharmacological weight loss treatments found 
that if weight loss, relative to the observed trend, remains constant for 5 years 
post-intervention before returning to baseline, the cost per QALY in the best 
performing non-pharmacological studies ranges from 429 to 24566 CHF/QALY 
(NICE 2007). Our cost-effectiveness model assumed that lifestyle intervention 
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effect on weight and cardiovascular risk factors lasts for 6 years based on the 
results obtained from meta-analysis of three years randomized clinical trials in 
overweight and obese people. This assumption is in line with the extended follow-
up of the Finnish Diabetes Prevention Study which lasted 7 years and resulted in 
sustained lifestyle changes and a reduction of diabetes incidence, which was 
maintained after the individual lifestyle counseling stopped (Lindstrom 2006). The 
study reported a 43% reduction in the relative risk related to the success in 
achieving the intervention goals of weight loss, reduced intake of total and 
saturated fat, increased intake of dietary fibre and increased physical activity. 
The value of information analysis places a limit on returns to further 
research. If the costs of the research exceed the EVPI, then the proposed 
research is not cost-effective (Claxton 2001). In our analysis, the maximum 
population EVPI was CHF 6.8 million in overweight subjects and CHF 3.2 million 
in moderate obese subjects. These values represent an upper limit on the costs 
associated with the decision uncertainty. Therefore, costs associated to proposed 
future research should not exceed this amount if the research would be 
considered cost-effective. 
The partial EVPI with the highest uncertainty was observed in the utilities 
of overweight male and female subjects aged 30 years and moderate obese 
female subjects aged 30 years. One possible explanation could be that utilities 
used in the model were obtained from the published literature (Macran 2004). 
Further investigations are necessary to evaluate the overweight and obese 
patient’s preferences on weight loss treatments in Switzerland. Further research 
is needed to calculate the expected benefits and the cost of sample information in 
order to determine the optimal study design such as follow-up time, sample size 
and patient allocation. 
A higher partial EVPI was observed in the BMI of overweight female 
subjects aged 40 years, overweight male subjects aged 50 years; moderate 
obese female subjects aged 60 years and moderate obese male subjects aged 
50 years. A higher uncertainty was observed also in moderate obese male 
subjects aged 50 in parameters such as cardiovascular risk factors and systolic 
blood pressure. Therefore, further research on the cardiovascular risk factors in 
overweight and obese people in Switzerland is recommended.  
Based on the results of our study we identified four factors that influence 
the uncertainty and implicit the EVPI. The first factor was the level of the 
maximum willingness to pay for an additional unit of health gain with lifestyle 
intervention. The EVPI depended on the value of the maximum acceptable 
threshold. This was due to the interaction between the maximum acceptable 
threshold and the uncertainty surrounding the decision. When the maximum 
acceptable threshold was close to the incremental cost-effectiveness ratio then 
the uncertainty surrounding the decision was maximized. The second factor was 
the uncertainty surrounding the decision to adopt the lifestyle intervention. The 
uncertainty surrounding this decision was an important element in the calculation 
of EVPI, with the EVPI increasing with increased uncertainty. Therefore, when the 
uncertainty surrounding a decision was low, the EVPI was negligible, for example 
in obese male subjects aged 40 years the EVPI was CHF 63 when results were 
discounted. The third factor was the size of the eligible population. The size of the 
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population eligible for treatment had a direct impact on the population level 
estimates of the EVPI. Where the population was large, the scaled up population 
values were larger. For example, the population values of the EVPI were larger 
for overweight male subjects aged 50 years than for overweight male subjects 
aged 60 years due to an increase incidence of male overweight subjects aged 50 
years. The fourth factor that influenced the uncertainty and EVPI in our model 
was represented by patient characteristics such as age, gender and BMI. Our 
analysis suggests that the allocation of funds between lifestyle intervention and 
standard care in the prevention and treatment of obesity and future research will 
depend crucially upon these four factors. 
Our study results are limited by several factors related to the structure of 
the cost-effectiveness model and the EVPI analysis. The model could be 
improved by having access to additional Swiss-specific data. So far, 
epidemiological data such as the correlation between BMI and the risk of 
complications, obesity related mortality data and changes in patient utility have 
not been recorded specifically for Switzerland. Further investigations should also 
take into account other important complications of obesity such as metabolic 
syndrome, colorectal cancer, gall bladder disease, sleep apnea and depression. 
Another limitation of our study consists in the estimation of the costs of obesity 
complications from secondary data sources.  
Both probabilistic sensitivity analysis and parameter EVPI were computed 
using Monte Carlo methods. Unfortunately, to obtain these measures accurately, 
very large numbers of model evaluations are needed, potentially millions. For 
computationally expensive computer models, evaluating these measures may 
then require lengthy computing times. Our model used for the probabilistic 
sensitivity analysis a number of 3000 simulations and for the partial EVPI a 
number of 50 simulations. To assess the validity of the study results, we 
performed additional analyses for different age groups in male and female using a 
number of 5000 simulations for the probabilistic sensitivity analysis and 250 for 
the partial EVPI. The new results of the parameter EVPI showed the existence of 
a slight over-estimating bias in using small numbers of Monte Carlo samples. 
However, the overall trend of the parameters presented in the results section was 
maintained. Further theoretical investigation of Monte Carlo bias in the context of 
parameter EVPI would be useful.  
 
Conclusion   
In summary, we applied the value of information analysis to evaluate the 
uncertainty in the cost-effectiveness of lifestyle interventions in overweight and 
obese people in Switzerland. The value of information analysis indicates that 
there is some uncertainty regarding the choice between lifestyle intervention and 
standard care intervention. The extent of the uncertainty depends on the 
maximum acceptable threshold, the uncertainty surrounding the decision to adopt 
the lifestyle intervention, the size of the eligible population and patient 
characteristics. The parameter EVPI suggests that if further research is 
commissioned, this should focus on the effectiveness of lifestyle intervention on 
the cardiovascular risk factors and quality of life of the overweight and obese 
people in Switzerland. 
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Health Policy Implications:  
Decision-Makers’ Attitude  
Towards Economic Evaluations 
of Medical Technologies 
 
 
 
 
 
 
 
 
Summary 
Increasing costs have generated concern among governments and healthcare 
providers who have realized the need for cost containment measures and more 
efficient resource utilization. Health economics is one potential source of 
information that can make healthcare more efficient. We conducted a literature 
review to summarize published literature on self-reported attitudes of healthcare 
decision-makers towards economic evaluations of medical technologies and to 
determine the extent to which economic evaluations are used in health policy 
decisions. Fifty-five articles investigated the use of economic evaluations on three 
levels of decision-making: central, local and physician level. Results indicate the 
use of economic evaluation information increased from limited/minor to moderate 
use. The influence of economic evaluations increased with the level of 
centralization of healthcare system. Barriers to use health economics research 
varied across levels and included health economics research-related barriers 
such as timely availability, lack of credibility, insufficient methodological quality 
and decision-context-related barriers including limited decision-makers’ 
knowledge, inflexibility in healthcare budgets and variability among healthcare 
organizations. For consistent policy-making it is important that similar 
recommendations for cost-effective interventions and programs are developed at 
all levels and that implementation is promoted by incorporating the appropriate 
incentives in healthcare provision. 
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Introduction 
Healthcare costs have increased dramatically in recent decades in all 
industrialized countries. Increasing costs have generated concern among 
governments and healthcare providers who have realized the need for cost 
containment measures and more efficient resource utilization. Health economics 
is one potential source of information that can make healthcare more efficient. 
Health economics has been described in various ways, but most commonly as a 
set of analytical techniques to assist healthcare decision-making to promote 
efficiency and equity (Shiell 2002). Publications in economics journals in the area 
of health economics increased almost 350% from 1990 to 2000 (Rubin 2003). 
Economic evaluation of medical technologies, an integral part of health 
economics, is used to help decision-makers when addressing problems arising 
due to the scarcity issue. Economic evaluations can play an important role in 
different types of decision-making, such as defining the basic health benefit 
package (Schreyögg 2005), setting the price of a new technology (García-Alonso 
2008), reimbursement decisions (Cohen 2007), formulary decisions (Weart 2007) 
and individual patient care (Chauhan 2008). The perspectives, techniques, 
decision constraints and available information differ across countries and often 
across decision–makers.  
The aim of the economic evaluations of healthcare programs is to serve 
as an aid to decisions that affect policy-making. If economic evaluations of 
healthcare programs were to have no impact on decision about allocation of 
resources to healthcare programs, carrying out such evaluations is a meaningless 
activity. Thus, it is crucial to explore the link between economic evaluations of 
medical technologies and their use in policy decision-making. We conducted a 
literature review to summarize and synthesize published literature on self-
reported attitudes of healthcare decision-makers towards economic evaluations of 
medical technologies. The aims of this literature review was to determine the 
extent to which economic evaluations are used in health policy decision-making, 
and to consider factors associated with the utilization of such research findings.  
 
Methods 
 A systematic literature review of published English language studies was 
conducted using MEDLINE, EMBASE and HEED from January 1995 to 
December 2007. We used a full set of Medical Subject Headings terms in the 
literature search. The following terms were used individually or in association: 
‘health economics’, ‘survey’ ‘decision-making’, ‘health policy’, ‘research 
utilization’, ‘priority setting’ ‘healthcare rationing’, ‘drug cost’, ‘medical technology’, 
‘formulary inclusion’ ‘pharmacy administration’, ‘pharmacies and therapeutics 
committees’. Cross-references were checked. 
This review was restricted to empirical research i.e. surveys investigating 
the attitudes toward economic evaluations among decision-makers and actual 
use pattern. In order to focus on the analyses of actual decision-making process 
and to gain the best insight into the decision-making process as a whole, we 
included only qualitative studies.  
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The term medical technology refers to pharmaceuticals, medical devices 
and health interventions such as surgical procedures. Economic evaluation 
studies were meant to include all formal studies comparing the costs and 
consequences of relevant alternatives using indicators like cost-effectiveness, 
cost-utility, cost-minimization and cost-benefit.  
Health economics evaluations may be used by a wide range of health 
care decision-makers. Politicians, public officials, insurers, health service 
administrators, and clinicians are among the most important users of such data. 
When considering the relevance of health economics studies, we assessed the 
impact on three levels of decision-makers: central, local and physician level. The 
central level includes decision-makers with a national or regional healthcare 
perspective responsible for the availability of effective and affordable healthcare 
programs for the whole population. This includes decisions about inclusion of 
drugs on national formularies, national guidance on the use of medical 
technologies, or development of national policies or programs (e.g. screening, 
immunization). The local level includes decisions on the development of local 
programs, the purchase of equipment, and the inclusion of drugs in hospital, 
practice, or health plan formularies. The physician level covers decisions of 
individual health care professionals at the patient level. A reviewer abstracted the 
relevant study characteristics using a standardized template. Results are 
presented as percentage (%) of characteristics and reported issues from 
evaluated studies. The estimated relative importance of the decision-making 
criteria in the studies is based on our interpretation of the study results. 
 
Results 
 
Included studies and population 
Using combined search strategies, we identified 3150 abstracts, of which 2757 
were excluded on the basis of titles. The remaining 393 abstracts were reviewed. 
Of these, 195 did not include empirical research, 94 were excluded based on the 
study population, 13 were systematic reviews, 36 were health policy discussions 
and the remaining 55 articles were included in our review.  Of 55 studies 
evaluated, 45 studies evaluated only one level of healthcare decision-maker, 6 
studies evaluated two levels of decision-makers and 4 studies evaluated three 
levels of decision-makers. Table 1 provides a summary of selected studies. Of 
studies evaluated, 21 studies investigated healthcare decision-making at central 
level, 33 at local level and 15 at physician level.  
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The number of empirical research investigating the use of economic evaluations 
in healthcare decision-making process increased substantially in the last 13 years 
in response to the growing number of health economics literature. Figure 1 
presents the cumulative number of studies evaluating the decision-maker’s 
attitude towards health economics research. 
 
Figure 1. Cumulative number of studies evaluating the use of economic evaluations in 
decision-making process. 
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Table 2 presents the study research population according to the level of decision-
maker. The study population includes the decision-makers interviewed in the 
selected studies. As expected there is an increasing number of responders with 
decreasing level of decision-maker i.e. the highest number of responders is on 
physician level followed by the local level and the central level. 
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The most investigated countries were United States (US) 18 studies, United 
Kingdom (UK) 17 studies, Canada 6 studies and the Netherlands 4 studies. For 
most countries, for example Germany, France, Italy and Spain, they were only 
one or two empirical studies. The most applied research method was face to face 
interviews (42%) followed by mail questionnaire (40%), telephone interview (17%) 
and web questionnaire (2%). Some of the studies combined different methods, for 
example mail survey and interviews for investigating committees. The majority of 
studies concentrated on pharmaceutical policy (60%), followed by policy 
regarding other health care interventions (17%) or both. 
 
Influence of economic evaluations on decision-making process 
The type of economic analysis used was mostly cost-effectiveness analysis 
(51%), followed with considerable distance by cost-minimization (16%), cost-
benefit analysis (13%) and cost-utility analysis (5%). Fifteen percent of the studies 
did not specify the type of analysis used by healthcare decision-makers. Cost-
effectiveness analysis was performed mostly on central level, whereas cost-
minimization analysis was used mostly at local and physician level where the 
price of the medical technology was sometime rated as one of the most important 
aspects. The sources of economic evaluations used by decision-makers were 
published literature 25%, evaluations performed by government organizations 
(e.g. National Institute for Clinical Excellence NICE) 24%, evaluations performed 
by the industry 22%, expert opinion 12%, clinical guidelines 9% and in-house data 
7%. 
Figure 2 presents the number of studies reporting the influence of 
economic evaluations on healthcare decision-makers. Overall, the participants 
interviewed considered economic evaluations useful to inform policy decisions. 
The impact on policy is reported moderate in majority of the studies. However, an 
increasing trend in using the economic evaluation information is observed on all 
levels of decision-making: 36% on central and local level and 29% on physician 
level. In addition to economic evaluation arguments other factors appear to 
influence healthcare decision-making as well. Clinical aspects such as efficacy 
and effectiveness, and safety data were still considered the most influential 
arguments. Different aspects characterized each decision level. At central level 
there was substantial influence of regulatory and political arguments. At local 
level, there was influenced by economics, especially the drug acquisition cost. 
The physician level was dominated by the patient, disease, and the administrative 
burden. 
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Figure 2. Studies reporting the influence of economic evaluations on health care 
decision-making 
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The way in which health economics research evidence translates into policy and 
practice tends to differ across levels of decision-makers. We investigated the 
extent to which information on economic evaluations of medical technologies is 
used by national and regional authorities according to the type of healthcare 
system (tax funded or social insurance) and the degree of regionalization 
(centralized or decentralized healthcare system). From more than 24 countries 
investigated, 54% have a social security system and 46% have a tax funded 
healthcare system. Of the evaluated countries 71% have a decentralized health 
care system. Figure 3 presents the perceived influence of economic evaluations 
of medical technologies on decision-making process according to different 
structure of the healthcare system and funding mechanism. We observed that the 
influence of economic evaluations increased with the level of centralization of 
healthcare system. In other words, the higher the level of decentralization the 
lower the level of impact of economic evaluations is observed. 
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Figure 3. Influence of economic evaluations by healthcare system and funding 
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Barriers and incentives to use economic research in decision-
making 
The majority of the studies reported barriers to the use of health economics data. 
There is a certain pattern of answers which can be found in all studies that 
reported barriers. Two major types of barriers have been identified: health 
economics research-related barriers and decision-context-related barriers. Figure 
4 presents the barriers in using the economic research and their perceived 
influence as reported by healthcare decision-makers. Health economics research-
related barriers included timely availability (the data is usually not available when 
decisions have to be made), lack of credibility (studies are often sponsored by 
pharmaceutical industry), insufficient methodological quality (studies used too 
many questionable assumptions and poor quality data), communication issue 
(lack of transparency in reporting, limited peer-reviewed publications) and limited 
transferability of economic evaluations to other locations. The most important 
decision-related-context barriers included limited knowledge of decision-makers in 
health economics research field, limited decision-makers acceptability of 
economic evidence and inflexibility in healthcare budgets i.e. difficulty in moving 
resources from one budget to another.  
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Figure 4. Barriers to use economic evaluations in decision-making process 
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Another barrier to the acceptance of the economic evaluations results is the so 
called ‘silo mentality’. Health care accounting system cannot recognize how 
increased expenditure in one area reduces spending in another area. For 
example, decision-makers who have the responsibility for the hospital budget may 
be reluctant to approve the use of a costly new medical technology, even if it 
reduces overall costs to the payer, the patient or even society as a whole. 
Several studies suggested ways to overcome barriers in using economic 
research in policy decisions. Figure 5 presents the reported incentives to use 
economic evaluations data. The majority of studies suggested that considerable 
effort must be directed at educating decision-makers at all levels about the 
techniques of health economics and the relevance of this information to their 
organization or practice. This in turn would contribute to a wider use of health 
economics research. The integration of cost-effectiveness information in clinical 
guidelines was seen as an important step to the wider application of research 
economics research findings. The EUROMET survey (Hoffman 2000), which 
investigated the impact of health economics studies on decision-making in nine 
European countries, suggested that the biggest barriers to use health economics 
findings were institutional barriers, including the difficulties in transferring budgets. 
In studies that investigated the impact of economic research at physician level 
some specific barriers were identified: difficulties in substituting one drug for 
another, fear of creating a credibility gap in the doctor patient relationship, 
difficulties in denying patients drugs they ask for and direct-to-consumer 
advertising about drugs and treatment in the US.  
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Figure 5. Incentives to use economic evaluations in decision-making process 
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Discussion 
Demonstration of meaningful clinical and economic value of medical technologies 
is becoming essential when negotiating access to funding. Examples of the 
factors contributing to the pressures faced when making resource allocation 
decisions include an ageing population, greater pressure on budgets, a rising 
incidence of disease, and changes in regulatory requirements. Irrespective of the 
factors contributing to attitude changes, the influence of economic evaluations 
information in healthcare decision-making remains critical. Even though the 
evaluation procedures will varies between countries, a more formalized approach 
to health technology assessment is becoming norm in most countries (Jönsson 
2008). The present study may thus be seen as further contributing to 
understanding of the ‘reasons behind allocation of healthcare resources’.  In 
addition and sometime in contrast to previous reviews on decision-makers’ 
attitudes (Kernick 2000, Drummond 2003, van Velden 2005), our research 
suggests the use of economic evaluation information in healthcare decision-
makers increased from limited/minor to moderate use (Figure 2). Moreover, an 
increasing trend in using economic research in health policy decision-making is 
observed at all level of decision-makers. This is not surprising giving the 
increased interest of government agencies and local decision-makers to 
determine value-for-money of medical technologies around the world. 
We observed that differences in healthcare systems/funding structures 
across countries can lead to variations in decision-maker’s reaction to economic 
evaluations information and requirements to support its dissemination. It is not 
surprising that the level of economic influence increased with the level of 
centralization of health care system. For example, in the tax funded health care 
system such as UK, the NICE incorporates health economics information 
systematically in its technology appraisals and disseminates these by means of 
leaflets, monographs, databases and web sites to all purchasers and providers in 
the UK. Recent research in the UK confirms that economic analysis is highly 
integrated into NICE’s technology appraisal process (Buxton 2006). Opposed to 
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this is the decentralized nature of the organization and funding of the healthcare 
system such as Sweden, Italy, and Spain. Regionalized councils and 
municipalities, where the health economics expertise is scarcer, are responsible 
for many aspects of health and social care, and sometimes regions even compete 
with each other in the uptake of new medical technologies without consideration 
of the economic evidence. 
At the central level, some countries have gone beyond merely developing 
academic guidelines for health economics evaluations. They now use such data 
as an element in reimbursement decisions and/or clinical recommendations i.e. 
Australia, Canada, UK. Whereas socialized medicine prevails in Australia, 
Canada and Europe, the private system dominates the US healthcare system. 
Notably, 30% of the surveys evaluated were conducted in the US. Federal and 
state governments and their agencies are minimally involved in regulating medical 
technologies expenditures in the US, therefore economic evaluations information 
have limited influence on decision-making process. Instead, local decision-
makers such as health maintenance organizations, pharmacy benefit 
management companies are increasingly interested in the potential of economic 
evaluations especially when making reimbursement decisions. Recently, a panel 
composed of medical and pharmacy directors of public and private health plans 
developed a strategic plan for incorporating cost-effectiveness analysis into US 
health policy decisions (Neumann 2008). The plan has three long-term goals: 
increasing use of cost-effectiveness analysis by the Centers for Medicare and 
Medicaid Services, creating infrastructure to support research and integrating 
cost-effectiveness analysis into other public and private initiatives. Whether this 
plan will successfully incorporate economic analysis in decision-making process 
at central and local level in US needs to be seen. However, such initiatives should 
be encouraged. 
At the physician level, clinicians recognize that the resources to treat all 
patients to the best of their abilities cannot be made available, and, therefore, 
there is a need in clinical decision-making to consider the costs and well as the 
effectiveness of treatments. This is illustrated by the increasing number of 
appraisals conducted by clinicians appearing in medical journals and by the 
evidence that general practitioners believe cost should be considered when 
choosing treatments for patients (Ryan 1990). There are some possible forms of 
action which may be taken to try to make clinicians consider the cost-
effectiveness of the various alternatives available some of them already in place 
in some countries. Firstly, it may be possible to provide regulations forcing 
clinicians to consider costs as well the benefit of treatment decisions. 
Alternatively, it may be possible to provide guidelines to enforce the effectiveness 
and cost-effectiveness of the existing healthcare technologies. The degree to 
which such incentives and regulations are introduced may determine the level of 
influence of economic evaluations. Practice guidelines can influence the individual 
treatment decisions of clinicians and local healthcare providers, but economics 
based recommendations still constitute a minority in these practice guidelines in 
almost all countries evaluated. Differences among countries can be noted in this 
respect as well. In the UK, NICE provides national guidance also through clinical 
guidelines, which are often also based on cost-effectiveness information. In 
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France, priorities for introducing clinical practice guidelines are mostly determined 
by the practitioners’ need (bottom-up demand), although policy-makers may also 
identify issues for which they would like to promote clinical guidelines (Orvain 
2004). In the Netherlands, a special program was funded to develop 31 practice 
guidelines incorporating cost-effectiveness information (Niessen 2007), but after 
termination of this program there was no more systematic attention for economic 
arguments in guideline development. 
Our study has several limitations. The heterogeneous mix of the studies 
on different decision-makers and across different geographical regions may have 
limited the generalizability of the study results due to complexity of the 
environment in many countries. Some of the surveys included in the review are 
quite dated at this point and may not be very relevant anymore given all of the 
changes in the healthcare environment since then. However, to have a better 
understanding of the impact of economic studies on healthcare decision-makers, 
those studies have been included. We may have not identified all relevant 
literature on this topic given the large implications in the international healthcare 
policy; however, an attempt to approach this complex issue was made by 
systematically assessing the literature. 
Self-reported attitudes of decision-makers towards economic research 
can be a useful and relatively rapid means of gaining the perspective and insights 
of key stakeholders who make or influence policy decisions. There are however, a 
number of limitations to such surveys. These include the difficulty in ensuring that 
all key decision-makers are included and the difficulty in obtaining sufficient 
feedback on the findings and conclusions from responders for validation. Like all 
surveys, they also capture a moment in time. This especially can be limiting with 
policy-maker surveys, since changes in governments can result in changes in key 
decision-makers and in program priorities. Given these limitations, policy-makers 
surveys are most appropriate as means of initially identifying key issues such as 
factors influencing the use of economic evaluations, barriers and incentives to its 
use. 
In conclusion, we observed different ways of incorporating economic 
evidence at the central, local and physician level. For consistent policy-making it 
is important that similar recommendations for cost-effective interventions and 
programs are developed at all levels and that implementation is promoted by 
incorporating the appropriate incentives in health care provision, in educating 
healthcare providers to understand the economics based guidance and to 
enhance the basis for implementation by involving them in developing the 
guidance. Our results indicate a trend in higher impact of economic arguments in 
all levels of decision-making. May be the best way forward is to focus on the 
cooperation between different disciplines in providing the best scientific evidence 
and produce guidance which is balanced in terms of integrating different societal 
values and is therefore widely accepted. In state run systems like the UK this has 
been achieved at the central level by NICE. In social insurance and more 
decentralized systems, however, the development and implementation of practice 
guidelines which are set up by multidisciplinary teams as well and systematically 
include cost-effectiveness information may proof the best way of overcoming the 
gap between the availability and use of health economics evidence.  
Chapter 7 141 
 
Acknowledgement 
This study did not receive funding. 
 Chapter 7 142 
 
 143 
Chapter 8                     
 
 
 
 
 
 
Discussion  
 
 
 
 
 
 
 
 
 
This chapter discusses the main conclusions of this thesis. All separate chapters 
ended with detailed conclusions and discussions of the results. We will not repeat 
these here. This final chapter brings together the various conclusions along the 
lines of the challenges presented in the introduction. In addition, this chapter will 
identify and discuss areas for further research. 
 
Methodological and practical challenges of health technology 
assessments 
 
The use of meta-analysis in systematic literature review 
Systematic review and meta-analytical methods are already common approaches 
to the assessment of health technology and increasing adoption of such 
approaches may be foreseen in response to increasingly wide emphasis on 
evidence-based approaches to medicine and healthcare. Chapter 2 presented a 
systematic literature review with meta-analysis to assess the long-term 
effectiveness of lifestyle interventions in the prevention and treatment of obesity. 
Despite its widespread use, meta-analysis continues to be a controversial issue. 
An important consideration is the possibility of heterogeneity between study 
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outcome estimates. It has been argued that producing an overall combined 
estimate for heterogeneous studies is wrong and leads to a result which is 
misleading, and impossible to interpret. A much used quote is that it is equivalent 
to: ‘combining apples and oranges and the occasional lemon’ (Rhee 2007). 
However, there are no clear guidelines outlining how variable study results have 
to be before it is deemed invalid to combine them. In chapter 2 we addressed the 
issue of heterogeneity by taking into consideration the following factors: we 
determined the study question of the evaluated studies, evaluated the similarities 
or dissimilarities in the study design, and looked if the heterogeneity of the 
outcomes can be explained. However, no consensus has been reached 
concerning the best strategy for dealing with heterogeneity; currently a large 
degree of subjectivity is required on the part of the reviewer. In chapter 2 we 
investigated the heterogeneity using the following techniques: funnel plot for 
publication bias, random effect model, subgroup analysis, sensitivity analysis, and 
quality assessment scores. 
Methodologies for critical appraisal of the research evidence, including 
ways of assessing the quality of the primary studies have been developed. These 
encompass the relatively simple fixed effect approaches, through random effects 
models, to more sophisticated hierarchical modeling (Branscum 2007). The more 
complex methods were largely devised to deal with heterogeneous outcomes, 
systematic variation between studies, and the need to incorporate a fuller set of 
components of variability into the model. Several of these methods have come 
under criticism. The fixed effect model assumes no heterogeneity between the 
study results i.e. the studies are all estimating one single true value underlying all 
the study results (Hasselblad 1995). Hence, all observed variation in the 
treatment effects between the studies is considered due to sampling error alone. 
The random effects method (DerSimonian 1986) incorporates an assumption that 
the different studies are estimating different, yet related, treatment effects. The 
random effects method is based on the inverse variance approach, making an 
adjustment to the study weights according to the extent of variation, or 
heterogeneity, among the varying treatment effects. Mengersen et al (2005) 
carried out a meta-analysis of the effect of passive smoking on lung cancer, and 
investigated the difference in results when using different methods. They state 
that different conclusions may have been drawn if only fixed or random effect 
methods had been used. 
Some authors (Covey 2007) investigated the effects of presenting 
treatment benefits in different formats on the decisions of both patients and health 
professionals. Three formats were investigated: relative risk reductions, absolute 
risk reductions, and number needed to treat or screen. The meta-analysis showed 
that treatments were evaluated more favorably when the relative risk format was 
used rather than the absolute risk or number needed to treat format. In chapter 2 
we measured the outcome as the ‘difference in means’ that is a standard statistic 
that measures the absolute difference between the mean values in the two 
groups in a clinical trial. It estimates the amount by which the treatment changes 
the outcome on average. It can be used as a summary statistic in meta-analysis 
when outcome measurements in all trials are made on the same scale. 
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The robustness of our meta-analysis was investigated through sensitivity 
analysis by incorporating the quality of the evaluated studies. Our sensitivity 
analysis did not change the results of the main analysis; therefore it strengthens 
the confidence that can be placed in these results. However, there are several 
practical issues to consider when assessing the quality of studies. The first issue 
is whether to blind the assessors to aspects of the randomized controlled trials. 
Previous research (Jadad 1996) investigated the effects of blinding, and found 
evidence to suggest that blinded assessment produced significantly lower and 
more consistent scores than open assessment. However, lifestyle interventions 
cannot be blinded in randomized controlled trials. To address this issue in chapter 
2, we made an adjustment in the 5-point Jadad score to use an appropriate 
quality check for open assessment in randomized controlled trials of lifestyle 
intervention. Another issue is that some large and complex trials report the details 
of study methodology in separate earlier publications. Some authors (Detsky 
1992) argue that looking at this material would probably increase quality score of 
the trial above the score it would achieve when considering it in isolation. 
It has long been accepted that research with statistically significant results 
is more likely to be submitted and published than work with null or non-significant 
results (Easterbrook 1991), which leads to a preponderance of false-positive 
results in the literature (Begg 1989). The implications of this for meta-analysis are 
that, even if all published studies have been identified, these may be only a 
subset of the studies actually carried out. Since positive results are more likely to 
be published than negative ones, combining only the published studies (Begg 
1989) uncritically may lead to an over optimistic conclusion. Publication bias has 
long been recognized as a problem in this regard since it means that the 
likelihood of finding studies is related to the results of those studies (Dickersin 
1992a). One way to investigate whether a review is subject to publication bias is 
to prepare a ‘funnel plot’ and examine this for signs of asymmetry. Effect 
estimates from small studies will therefore scatter more widely at the bottom of 
the graph, with the spread narrowing among larger studies. In chapter 2 we 
investigated the effect of publication bias by plotting the outcome measure, in this 
case body weight, against the standard error. Here the treatment effect did not 
lead to funnel plot asymmetry. However, it is worth mentioning that although 
funnel plots may alert reviewers to a problem which needs considering, they do 
not provide a solution to this problem. The only satisfactory way to address 
publication bias and the inadequate quality of individual trials is through 
prospective registration of trials (Dickersin 1992b) and improvements in the 
quality of the conduct, analysis and reporting of studies, meta-analyses and 
systematic reviews (Begg 1996, Moher 1998). 
However, despite these drawbacks, meta-analysis has several advantages. If 
it is well conducted, meta-analysis allows for a more objective appraisal of the 
evidence, which may lead to resolution of uncertainty and disagreement. Meta-
analysis may reduce the probability of false negative results and thus prevent 
undue delays in the introduction of effective treatments into clinical practice. 
Meta-analysis of a large number of individual studies or of individual patient data 
allows testing of a priory hypothesis regarding treatment effects in subgroups of 
patients. In conclusion, meta-analysis is a potentially powerful technique to 
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systematically review, analyze, and synthesize the body of research on a specific 
medical intervention. 
 
Measurement of patient reported outcomes 
Chapter 3 demonstrated the validity and subject acceptability of the EDC version 
of the Irritable Bowel Syndrome-Quality of Life measure (IBS-QOL), EuroQoL 
(EQ-5D), and the Work Productivity and Activity Impairment Questionnaire for 
Irritable Bowel Syndrome (WPAI:IBS) as compared to the existing paper versions.  
Traditionally, health-related quality of life data have been collected through patient 
self-report questionnaires printed on paper forms. Recently, the electronic 
methods of data collection are increasingly used in clinical trials. Although a 
concern exists that patients, particularly elderly, may be resistant to using new 
technology, several studies in different disease areas have suggested that EDC 
methods were preferred over traditional paper-and-pen methods by elderly 
volunteers and patients (Yarnold 1996). Surveys in patients with diabetes, 
gastrointestinal and psychiatric disease found that interactive computer programs 
were well accepted by the patients and provided reliable information (Pouwer 
1998). The development of automated computer systems is therefore a promising 
approach to collection of health-related quality of life data in busy clinical 
practices. However, before a new method of administration of existing validated 
questionnaires can be recommended for wider use, the method should be 
evaluated for its effect on the reliability and validity of the instrument and for its 
effect on patient responses. This type of study represents a challenge for 
producers of medical technologies as they are including this evidence as part of 
their submission for market approval. In particular, the challenges related to the 
electronic validation study presented in chapter 3 include the following aspects: 
small sample size (72 patients), recruitment problems, e-diary programming, and 
data analysis issues. The study tried to estimate a balance between the following 
impacts: the minimum sample needed to effectively run some of the statistical 
tests is usually 50 but depends on the number of items in measure; the types of 
tests needing to be run (e.g. a larger sample would be needed if we are factoring 
subscales), the target population and the condition, and resource availability (e.g. 
needs of the study design, logistical limitation). The study encountered 
recruitment problems due to the fact that IBS is a disease that occurs 
predominantly in female, therefore an equal number of male patients was 
challenging. Another challenge was related to programming of the e-diary: some 
questions had a long text and therefore were divided into two screen shots, the 
Visual Analog Score of the EQ-5D could not be programmed on the vertical axis 
but horizontally, the skip button function was not included so that the patients 
would not have the option to skip a question. The later would have had 
implications for the missing data which is crucial for a small sample size study.  
All these programming issues posed a danger of EDC not being equivalent to the 
paper version format. However, such decisions had to be made in order to ensure 
the completeness of the study. As the evaluation of PRO endpoints in medical 
interventions continues to grow, there is an increasing interest in using these 
outcomes for labeling and promotional purposes. It is vital that these claims be 
based upon sound scientific evidence. 
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The use of decision analytic models 
The use of decision-analytic modeling for HTA has increased exponentially in 
recent years. The process of decision analytic modeling is now seen as central to 
the process of HTA (Philips 2004). Usually their objective is to obtain a clear 
understanding of the relationship between incremental cost and effect in order to 
assess relative cost-effectiveness and to determine which interventions should be 
adopted given existing information. Decision analytic models provide a key role in 
translating the uncertainty associated with parameters (e.g. the cost of a 
particular adverse event, the quality of life impact of a condition or the relative risk 
reduction associated with a specific intervention) into the uncertainty associated 
with making a decision regarding the use of particular technologies (Claxton 
2002). They are also a valuable tool for quantifying the implications (in terms of 
resource costs and health gain forgone) of that decision uncertainty which, in the 
form of expected value of perfect information, can be used to set priorities for 
future research (Claxton 2001). 
Chapter 4 and 5 presented two examples of decision analytic models 
developed to inform decision-making process. The two cost-effectiveness models 
resulted in the dominance of the new medical intervention over existing treatment 
and are therefore in contrast with the more common outcome, that one 
intervention is both more effective and more costly allowing a less straightforward 
recommendation.  
Given that decision models are being used more widely as part of HTA, it 
is important that the rigor of such studies is constantly enhanced. There are, 
however, a large number of specific issues for methods in decision modeling such 
as identification of parameter estimates from literature, bias in parameter 
estimates and extrapolation of treatment beyond the duration observed in clinical 
studies. 
Decision models usually include a large range of different types of 
parameters, such as treatment effects, baseline event rates which may relate to 
the natural history of the condition, quality of life effects, health state values or 
utilities, resource use and unit costs. It is very rarely the case that one source of 
information will provide data for all these parameter estimates. The process of 
searching for information to populate each parameter in a decision model is 
extremely resource intensive. Decision models often have to be developed rapidly 
to inform particular decisions at a certain point in time. We address this issue in 
chapter 5 by performing a systematic literature review to search for data input. 
We focused our attention on parameters that we expected to be more sensitive 
and likely to have the largest influence on the results of the model such as body 
weight, cardiovascular risk factors, and cost of medical interventions. As part of 
the process of literature searching for parameter estimation, we also identified 
information that contributed to the development of the structure of the model. 
Another issue in decision modeling relates to bias in parameter estimates. 
Despite an emphasis in the methods literature on the need to derive treatment 
effect estimates from randomized controlled studies, which, in principle, exhibit 
absence of selection bias, this may not be possible for all decision problems. In 
the absence of trial data, there is little guidance on how to adjust estimates of 
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treatment effect from observational studies where there are risks of selection bias. 
However, to avoid this issue, both models presented in chapter 4 and 5 used 
parameter estimates from randomized controlled studies.  
One big challenge that regulatory agencies have to face in terms of the 
uncertainty surrounding existing evidence relates to costs and outcomes which 
have not been observed directly in trials. A feature of many trials is their short-
term follow-up. This is particularly true of Phase III regulatory trials where there is 
a strong need to satisfy the licensing authorities and hence to get the product to 
market as swiftly as possible. For those interventions between which costs and 
benefits are likely to differ over an extensive time period, there will inevitably be a 
mismatch between trial follow-up and the appropriate time horizon of the cost-
effectiveness analysis as was the case in chapter 4. This required the decision 
model to estimate the costs and health outcomes beyond the trial, together with 
the uncertainty associated with the extrapolation.   
 In conclusion, decision analytic models represent an explicit way to 
synthesize evidence currently available on the outcomes and costs of alternative 
(mutually exclusive) medical interventions. Given that the evidence base 
associated with new medical interventions will always have weakness and 
limitations; the adoption decision requires an analytical framework which is 
explicit in its handling of uncertainty. 
 
Characterizing uncertainty in decision analytic models 
Uncertainty is ubiquitous in all HTA decision models. Within modeling, 
researchers have tended to distinguish between parameter, structural and 
methodological uncertainty (Akehurst 2000). It has been suggested that the 
limitations of the chosen model structure should be acknowledged (Ramsey 
1999) and a sensitivity analysis using alternative model structures should be 
performed (ISPOR 2003). In chapter 4 and 5 the structure of our models was 
dictated by the available data input, therefore the structural uncertainties could 
not be properly addressed. No proven methods exist to evaluate the structural 
uncertainties except to compute cost-effectiveness estimates for each alternative 
structural assumption and to examine the appropriateness of the results (Hay 
1999). We addressed the methodological uncertainty in chapter 4 and 5 by using 
alternative discounting assumptions in line with the recommended way of 
addressing this issue (Halpern 1998). 
 The principal focus of uncertainty in literature has been on parameter 
uncertainty. Some suggest that parameters with the greatest level of uncertainty, 
such as those derived from expert opinion or those with greatest influence on the 
model outcomes, should be subjected to sensitivity analysis (Halpern 1998, Soto 
2002) whereas others suggest that it should be the key clinical variables and the 
main cost drivers (Nuijiten 1998, Ramsey 1999). Nevertheless, the parameters 
and the value chosen for the sensitivity analysis should be presented and justified 
(ISPOR 2003). There is disagreement about the most appropriate approach to 
exploring parameter uncertainty. Parameter uncertainty can be addressed by 
univariate, multivariate or probabilistic sensitivity analysis, analysis of extremes, 
joint confidence intervals, bootstrap techniques or Monte Carlo simulation (Hay 
1999). To address parameter uncertainty, chapter 4 and 5 used probability 
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distribution and Monte Carlo simulation rather than a point estimate. One reason 
for performing probabilistic sensitivity analysis in chapter 5 was to determine 
whether it would be worthwhile to seek better data for future decisions. 
Recommendations for the conduct or future design of research to obtain further 
data can be based on informal interpretation of the implications of sensitivity 
analysis or formal value of information techniques. 
There has been an increasing interest in using expected value of 
information theory in medical decision-making, to identify the need for further 
research to reduce uncertainty in decision and as a tool for sensitivity analysis 
(Claxton 2001). Chapter 6 highlights the importance of identifying, quantifying, 
and incorporating parameter uncertainty in decision models. In addition to the 
precision of the data, the quality of the evidence available on a particular part of 
the model may be limited. In our model, this was seen in the link between weight 
loss and cardiovascular risk factors.  
Chapter 6 demonstrated that Bayesian decision theory and value-of-
information analysis is a valuable and practical framework within which two 
conceptually separate decisions problems were addressed: the selection of the 
lifestyle intervention strategy given existing information, and identification of the 
value of further information collection to inform this choice in the future. However, 
by observing an expected value of perfect information greater than the cost of 
additional research provides only the necessary but not sufficient condition for 
deciding to acquire more experimental information i.e. conducting a clinical trial. 
For a full analysis it is necessary to estimate the benefits of sampling, or the 
expected value of sample information for the patient population, and the cost of 
sample information, including the additional treatment and reporting cost. The 
expected value of sample information was not studied in our research.  
Given that reimbursement authorities call for additional research on a new 
technology, even when these authorities approve the use of the therapy in 
question, data on value of information is expected to be very valuable. The formal 
use of value of information techniques will likely be increased over time in line 
with the recently growth in conditional reimbursement. 
 
The use of economic evaluations in decision-making  
Chapter 7 looked at the way health economics information is used in healthcare 
decision-making process. It evaluated the influence of economic research at the 
national, local and physician levels. Our review indicates that there is a 
considerable interest amongst policy decision-makers in health economics 
research, but that only moderate use was found at central, local and physician 
level. The influence of economic evaluations depends on several considerations, 
including the information needs of decision-makers, transparency of the economic 
evaluation and subsequent decision-making, mechanisms for enforcing the 
decision, and processes for monitoring and reappraising the evidence (Hutton 
2006, Zentner 2005). For example, the gap between the long-term perspective of 
technology assessments and the short-term perspectives of policy-makers can 
limit the usefulness of recommendations (Neumann 2004). Moreover, broader 
health system characteristics, such as decentralized management, inadequate 
public resources or ‘silo’ budgeting, as well as existing incentives for 
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manufacturers and academics to deliver research that is interesting rather than 
practical and focused, may also prevent the best use of economic evaluation 
(Rutten 2005; OECD 2003). 
The ability of HTA to maximize health for a given budget is difficult to 
assess in practice. Obstacles to effective assessment include the many other 
factors influencing policy and practice decisions, and the long-term nature of 
some of the effects of HTA such as changes in expectations and behavior 
patterns of users (Hailey 2007). If recommendations are to be implemented and 
the technologies taken up, there must be a clear and well communicated 
decision-making process in place. A lack of a defined process can create doubts 
over the legitimacy of decisions and therefore be less likely to have the support of 
stakeholders. It is difficult to incorporate evidence into poor-defined decision-
making processes because the producers of evidence will be less likely to deliver 
timely and relevant advice. Part of instituting a clear decision-making process 
involves identifying an assessment framework that aligns incentives with evidence 
and health system objectives. 
HTA has become an important mechanism for supporting priority-setting 
and decision-making. In particular, the growth of HTA reflects the demand for well 
founded information to support evidence-based decisions on the adoption and 
provision of health technologies. While there is general consensus that HTA 
provides value, this brief has highlighted a number of issues that can affect – 
positively and negatively – the effectiveness and impact of HTA. Successful 
implementation of HTA can be facilitated if there are appropriate policy 
instruments and regulatory levels available; a prior commitment by decision-
makers to use assessment reports in decision-making process; available 
resources to implement decisions; stakeholder involvement; and transparency in 
both assessment and decision-making process.  It nevertheless remains a 
challenge and one of the least developed areas of the overall HTA process. 
 
Areas for further research 
Many technical and methodological hurdles remain, and they need further 
investigation and research. They include the ability of summary measures to 
capture other benefits important to patients and the public; the generalisability of 
studies beyond a particular setting or country; the inability to account for the 
opportunity costs of expensive, new technologies; and the comparability between 
health state elicitation instruments. 
HTA assessments are only helpful if they are used to support decision-
making. Relevant stakeholders should be involved in order to facilitate the 
acceptance and implementation of decisions. There must be a transparent and 
well-communicated decision-making process to give legitimacy to subsequent 
recommendations. The availability of relevant policy instruments and collaboration 
between national and international HTA bodies also facilitate effective and 
efficient implementation. Existing evidence shows that stakeholder involvement 
can lead to greater transparency, relevance and acceptance of decisions, but little 
attention has been paid to how they are involved in the assessment process and 
how and when their perspectives are considered. More studies should be 
supported on the role and influence of various stakeholders, especially patients. 
Chapter 8 151 
International collaboration between across HTA bodies can help facilitate 
methods development and more efficient assessment process, thereby improving 
the impact of HTA. An example is the European Network for Health Technology 
Assessment (EUnetHTA 2007), which was developed in response to an EU 
request for a formal, sustainable European network. International partnerships 
and networks are necessary to improve coordination, reduce duplication of effort, 
develop practical tools for HTA and improve the transfer of HTA into policy. 
There is a lack of understanding about the ‘real world’ impact of HTA, not 
only on decision-making, but also on health outcomes, care delivery, healthcare 
costs, and research innovation. Several challenging questions remain regarding 
the circumstances surrounding the practical use of economic evidence in 
decision-making and priority-setting (When is it specifically used? How are criteria 
applied in practice and how are they weighted against the broad spectrum of 
decision factors? For a given disease area or public health problem, has HTA 
appropriately and accurately identified interventions that have led to improved 
health outcomes? Has the use of HTA led to better managed healthcare budgets 
or a decrease in healthcare costs? Does HTA provide sufficient incentives to 
facilitate innovative research and development? Has this ‘fourth hurdle’ in the 
reimbursement process prevented manufacturers from investing in new and 
innovative therapies? How can HTA be more broadly applied?). More focused 
research in these areas is needed. Greater efforts should be made to set up a 
formal evaluation component in the HTA process. Only by securing a better 
understanding of the decision-making process and the practical application of 
HTA can the impact of economic evaluation be enhanced. 
There is limited information on the use of HTA for identifying areas of de-
investment. More research is needed to identify ineffective and obsolete 
technologies and interventions. Reassessment after a technology has been used 
in practice is also an important mechanism in ensuring effective implementation. 
Regular review and re-evaluation are crucial in ensuring the availability of cost-
effective and value-added medical technologies. While significant advances have 
been made on assessment methodologies, there is limited knowledge of how 
non-quantifiable factors are considered in the HTA process; this is especially true 
of equity concerns. Further exploration is needed to find out how such issues are 
taken into account in both assessment and subsequent decision-making, in order 
to address the social implications and constraints of efficient and equitable health 
care. 
There is also a lack of research on the systematic assessment of public 
health interventions, especially those focused on prevention. Until now HTA has 
focused particularly on pharmaceuticals. In this thesis we give examples of how 
other medical interventions such as lifestyle intervention could be assessed. The 
application of the principles and methods of economic evaluations to preventive 
measures should be further explored, in an attempt to move towards a more 
evidence-based approach to important population health issues such as obesity 
or smoking. Given the limited evidence on the economic evaluation of public 
health interventions, more research should be funded to identify what 
assessments have been done so far, and what they revealed. 
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There is an increasing need to better account for uncertainty in 
assessment and decision processes, such as conditional approvals to make new 
technologies available while gathering additional data to address areas of 
uncertainty. Conditional approvals provide for the later collection of real-world 
data and reduce the potential opportunity costs of making inappropriate or 
inaccurate decisions. This thesis gave examples of how to methodologically 
address the uncertainty in the economic evaluations of medical technologies. 
However, further research is needed in conditional approvals using real word data 
to assess the uncertainty surrounding new and emerging technologies. 
In conclusion, HTA offers extensive opportunities to support governments 
and other stakeholders, although issues remain concerning its use in, and impact 
on, healthcare policy and decision-making. Many of these have been highlighted 
in this thesis. The role of HTA in decision-making has grown substantially, but the 
need and demand for policy-makers to employ and translate evidence-based 
decisions into direct effects on health care costs and outcomes will probably 
increase in the next years. 
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Summary  
 
 
 
 
 
 
 
 
 
 
 
 
Health technology assessment (HTA) originated from the spread of costly medical 
equipment and growing concerns over the ability and willingness of taxpayers and 
health insurers to pay for them. HTA include a range of medical interventions, 
including drugs, medical devices, medical and surgical procedures, and the 
organizational and support systems used in care provision. It involves evaluating an 
intervention through the production, synthesis, and/or systematic review of a range 
of scientific and non-scientific evidence. The evidence typically considered includes 
safety, efficacy, cost, and cost-effectiveness, as well as the social, organizational, 
legal, and ethical implications. The main aim of HTA is to provide a range of 
stakeholders, typically those involved in funding, planning, purchasing, and 
investing in healthcare, with accessible, useable, and evidence-based information 
that will guide decisions about technology and the efficient allocation of resources. 
It has been called ‘the bridge between evidence and policy making’, because it 
provides information for health care decision-makers at macro-, meso-, and micro-
levels. In particular, the increased use of medical technologies has encouraged 
decision-makers to rely on HTA to help determine the reimbursement status and 
pricing of interventions. HTA also contributes in many ways to the knowledge base 
for improving the quality of care, especially in supporting the development of clinical 
practice guidelines and health service standards. 
The present thesis addresses some of the methodological challenges of 
the health technology assessment and evaluates the impact of economic 
evaluations in healthcare decision-making process. 
 
The use of meta-analysis in systematic literature review 
Systematic reviews have a central role in evidence based-medicine. The 
quantitative systematic review, also known as meta-analysis provides a logical 
structure for quantifying the existing evidence. Meta-analysis offers the opportunity 
to critically evaluate and statistically combine results of comparable studies or trials. 
The aim is to get a consistent estimation of the global effect of a procedure on a 
specified outcome by increasing the number of observations and statistical power. 
This thesis presents the results of a systematic literature review with meta-analysis 
on the effectiveness of lifestyle intervention in the prevention and treatment of 
obesity. The global rise in obesity prevalence continues to be a threat to people’s 
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health. This review is part of a HTA in the prevention and treatment of obesity 
performed for Swiss Ministry of Health to support the decision to allocate funds in 
the prevention of obesity programs in Switzerland in 2007. The systematic review 
provides new information on the effectiveness of lifestyle interventions by assessing 
the mid- to long-term effects on weight and cardiovascular risk profile in overweight 
and obese people. An important consideration when performing meta-analyses is 
the possibility of heterogeneity between studies outcome estimates. It has been 
argued that producing an overall combined estimate for heterogeneous studies is 
wrong and leads to a result which is misleading, and impossible to interpret. 
However, there are no clear guidelines outlining how variable study results have to 
be before it is deemed invalid to combine them. We address this issue of 
heterogeneity by taking into consideration the following factors: we determined the 
study question of the evaluated studies, evaluated the similarities or dissimilarities 
in the study design, and looked if the heterogeneity of the outcomes can be 
explained. However, no consensus has been reached concerning the best strategy 
for dealing with heterogeneity; currently a large degree of subjectivity is required on 
the part of the reviewer. In this thesis we investigated the heterogeneity using the 
following techniques: funnel plot for publication bias, random effect model, 
subgroup analysis, sensitivity analysis, and quality assessment scores. We 
concluded that meta-analysis is a potentially powerful technique to systematically 
review, analyze, and synthesize the body of research on a specific medical 
intervention. 
 
Measurement of patient reported outcomes 
Patient reported outcomes provide the patient perspective on the effectiveness of 
treatment. Patients, clinicians, pharmaceutical industry, decision-makers, payers 
and regulatory authorities acknowledge the need to understand the impact of 
symptoms and diseases on patients’ lives and to evaluate how treatment affects 
patient functioning and well-being as a criterion for licensing new medications and 
for policy decisions. Traditionally, patient reported outcome data in clinical trials 
have been collected through patient self-report questionnaires printed on paper 
forms. Recently, the electronic methods of data collection are increasingly used in 
clinical trials. Although a concern exists that patients, particularly elderly, may be 
resistant to using new technology, several studies in different disease areas have 
suggested that EDC methods were preferred over traditional paper-and-pen 
methods. For patient reported outcome endpoint data to be accepted as evidence 
of treatment effectiveness there must be evidence documenting the instrument’s 
conceptual framework, content validity, and psychometric qualities, including 
reliability, validity and responsiveness. 
This thesis presents the data collected from a study that establishes the 
validity of the electronic versions of three quality of life measures in comparison to 
the existing paper versions. A selective 5-HT4 receptor partial agonist was 
developed for the treatment of functional gastrointestinal dysmotility disorders by 
Novartis Pharma. A multinational clinical trial has been completed using electronic 
data collection. In order to evaluate changes in patient reported outcomes, standard 
instruments were included to assess change in patients’ quality of life (IBS-QOL), 
productivity (WPAI:IBS-C), and utility (EQ-5D).  For health technology 
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manufacturers it is important to provide evidence of the validity of the quality of life 
instruments in the electronic format as compared to paper version. This type of 
study represents a challenge for producers of medical technology which have to 
include this evidence as part of their submission for market approval. In particular, 
the challenges encountered by electronic validation study presented in this thesis 
included the following aspects: small sample size (72 patients), recruitment 
problems, e-diary programming, and data analysis issues. All these programming 
issues posed a danger of the electronic data capture not being equivalent to the 
paper version format. However, the study proved to be successful. It is vital that 
patient reported outcome claims be based upon sound scientific evidence. 
 
The use of decision analytic models 
Mathematical modeling is used widely in economic evaluations of medical 
interventions. Health economics models represent an important analytic framework 
to generate estimates of cost-effectiveness. The purpose of modeling is to structure 
evidence on clinical and economic outcomes in a form that can help to inform 
decisions about clinical practices and healthcare resource allocations. Models 
synthesize evidence on health consequences and costs from many different 
sources, including data from clinical trials, observational studies, insurance claim 
databases, case registries, public health statistics, and preference surveys. The 
use of decision-analytic modeling for health technology assessment has increased 
exponentially in recent years. 
Given that decision models are being used more widely as part of HTA, it is 
important that the rigor of such studies is constantly enhanced. There are, however, 
a large number of specific issues for methods in decision modeling such as 
identification of parameter estimates from literature, bias in parameter estimates 
and extrapolation of treatment beyond the duration observed in clinical studies. We 
addressed these issues in two decision analytic models developed to inform 
decision-making process. One model presents the development and results of a 
cost-effectiveness model of zoledronic acid versus risedronate in Paget’s disease 
of bone. Zoledronic acid is a third generation of nitrogen containing bisphosphonate 
seeking approval for Paget’s disease of bone indication. For registration purposes 
two six-month randomized clinical trials were performed in order to evaluate the 
safety and efficacy of intravenous zoledronic acid for the treatment of Paget’s 
disease of bone using oral risendronate as a comparator. The economic model, 
based on the two clinical trials, goes beyond six-month and evaluates the cost-
effectiveness of zoledronic acid versus standard therapy, risedronate, for the first 
two years of market access of zoledronic acid in the United Kingdom. 
The second model presents the development and results of an economic 
analysis that evaluates the lifetime effects of three-year lifestyle intervention in the 
prevention and treatment of obesity. The model estimates the cost-effectiveness of 
lifestyle intervention versus standard treatment in overweight and obese people in 
Switzerland. The model is a key component of the HTA that was carried out for 
lifestyle intervention in obesity area. Probabilistic sensitivity analysis was 
undertaken to establish the uncertainty associated with the decision to adopt the 
lifestyle intervention program in the prevention and treatment of obesity. 
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We concluded that decision analytic models represent an explicit way to 
synthesize evidence currently available on the outcomes and costs of alternative 
medical interventions. Given that the evidence base associated with new medical 
interventions will always have weakness and limitations; the adoption decision 
requires an analytical framework which is explicit in its handling of uncertainty. 
 
Characterizing uncertainty in decision analytic models 
Most review agencies conduct or require sensitivity analyses on all variables that 
could potentially influence the overall results of the economic evaluation. This is 
because of the uncertainty inherent in conducting economic evaluations, 
specifically over the value of particular estimates and their relative effect on costs 
and benefits. The stipulation for sensitivity analyses comes from the need to test or 
verify the robustness of the findings. Traditionally, the uncertainty has been 
examined using sensitivity analysis. In the recent years there has been 
considerable emphasis on the development of appropriate statistical methods for 
handling uncertainty in economic evaluations of medical interventions, with a 
tendency to move from univariate sensitivity analysis towards probabilistic 
descriptions of uncertainty e.g. cost-effectiveness planes, cost-effectiveness 
acceptability curves and distributions of incremental net benefit. Value of 
information analysis is a natural methodological extension of Bayesian decision 
theory that quantifies the existing level of uncertainty and estimates the impact on 
the expected net benefit of alternative decision options through obtaining perfect 
information on model parameters. We addressed the uncertainty in this thesis by 
performing probabilistic sensitivity analysis and by evaluating the value of additional 
information. We used the value of information analysis on a probabilistic cost-
effectiveness model of lifestyle intervention in overweight and obese people to 
evaluate the uncertainty. Our analysis quantified the uncertainty surrounding the 
decision to adopt lifestyle intervention. 
Given that reimbursement authorities call for additional research on a new 
technology—even when these authorities approve the use of the therapy in 
question—data on value of information is expected to be very valuable. The formal 
use of value of information techniques will likely be increased over time in line with 
the recently growth in conditional reimbursement. 
 
The use of economic evaluations in decision-making  
The importance of health economics research utilization in policy-making 
and of understanding the mechanisms involved is increasingly recognized. The 
existence of relevant research, though necessary, is not sufficient. Evidence-based 
policy is difficult to achieve and it is widely agreed that health policies do not reflect 
research evidence to the extent that in theory they could. In this thesis we assessed 
the use of research evidence relating to economic analyses in healthcare decision-
making. We conducted a literature review to summarize and synthesize published 
literature on self-reported attitudes of healthcare decision-makers towards 
economic evaluations of medical technologies. The aims of this literature review 
was to determine the extent to which economic evaluations are used in health 
policy decision-making, and to consider factors associated with the utilization of 
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such research findings. Examination of the policy-making process confirms it to be 
complex, with many genuine obstacles to evidence-based policy-making at the 
same time as there are factors that could increase research utilization. 
The place of HTA in the decision-making process can affect the extent to 
which evidence is used to inform policy and priority-setting. Countries often 
disagree on the use of HTA recommendations. Some support recommendations on 
the grounds that experts are the best people to provide them, while others prefer 
decision-makers to make recommendations in the light of political context and other 
country-specific circumstances. However, decision-makers may not have the 
technical expertise to understand the methodological strengths and weaknesses of 
an assessment. Improvements are still needed, but much has been done by 
assessment bodies to enhance the accessibility and usability of HTA among 
different audiences such as policy-makers, health professionals, and general 
public. Although different decision structures provide policy-makers with a wide 
range of discretion, not employing HTA evidence may lead to inefficient, ineffective, 
and inequitable healthcare. 
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Samenvatting 
 
 
 
 
 
 
 
 
 
Health technology assessment (HTA) is een beoordelingsmethode voor 
gezondheidstechnologie die is ontstaan vanuit de bredere beschikbaarheid van 
kostbare medische apparatuur en een toenemende bezorgdheid over het 
vermogen en de bereidheid van belastingbetalers en ziektekostenverzekeraars om 
daarvoor te betalen. Deze methode richt zich op uiteenlopende medische 
interventies, zoals geneesmiddelen, medische apparatuur, geneeskundige en 
chirurgische procedures en de organisatorische en ondersteunende systemen die 
bij het bieden van zorg worden gebruikt. Een onderdeel ervan is de evaluatie van 
een interventie door verschillende wetenschappelijke en niet-wetenschappelijke 
empirische gegevens te produceren, te combineren en/of systematisch te 
beoordelen. Kenmerkende aspecten die hierbij worden bekeken zijn veiligheid, 
werkzaamheid, kosten en kosteneffectiviteit, alsmede sociale, organisatorische, 
juridische en ethische implicaties. Het hoofddoel van HTA is het aan de 
verschillende belanghebbenden, met name aan degenen die in de 
gezondheidszorg betrokken zijn bij de financiering, planning, inkoop en 
investeringen, verschaffen van toegankelijke, bruikbare en empirisch onderbouwde 
informatie als een richtlijn bij de besluitvorming over technologie en een doelmatige 
toewijzing van middelen. Deze beoordelingsmethode wordt wel ‘de brug tussen 
empirie en beleid’ genoemd, omdat ze informatie levert aan de besluitvormers in de 
gezondheidszorg op macro-, meso- en microniveau. Met name het toegenomen 
gebruik van medische technologie heeft ertoe geleid dat de beslissers op HTA 
vertrouwen bij het bepalen van de vergoedingsstatus en de prijs van interventies. 
HTA draagt ook op allerlei manieren bij aan kennis waarmee de kwaliteit van de 
zorg kan worden verbeterd, met name als hulpmiddel bij het ontwikkelen van 
richtlijnen voor de klinische praktijk en van standaarden in de gezondheidszorg. 
 
Het gebruik van meta-analyse in systematisch literatuuronderzoek 
Systematisch literatuuronderzoek speelt een centrale rol bij empirisch 
onderbouwde geneeskunde. Kwantitatief systematisch literatuuronderzoek, ook wel 
meta-analyse genoemd, biedt een logische structuur om het bestaande empirische 
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materiaal te kwantificeren. Meta-analyse geeft de gelegenheid om de resultaten 
van vergelijkbare onderzoeken of experimenten kritisch te beoordelen en statistisch 
te combineren. Het doel hiervan is een consistente schatting te krijgen van het 
algemene effect van een procedure op een bepaald resultaat door het aantal 
waarnemingen en de statistische kracht te verhogen. Dit proefschrift presenteert de 
resultaten van een systematisch literatuuronderzoek waarbij een meta-analyse is 
uitgevoerd naar de doeltreffendheid van leefstijlinterventie bij de preventie en 
behandeling van obesitas. De algemene toename van obesitas is nog altijd een 
bedreiging voor de volksgezondheid. Dit onderzoek maakt deel uit van een HTA 
van de preventie en behandeling van obesitas die voor het Zwitserse Ministerie van 
volksgezondheid werd uitgevoerd als ondersteuning van de beslissing om in 2007 
programma’s voor de preventie van obesitas te financieren. Het systematische 
onderzoek levert nieuwe informatie over de doeltreffendheid van leefstijlinterventies 
door een schatting te geven van de middellange- en langetermijneffecten op het 
gewicht en het cardiovasculaire risicoprofiel van mensen met overgewicht en 
obesitas. Een belangrijk aspect bij het uitvoeren van een meta-analyse is de 
mogelijke heterogeniteit van de schattingen op grond van de onderzoeksresultaten. 
Men heeft betoogd dat het bepalen van een overkoepelende gecombineerde 
schatting bij heterogene onderzoeken verkeerd is en tot een misleidend resultaat 
leidt dat onmogelijk geïnterpreteerd kan worden. Er bestaan echter geen duidelijke 
richtlijnen die aangeven hoe sterk onderzoeksresultaten moeten verschillen, wil het 
combineren ervan niet langer geldig worden geacht. Op het punt van de 
heterogeniteit zijn de volgende factoren bekeken: de onderzoeksvraag van de 
geëvalueerde onderzoeken is bepaald, de overeenkomsten en verschillen in de 
onderzoeksopzet zijn geïnventariseerd, en nagegaan is of de heterogeniteit in de 
uitkomsten verklaarbaar was. Er bestaat echter geen overeenstemming over wat 
de beste strategie is voor de aanpak van heterogeniteit; momenteel is nog een 
grote mate van subjectiviteit van de onderzoeker vereist. In dit proefschrift is de 
heterogeniteit onderzocht met behulp van de volgende technieken: een funnel plot 
voor de publicatiebias, een random effect model, subgroepanalyse, 
gevoeligheidsanalyse en quality assessment-scores. De conclusie is dat meta-
analyse in potentie een krachtige techniek is voor het systematisch onderzoeken, 
analyseren en samenvatten van bestaand onderzoek naar een specifieke medische 
interventie. 
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Meting van door de patiënt gerapporteerde resultaten 
Door de patiënt gerapporteerde resultaten geven het perspectief van de patiënt aan 
op de doeltreffendheid van de behandeling. Patiënten, clinici, de farmaceutische 
industrie, beleidsvormers, financiers en regelgevende instanties erkennen dat er als 
criterium voor het toelaten van nieuwe medicijnen en voor beleidsbeslissingen 
behoefte is aan inzicht in de gevolgen van symptomen en ziektes voor het leven 
van patiënten en aan een evaluatie van de invloed van de behandeling op het 
functioneren en het welzijn van de patiënt. Traditioneel werden deze gegevens over 
het door de patiënt ervaren resultaat verzameld aan de hand van door de patiënt 
zelf ingevulde vragenlijsten op papier. Sinds kort worden bij klinische experimenten 
steeds vaker elektronische vormen van dataverzameling gebruikt. Weliswaar is er 
enige bezorgdheid dat met name oudere patiënten zich misschien verzetten tegen 
het gebruik van deze nieuwe techniek, maar uit een aantal onderzoeken op het 
gebied van verschillende ziektes blijkt dat elektronische dataverzamelingsmethodes 
de voorkeur hebben boven de traditionele methode met pen en papier. Door de 
patiënt gerapporteerde resultaten gelden pas als empirisch bewijs voor de 
doeltreffendheid van de behandeling als van het meetinstrument het begripsmatige 
kader, de validiteit van de inhoud en de psychometrische eigenschappen zijn 
vastgelegd, met inbegrip van de betrouwbaarheid, validiteit en gevoeligheid. 
 Dit proefschrift presenteert gegevens die zijn verzameld in een onderzoek 
waarin de validiteit van de elektronische versie van drie metingen van de kwaliteit 
van leven wordt vergeleken met de bestaande papieren versies. Het onderzoek 
betrof een selectieve 5-HT4-receptor partiële agonist, die was ontwikkeld voor de 
behandeling van functionele gastro-intestinale dysmotiliteitsstoornissen. Hierbij 
werd een multinationaal klinisch onderzoek afgesloten met behulp van 
elektronische dataverzameling. Om verschillen in door de patiënt gerapporteerde 
resultaten te evalueren werden standaardinstrumenten opgenomen waarmee 
verandering wordt gemeten in de kwaliteit van leven (IBS-QOL), de productiviteit 
(WPAI:IBS-C) en de utiliteit (EQ-5D) van de patiënt. Voor fabrikanten van 
gezondheidstechnologie is het belangrijk om empirisch te bewijzen dat de 
meetinstrumenten voor de kwaliteit van leven in elektronische vorm even valide zijn 
als de papieren versie. Dergelijk onderzoek is een uitdaging voor de producenten 
van medische technologie, want dit empirische bewijs is onderdeel van de 
aanvraag voor toestemming om hun product om op de markt te brengen. In dit 
proefschrift komen met name de volgende aspecten van elektronisch 
validatieonderzoek aan de orde: de kleine steekproefomvang (72 patiënten), 
wervingsproblemen, het programmeren van elektronische dagboeken en zaken 
rond de gegevensanalyse. Alle punten rond het programmeren hielden het risico in 
dat de elektronische methode van gegevensverzameling niet gelijkwaardig was met 
de papieren versie. Het onderzoek bleek echter succesvol. Het is van vitaal belang 
dat uitspraken over door de patiënt gerapporteerde resultaten op degelijk 
wetenschappelijk empirisch bewijs zijn gebaseerd. 
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Het gebruik van besliskundige modellen 
Bij een economische evaluatie van medische interventies worden vaak wiskundige 
modellen gebruikt. Het gebruik van modellen in gezondheidseconomie vormt een 
belangrijk analytisch instrument om schattingen van de kosteneffectiviteit te 
verkrijgen. Het doel van modellen is dat ze de klinische en economische empirische 
gegevens zodanig structureren dat dit bijdraagt aan de onderbouwing van 
beslissingen in de klinische praktijk en aan het toewijzen van middelen in de 
gezondheidszorg. Modellen vatten empirische gegevens over de 
gezondheidseffecten en kosten samen vanuit veel verschillende bronnen, zoals 
gegevens uit klinische proeven, observatieonderzoeken, databanken met 
verzekeringsclaims, gevalsbeschrijvingen, gezondheidsstatistieken en 
preferentieonderzoeken. Het gebruik van besliskundige modellen bij de beoordeling 
van gezondheidstechnologie is de laatste jaren exponentieel gestegen. 
 Omdat beslissingsmodellen steeds vaker als onderdeel van HTA worden 
gebruikt, is het belangrijk dat de validiteit van dergelijk onderzoek wordt vast 
gesteld. Er zijn allerlei methodologische punten die specifiek zijn voor het opstellen 
van beslissingsmodellen, zoals het correct afleiden van parameterschattingen uit 
de literatuur, het vermijden van vertekening in de schattingen van parameters en 
een verantwoordede extrapolatie naar een behandeling die langer duurt dan de 
periode die in de klinische proeven is geobserveerd. Op deze punten wordt 
ingegaan voor twee besliskundige modellen die werden ontwikkeld om het 
besluitvormingsproces te onderbouwen. Het eerste model geeft de ontwikkeling en 
resultaten weer van een model voor de kosteneffectiviteit van zoledroninezuur 
versus risedronaat bij de botziekte van Paget. Zoledroninezuur is een derde 
generatie stikstof bevattend bisfosfonaat, waarvoor toestemming werd gevraagd 
voor gebruik bij de botziekte van Paget. Voor deze registratie werden twee 
gerandomiseerde klinische tests van zes maanden uitgevoerd om de veiligheid en 
werkzaamheid te evalueren van intraveneuze toediening van zoledroninezuur bij de 
behandeling van de botziekte van Paget, met als vergelijking orale toediening van 
risedronaat. Het economische model dat op deze twee klinische proeven is 
gebaseerd, gaat verder dan zes maanden en evalueert de kosteneffectiviteit van 
zoledroninezuur versus de standaardbehandeling met risedronaat voor de eerste 
twee jaren waarin zoledroninezuur in het Verenigd Koninkrijk op de markt is. 
 Het tweede model geeft de ontwikkeling en resultaten weer van een 
economisch ramingsmodel voor de invloed op de levensduur van drie jaar 
leefstijlinterventie versus de standaardbehandeling van mensen met overgewicht 
en obesitas in Zwitserland. Dit model was een sleutelonderdeel van de HTA  die 
werd uitgevoerd voor leefstijlinterventie op het gebied van obesitas. Met behulp van 
probabilistische gevoeligheidsanalyse werd de onzekerheid bepaald bij de 
beslissing om het leefstijlinterventieprogramma in te voeren ter voorkoming en 
behandeling van obesitas. 
 De conclusie was dat besliskundige modellen een expliciete methode zijn 
om de huidige beschikbare gegevens over de resultaten en kosten van alternatieve 
medische interventies samen te vatten. Omdat de grondslag van empirische 
gegevens in verband met nieuwe medische interventies altijd zwakke punten en 
beperkingen zal hebben, vereist dit de toepassing in een analytisch kader waarin 
de aanpak van onzekerheid expliciet is aangegeven. 
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Aangeven van onzekerheid in besliskundige modellen 
In de meeste onderzoeksmethodes worden gevoeligheidsanalyses uitgevoerd of 
vereist voor alle variabelen die mogelijkerwijs van invloed zijn op de 
overkoepelende resultaten van de economische raming. Dat is een gevolg van de 
onzekerheid die inherent is aan economische ramingen, met name voor de waarde 
van bepaalde schattingen en hun relatieve invloed op kosten en baten. Deze 
voorwaarde van gevoeligheidsanalyse komt voort uit de noodzaak om de 
robuustheid van de uitkomsten te toetsen of te verifiëren. Traditioneel wordt de 
onzekerheid onderzocht met behulp van gevoeligheidsanalyse. De laatste jaren is 
er een grote nadruk geweest op het ontwikkelen van geschikte statistische 
methodes om de onzekerheid aan te pakken bij economische ramingen voor 
medische interventies, waarbij de tendens is om van univariate 
gevoeligheidsanalyses over te stappen op probabilistische beschrijvingen van de 
onzekerheid, zoals kosteneffectiviteitsvlakken, aanvaardbaarheidskrommen voor 
de kosteneffectiviteit en verdelingen van de marginale netto opbrengst. De analyse 
van informatiewaarde is een logische uitbreiding van de Bayesiaanse 
beslissingstheorie, die het bestaande niveau van onzekerheid kwantificeert en de 
invloed ervan op de verwachte netto opbrengst van mogelijke alternatieve 
beslissingen schat door de waarde van volmaakte informatie over de parameters 
van het model te beschouwen. In dit proefschrift is de onzekerheid onderzocht met 
een probabilistische gevoeligheidsanalyse en door de waarde van extra informatie 
in te schatten. De analyse van informatiewaarde is toegepast op een probabilistisch 
kosteneffectiviteitsmodel voor leefstijlinterventie bij mensen met overgewicht en 
obesitas. Deze analyse kwantificeert de onzekerheid rond de beslissing om over te 
gaan tot leefstijlinterventie. 
 Omdat vergoedingsinstanties bij een nieuwe technologie om aanvullend 
onderzoek vragen – zelfs als die instanties het toepassen van de betreffende 
therapie goedkeuren – is te verwachten dat gegevens over de informatiewaarde 
heel waardevol zijn. Het formele gebruik van technieken om de informatiewaarde te 
bepalen zal waarschijnlijk in de loop van de tijd toenemen, in het verlengde van de 
recente groei van voorwaardelijke vergoedingen 
 
Het gebruik van economische ramingen bij besluitvorming 
Dat het belangrijk is om van gezondheidseconomisch onderzoek gebruik te maken 
bij beleidsbeslissingen en om inzicht te krijgen in de betrokken mechanismes, wordt 
in toenemende mate onderkend. Het bestaan van relevant onderzoek is weliswaar 
noodzakelijk, maar niet voldoende. Empirisch onderbouwd beleid is moeilijk te 
verwezenlijken en er is brede overeenstemming dat de beleidsmaatregelen op het 
terrein van de gezondheid de onderzoeksbevindingen niet zo goed weerspiegelen 
als in theorie mogelijk zou zijn. In dit proefschrift is het gebruik beoordeeld van aan 
economische analyses gerelateerde onderzoeksresultaten bij de besluitvorming in 
de gezondheidszorg. Voor dit proefschrift is een literatuuronderzoek uitgevoerd 
waarin een overzicht en een samenvatting werd gegeven van de gepubliceerde 
literatuur over de zelf-gerapporteerde houding van beleidsmakers in de 
gezondheidszorg tegenover economische ramingen voor medische technologie. 
Het doel van dit literatuuronderzoek was te bepalen in hoeverre economische 
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ramingen worden gebruikt bij beleidsmatige besluitvorming in de gezondheidszorg 
en de factoren te bekijken die meespelen bij het gebruik maken van dergelijke 
onderzoeksresultaten. Onderzoek van het beleidsvormingsproces bevestigt dat dit 
complex is, met veel reële hindernissen voor empirisch onderbouwd beleid, terwijl 
er tegelijkertijd ook factoren zijn die het gebruik maken van onderzoek kunnen 
versterken. 
De plaats van HTA in het besluitvormingsproces kan van invloed zijn op de 
mate waarin empirisch materiaal wordt gebruikt als onderbouwing voor het beleid 
en voor het stellen van prioriteiten. Landen zijn het vaak niet eens over het 
toepassen van de aanbevelingen van HTA. Sommigen steunen deze omdat 
deskundigen de meest aangewezen personen worden geacht om aanbevelingen te 
doen, terwijl anderen er de voorkeur aan geven dat besluitvormers aanbevelingen 
doen in het licht van de politieke context en andere voor dat land specifieke 
omstandigheden. De besluitvormers hebben echter misschien onvoldoende 
technische expertise om de methodologische sterke en zwakke punten van een 
beoordeling te begrijpen. Verbeteringen zijn nog steeds noodzakelijk, maar er is 
door beoordelingsinstanties al veel aan gedaan om de toegankelijkheid en 
bruikbaarheid van HTA te verbeteren voor de verschillende doelgroepen, zoals 
beleidsmakers, gezondheidsprofessionals en het algemene publiek. Hoewel 
uiteenlopende beslissingsstructuren beleidsmakers van een breed scala aan 
beoordelingsmogelijkheden voorzien, kan het niet of verkeerd gebruiken van de 
resultaten van HTA leiden tot ondoelmatige, ondoeltreffende en onrechtvaardige 
gezondheidszorg. 
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List of abbreviations 
 
 
 
 
ALP Alkalin phosphatase 
BMI Body mass index 
BP Bisphosphonates 
CEA Cost-effectiveness analysis 
CH Switzerland 
CHF Swiss Francs 
CMA Comprehensive meta-analysis 
DBP Diastolic blood pressure 
EDC Electronic data capture 
EMEA European Agency for the Evaluation of Medicinal Products 
EVPI Expected value of perfect information 
EQ-5D EuroQol (standardized instrument for use as a measure of health outcome) 
FPG Fasting plasma glucose 
FLS Flu like syndrome 
FDA Food and Drug Administration 
GP General practitioner 
HbA1c Heaemoglobin A1c 
HDL High density lipoprotein cholesterol 
HTA Health technology assessment 
IBS Irritable bowel syndrome 
IBS-QOL Irritable bowel syndrome quality of life questionnaire 
ICC Intraclass correlation coefficients 
ICD International Classification of Disease 
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LY Life-years 
LDL Low density lipoprotein cholesterol 
MCS Mental component score 
NHS National Health System 
NICE National Institute of Clinical Excellence 
PDB Paget’s disease of bone 
PCS Physical component score 
PPI Proton pump inhibitor 
PRO Patient reported outcome 
RIS Risedronate 
SAP Serum alkaline phosphatase 
SBP Systolic blood pressure 
TC Total cholesterol 
TG Triglyceride 
VAS Visual analog scale 
ZOL Zoledronic acid 
WHO World Health Organization 
WPAI:IBS Work productivity and activity impairment irritable bowel syndrome questionnaire 
QALY Quality adjusted life years 
2h-PG Two hours plasma glucose 
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